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INTRODUCTION 
Over the last century, cancer has increasingly become one of the most important 
causes of death and due to the aging patient population in the developed countries, 
cancer will remain one of the major health problems of the future 1. The signing of the 
National Cancer Act of 1971 by then U.S. President Richard Nixon is in general consid-
ered the start of a worldwide “War on Cancer”, to eradicate the disease as a major 
cause of death 2,3. Although it was not described as a "war" in the legislation itself, the 
aim of the “War on Cancer” refers to a joint effort to find a cure for cancer by a huge 
increase of scientific research worldwide, to improve the understanding of cancer bi-
ology, and the development of more effective cancer treatments 3. Hitherto, it was 
thought that the finding of a cure for cancer was only years away. However, despite 
enormous amounts of money and time spend in scientific research the last decades, 
nearly 40 years after this war began, cancer still remains one of the leading causes of 
death in Europe, the United States and other developed countries. In 2007 cancer ac-
counted for 7.9 million deaths worldwide and around 1.7 million deaths in Europe 
alone 1. Figure 1 shows the progression of leading causes of death over time. In con-
trast to heart disease, stroke, and unintentional injuries, it is apparent that there is 
little to no reduction in the number of cancer related deaths over the last decades. For 
example, the prognosis of lung cancer, which causes the most cancer related deaths in 
men and is the third cause of cancer deaths in women, remains disappointingly poor. 
Lung cancer can be divided in two subtypes, small cell lung cancer and non-small cell 
lung cancer (NSCLC), which accounts for the vast majority of all lung cancer cases 
(±80%). Currently, patients with NSCLC have an average one year survival of about 40% 
and a 5-year survival of 15% 1. Surgery is often chosen for the treatment of early stage 
NSCLC patients. Unfortunately, NSCLC is not frequently detected at early stages and 
typically patients have an advanced stage at the time of diagnosis and are considered 
inoperable. For these patients, a combination of chemotherapy and radiotherapy is 
often elected as the treatment modality 4. Besides distant metastasis, one of the main 
reasons of poor patient prognosis is that local tumour control commonly fails (e.g. the 
tumour of 70% of all NSCLC cancer patients cannot be controlled by cancer treat-
ments) 5-7. Therefore, new investigations to improve local tumour control are war-
ranted to improve patient outcomes. 
Personalized medicine  
Despite little progress in the treatment of cancer over the past century, there has been 
a tremendous increase in our basic understanding of cancer at the molecular level that 
has revealed an enormously complex disease. It has become increasingly clear that due 
to patient specific gene mutations and other specific tumour characteristics, in princi-
ple every patient has his own ‘disease’, and therefore should receive a specific treat- 
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Figure 1 
Leading causes of death for all ages. All death rates are age adjusted.  
(Report: Health, United States, 2008National Center for Health Statistics 8) 
 
ment. Besides the standard cancer treatment modalities, like surgery, chemother-
apy,and radiotherapy, more and more targeted agents become available to which of-
ten only a small subpopulation responds. New medical diagnostic technology has re-
sulted in an ever increasing amount of patient specific information for example, from 
non-invasive imaging, gene-arrays, pathology, and blood biomarkers. Therefore, it is a 
challenge to select from all the therapeutic options the optimal treatment based on all 
the available diagnostic data. The concept of using advanced diagnostic capabilities to 
tailor treatment is called “personalized medicine”. The goal of personalized medicine is 
to individualize towards the specific characteristics of a patient, tumour genotype and 
the patient’s wishes, instead of the currently common “one size fits all” treatment mo-
dalities. This concept is motivated by the fact that patients with similar disease stage 
often show a large variation in response to systemic therapy and radiotherapy, for 
both efficacy and toxicity (Figure 2).  
The concept of dose painting of radiation 
Radiotherapy is the medical use of high energy photon beams to deliver and localize 
amounts of ionizing radiation (radiation dose) to regions of malignant cells in 
thetreatment of cancer. As radiotherapy is the only treatment modality that can ex-
ploit its therapeutic effect in the three dimensions of space, dose painting refers to a 
methodology to individualize the treatment by guiding the radiotherapy dose towards  
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Figure 2  
In a group of patients with the same diagnosis and the same prescribed treatment, there are 
subpopulations that differ in the benefit and the toxicity of the selected treatment. Note, that 
only group A has an optimal treatment, group B experiences toxicity, and in group C and D the 
treatment is even not beneficial. 
 
intra tumour regions of biologic treatment-resistance 9-13. Indeed, in recent years it has 
become clear that tumours are not homogeneous,guiding the radiotherapy dose to-
wards intra tumour regions of biologic treatment-resistance 9-13. Indeed, in recent 
years it has become clear that tumours are not homogeneous, but heterogeneous for 
various biologic characteristics, like tumour cell density, normal tissue involvement, 
vasculature, hypoxia, proliferation, gene expression and drug uptake 11,14,15. Tumour 
heterogeneity is exhibited both at the microscopic and macroscopic level. Therefore, it 
is likely that there exist large spatial differences in the probability to eradicate distin-
guishable tumour sub-volumes by radiotherapy, chemotherapy, targeted agents, 
and/or their combinations. Therefore, to strive for a homogeneous radiation dose dis-
tribution, as now is current practice, seems illogical as some areas receive a dose that 
is not enough for eradication, and in other, more sensitive regions, dose is wasted. 
Also, an overall increase of the dose in the tumour is not possible due to the increasing 
dose in the normal tissues, resulting in more toxicity after therapy. Therefore, a het-
erogeneous dose distribution, matching the profile of intra tumour differences of ra-
dio-curability, seems to be the rational choice. 
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Figure 3 
Schematic representation of dose painting exploiting intra tumour heterogeneity of treatment 
resistance and decreased drug uptake before treatment (left) and during treatment (right). Note 
that if changes occur during treatment of the intra tumour drug uptake, e.g. due to regions of 
enhanced perfusion due to RT (top right), the treatment plan has to be adapted (bottom right). 
Dose painting in combination with systemic therapies 
For the treatment of the most advanced cancers radiotherapy is often combined with 
systemic therapies, typically consisting of chemotherapy, immunotherapy or biological 
response modifiers. These systemic therapies can have large intra tumour differences 
of the therapeutic effect, due to accessibly issues, e.g. large antibodies have limited 
reach into the less perfused tumour regions, and due to sensitivity issues of the tu-
mour cells to the drug, e.g. resistance to targeted agents. Therefore, if the areas of 
failure of systemic therapies can be identified using non-invasive imaging, the dose can 
be directed towards these ‘volumes’ of resistance (Figure 3). Here molecular imaging 
can be used to: I) visualize biologic characteristics known to be related with treatment-
resistance, like metabolism and hypoxia, and II) to image the uptake of drugs. Recent 
advances of PET imaging allow for the visualisation of drug uptake even days after ad-
ministration with a high sensitivity. As various studies have shown that the absorption 
of the drugs is often heterogeneous, this indicates that accessibility of tumour tissue 
by large monoclonal antibodies can be an important factor for intra tumour differ-
ences of therapy response and resistance. Therefore, also imaging of drug uptake can 
be valid to identify tumour sub-volumes for dose painting. 
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Identification of biologic characteristics using 18F-deoxyglucose 
Before the concept of dose painting can be tested in clinical settings, it is crucial to 
identify the regions of resistance of treatment using non-invasive imaging. Here mo-
lecular imaging can be used to visualize biologic characteristics known to be related 
with treatment-resistance, like hypoxia and metabolism. For this purpose novel tracers 
for positron emission tomography (PET) imaging, like hypoxia markers 10,15,16, or con-
ventional tracers like 18F-deoxyglucose (FDG) measuring tumour glucose metabolism 
17,18, can be used. FDG is the workhorse in the field of oncology for diagnostic and 
prognostic purposes that has led to improved clinical decision making in a large quan-
tity of cancer patients 19. Many investigations have shown that high FDG uptake is a 
prognostic indicator for poor patient survival both treated with radiotherapy and sur-
gery 20-24. During the past decades FDG has become widely available and a lot of pro-
gress was made in standardisation and reproducibility of FDG-PET imaging 25,26, further 
improving the usability in the clinic. The underlying biology for FDG uptake is complex 
as it measures the uptake of glucose in cells by adenosine triphosphate (ATP) inde-
pendent glucose transporters. This makes FDG uptake specific to the metabolic path-
way although this pathway is known to influence numerous other processes to facili-
tate cancer 27,28. Consequently, FDG uptake in the tumour does not reflect a single bio-
logic characteristic, but is correlated to although certainly not specific for, radio-
resistance, proliferation 29, cell density 30, hypoxia 24,31-33, mitochondrial dysfunction 34, 
and lipogenesis 35. Furthermore, in a pre-clinical investigation, it has been shown that 
an increase of radiation dose showed a higher local control for tumours with higher 
FDG uptake compared to tumours with lower FDG uptake 36, affirming the relation be-
tween FDG-uptake and radio-resistance.  
 
A straightforward way to identify recurring regions of treatment resistance is to iden-
tify the residual tumour locations following treatment. This approach is referred to as 
“pattern of relapse studies” in journal publications. One method of investigating the 
location of the residual tumour masses is assessing metabolic response within the pri-
mary tumour with using FDG-PET imaging after treatment 17. Several studies indicated 
that patients with metabolically active residual masses after treatment have a poorer 
prognosis compared to patients without residual metabolic activity 17,37, underlining its 
clinical validity.  
Non invasive imaging of the drug Cetuximab 
Recent advances in PET imaging allow for the visualisation of drug uptake even days 
after administration with a high sensitivity. The uptake of drugs can be assessed by 
labelling the drug itself with radio-nuclides, and follow the tracer uptake over time 
with PET imaging 38. An example of such a drug is the monoclonal antibody Cetuximab 
(IMC-225, Erbitux) specifically targeting the epidermal growth factor receptor (EGFR), a 
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molecule at the cell membrane 39-41. EGFR is a member of the ErbB family and has been 
shown to play an essential role in the upregulation of tumour cell proliferation, differ-
entiation and survival 42,43. EGFR expression is commonly found in a significant number 
of human malignancies and its expression is associated with tumour aggressiveness 
and overall treatment resistance 44,45. As a result, EGFR targeting has been explored as 
a possible anti-tumour strategy. Cetuximab is an example of a monoclonal antibody 
which blocks the ligand-binding domain of EGFR with high affinity, thereby preventing 
downstream signalling 39,46. Consequently, Cetuximab is considered as a promising new 
targeted agent and is increasingly used in clinical trials, mainly in combination with 
chemo- or radiotherapy 40,47. Despite extensive use of Cetuximab in clinical settings, 
much is unknown about the patient-specific tumour uptake and overall pharmacoki-
netics of Cetuximab 40,44,45. Moreover, only a small sub-population of patients benefits 
from Cetuximab treatment, were often discrepancies between Cetuximab uptake and 
EGFR expression levels have been reported 48-51. Also, due to the toxicity related with 
Cetuximab treatment, there is a strong incentive to identify patients who are less likely 
to benefit from Cetuximab treatment and spare them undue toxicity. Therefore, the 
non-invasive quantification of in vivo Cetuximab uptake in tumours and healthy tissue 
could provide crucial prognostic indicators, usable for selecting patients suitable for 
Cetuximab treatment and optimizing dosage, but also identifying intra tumour areas 
for dose painting. 
 
Several groups have used Cetuximab itself as an imaging agent because it has several 
advantages for visualizing its distribution in normal and tumour tissues. The majority of 
these Cetuximab-based non-invasiveimaging probes are labelled with SPECT and PET 
isotopes 52-58. Some studies were limited by the use of relatively short half-life (t1/2) 
isotopes (99mTc: 6 h and 64Cu: 12 h) which are incompatible with the long biologic half-
life of Cetuximab in the blood pool 55. Another isotope for PET imaging often suggested 
for antibody imaging is Iodine-124, because its long physical half-life (t1/2 = 100.3 
hours) allows imaging even days after injection. However, an important disadvantage 
of Iodine-124 is the rapid degradation of the radioiodinated antibody upon internaliza-
tion, leading to PET images of less quality which does not reflect the actual tumour 
uptake of the antibody 53. Based on the findings of Verel et al.38,59, the positron emitter 
Zirconium-89 (89Zr) displays ideal characteristics for usage with antibodies 60. 89Zr dem-
onstrates a long physical half-life (t1/2 = 78 hour) and, upon internalization of the anti-
body, is trapped intracellularly in lysosomes (phenomenon of residualization) 41,61. 
Moreover, radio-labelling of Cetuximab with 89Zr does not influence its binding poten-
tial to EGFR, resulting in an immunoreactive fraction of about 95% 60. For these rea-
sons, 89Zris an ideal radionuclide for the labelling of slow kinetic intact antibodies with 
high quality standards, and is successfully used in pre-clinical 62 and clinical settings 
53,63,64.  
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It is expected that the implementation of dose painting in combination with systemic 
therapies in clinical settings, will yield major steps in better local control rates, thereby 
improving survival and the quality of life, urgently needed in cancer treatment. A pre-
requisite for the concept of dose painting is that the areas of biologic treatment resis-
tance and limited drug uptake can be identified, as these areas can be compensated 
with a higher radiation dose. 
OBJECTIVE OF THE THESIS 
The general hypothesis is that solid tumours are heterogeneous in their sensitivity to 
treatment by biologic resistance and drug uptake. Therefore, this thesis investigates if 
molecular imaging of biologic characteristics and drug uptake can be used to identify 
regions of treatment resistance, thereby enabling personalized medicine by dose 
painting. There were two specific research aims:  
 
I)  The non-invasive identification treatment-resistant areas using a pre-treatment 
FDG-PET-CT scan for dose painting studies. 
II)  The development and validation of novel image probes for pre-clinical and clinical 
imaging of the drug Cetuximab. 
Outline of the thesis 
As the work presented in this thesis can be divided in two distinct parts, these are 
separately presented to the reader. At first, in this Chapter 1, an introduction for the 
work presented in this thesis is given. Also the role of radiation oncology in personalize 
medicine is introduced.  
Part 1:   Identification of radioresistance: Rational for dose painting 
The first part of this thesis describes the identification of radioresistance using FDG-
PET-CT imaging. For this purpose critical questions have to be answered: I) is it possible 
to identify treatment-resistant areas within the tumour using a pre-treatment FDG-
PET-CT scan? and II) do these areas remain stable within the tumour during a course of 
radiotherapy? 
 
Chapter 2 presents a study that assessed if it is possible to identify the location of ra-
dioresistance using a FDG-PET-CT scan before treatment. Specifically, we assessed for 
the first time if the location of residual disease after treatment was similar to the loca-
tion of high FDG-uptake within the tumour before treatment. This work was per-
formed in a MAASTRO dataset. 
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In Chapter 3 a study is presented if the results of Chapter 4 can be validated in an in-
dependent dataset from the Princess Margaret Hospital (PMH) in Toronto, Canada. 
Validation in external datasets is important for evidence of the results.  
 
Chapter 4 describes a validation study in another dataset from the Radboud University 
Medical Center in Nijmegen, the Netherlands. This dataset is not only independent, 
but also prospectively gathered.  
 
Chapter 5 describesa study that assessed if these FDG uptake zones remained stable 
during a course of fractionated radiotherapy. This critical question has to be answered 
before selectively boosting parts of the tumour is possible.  
Part 2:   Non invasive imaging of drug uptake: From the bench to the clinic 
This second part of the thesis is about the development of image tracers for the visu-
alisation of drug uptake. In specific, we labelled the monoclonal antibody Cetuximab 
targeting the epidermal growth factor receptor (EGFR). We have developed in vitro 
and in vivo image probes to investigate the distribution of Cetuximab non-invasively. 
 
In Chapter 6 a study with the fluorescent image probe Cetuximab labelled Oregon 
Green 488 is presented to the reader. Here, the in vitro binding of Cetuximab to EGFR 
and the mutant EGFRvIII was investigated, as well as the ex vivo distribution of Cetuxi-
mab and the EGFR. 
 
Chapter 7 presents an in vivo study with Cetuximab labelled with the positron emitter 
Zirconium-89 (89Zr) for PET imaging. Here, the uptake of 89Zr-Cetuximab was investi-
gated non-invasively in tumours with varying EGFR expression levels up to days after 
injection.  
 
In Chapter 8 a study is described that investigated the in vivo uptake of 89Zr-Cetuximab 
in cancer patients. This phase I study was performed to assess the toxicity and image 
quality in a limited number of patients. 
General discussion and future perspectives 
Chapter 9 gives a general discussion of the results presented in this thesis and looks at 
future perspectives.  
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ABSTRACT 
Background and Purpose 
Non-small cell lung cancer (NSCLC) tumours are mostly heterogeneous. We hypothe-
sized that areas within the tumour with a high pre-radiation 18F-deoxyglucose (FDG) 
uptake, could identify residual metabolic-active areas, ultimately enabling selective-
boosting of tumour sub-volumes. 
 
Material and Methods 
Fifty-five patients with inoperable stage I-III NSCLC treated with chemo-radiation or 
with radiotherapy alone were included. For each patient one pre-radiotherapy and one 
post-radiotherapy FDG-PET-CT scans was available. Twenty-two patients showing per-
sistent FDG-uptake in the primary tumour after radiotherapy were analyzed. Overlap-
fractions (OF) were calculated between standardized uptake value (SUV) threshold-
based auto-delineations on the pre- and post-radiotherapy scan.  
 
Results 
Patients with residual metabolic-active areas within the tumour had a significantly 
worse survival compared to individuals with a complete metabolic response (p=0.002). 
The residual metabolic-active areas within the tumour largely corresponded (OF>70%) 
with the 50%SUV high FDG-uptake area of the pre-radiotherapy scan. The hotspot 
within the residual area (90%SUV) was completely within the GTV (OF=100%), and had 
a high overlap with the pre-radiotherapy 50%SUV threshold (OF>84%).  
 
Conclusion 
The location of residual metabolic-active areas within the primary tumour after ther-
apy corresponded with the original high FDG-uptake areas pre-radiotherapy. There-
fore, a single pre-treatment FDG-PET-CT scan allows for the identification of residual 
metabolic-active areas.  
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INTRODUCTION 
Lung cancer still remains one of the most frequent and lethal solid tumours 1. Although 
the prognosis has improved, in locally advanced non-small cell lung cancer (NSCLC), the 
5-year survival is 20 % at best 2-7. As the improved long-term survival with concurrent 
chemo-radiation compared to sequential chemotherapy and radiotherapy is due to 
improved local tumour control, strategies to increase local tumour control are war-
ranted 6-8. Local tumour failure is indeed still observed in about 70 % of patients 5-7.  
 
An important strategy to improve local tumour control is to escalate the radiation 
dose, because a higher dose has been shown to yield a higher local control rate 9-11. 
However, radiation dose increase is limited by the toxicity of radiation to normal tis-
sues such as the lungs and the spinal cord. Although accelerated, high-dose schedules 
based on normal tissue constraints have shown promising results 12-14, innovative 
strategies are needed to be able to deliver doses up to 120 Gy, which are needed to 
obtain local tumour control rates over 90 % 15. A possibility to achieve this goal would 
be to take advantage of intra-tumour heterogeneity. It has become increasingly clear, 
that a tumour is heterogeneous for varying characteristics, possibly also for radio-
resistance 16,17. Indeed, molecular imaging studies showed significant differences in 
perfusion, hypoxia, cell density and proliferation within the tumour 18-22. As the tumour 
is thus probably composed of areas with different radio-resistance, a strategy to de-
liver a non-uniform dose-distribution seems logical. It appears to be a way to design 
volumetric maps of radio-resistance using molecular imaging and to redistribute the 
radiation dose according to this. More resistant areas within the tumour could thus 
receive higher doses whilst reducing the dose to more susceptible zones with the same 
normal tissue exposure 18.  
 
18F-deoxyglucose (FDG) is a commonly used marker in oncology for the assessment of 
glucose metabolism 23. FDG uptake in the primary tumour before treatment is prog-
nostic for survival in patients with NSCLC, both treated with surgery and radiotherapy 
24-28. The metabolic response of patients after radiotherapy or chemo-radiation is cor-
related with survival 29. In a pre-clinical investigation an increase of radiation dose 
showed a higher local control for tumours with higher FDG uptake compared to tu-
mours with lower FDG uptake 17. Therefore, we hypothesized that the high FDG uptake 
locations before treatment could prossibly identify more radioresistant areas within 
the tumour.  If true, an increase survival could be expected from radiation dose redis-
tribution according to FDG uptake pre-radiotherapy. In an earlier study, we demon-
strated that for NSCLC, the high-uptake areas of FDG within the tumour remained sta-
ble during a course of fractionated radiotherapy for NSCLC 30, being a prerequisite for 
selective radiation boosting of these zones. In the present study, we investigated 
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whether the high FDG uptake area within the primary tumour before treatment indeed 
identifies the location of the residual metabolic-active areas after treatment. 
METHODS 
Patient Characteristics 
Fifty-five patients (16 women and 39 men) with inoperable non-small cell lung cancer 
(NSCLC), UICC stage I-III, treated with radical radiotherapy (RT) alone (11 patients) or 
with sequential chemo-radiotherapy (44 patients) were studied as part of two phase II 
trials (NCT00573040, NCT00572325). No concurrent chemo-radiotherapy was given. 
The sequential chemo-radiotherapy schedule consisted of 3 cycles of carboplatin or 
cisplatin and gemcitabine before the start of RT. Patients were included from January 
2005 until February 2007. Mean age was 65.4 years (range: 44-83 years). The Medical 
Ethics Committee according to the Dutch law approved the trial. All patients gave writ-
ten informed consent before entering the studies. Two FDG-PET-CT scans were avail-
able for each patient. The first scan was performed on average 12.8 days (range: 1-56 
days) before start of RT while the second scan was performed 86.1 days (range: 49-184 
days) after the end of RT.For the patients receiving sequential chemo-radiotherapy 
was the pre-RT scan performed after the chemotherapy. No treatment was given to 
any of the patients between the end of RT and the post-RT scan.  
Radiotherapy Simulation 
Patients were simulated in radiotherapy position on a dedicated PET-CT-simulator with 
both arms above the head. For the FDG-PET-CT scans a Siemens Biograph (SOMATOM 
Sensation-16 with an ECAT ACCEL PET scanner) was used. An intravenous injection of 
(weight * 4 + 20) MBq FDG (Tyco Health Care, Amsterdam, The Netherlands) was fol-
lowed by 10 ml physiologic saline. After a 45 minutes uptake period, during which the 
patient was encouraged to rest, PET and CT images were acquired. A spiral CT (3 mm 
slice thickness) with intravenous contrast was performed covering the complete tho-
racic region. 
Radiotherapy Planning 
Radiotherapy planning was performed on a XiO (Computerized Medical Systems, St 
Louis, Missouri) treatment planning system, based on a convolution algorithm using 
inhomogeneity corrections. The Gross Tumour Volume (GTV) and the Planning Target 
Volume (PTV) were defined for all patients, based on PET-CT data 13. The Clinical Target 
Volume (CTV) was defined as the GTV with a 5 mm margin incorporating microscopic 
disease. Subsequently, this CTV was expanded with 1 cm to draw the PTV to incorpo-
Identification of Residual Metabolic Areas  27
rate the internal respiratory motion and setup errors. Contouring of the lungs was car-
ried out automatically by the treatment planning system. The volume of both lungs 
excluding the GTV was used for the calculation of the mean lung dose (MLD). The spi-
nal cord was drawn throughout the whole CT scan, considered to be at the inner mar-
gin of the bony spinal canal. A 3D conformal treatment plan was calculated on the PTV 
for all patients according to ICRU 50 guidelines 31. Dosimetric values were calculated on 
the basis of dose-volume histograms and dose distributions on each axial CT plan. For 
each patient, the radiation dose was escalated to an individualized maximal total tu-
mour dose, applying an MLD of 19 Gy while respecting a maximum spinal cord dose of 
54 Gy 14. The maximal total tumour dose allowed was 79.2 Gy. There were no eso-
phageal dose constraints. Radiotherapy was delivered twice a day, 5 days per week, 
with a minimum of 8 hours between the two fractions. In all patients, individualized 
patient dosimetry using electronic portal imaging devices was performed 32. 
 
Figure 1 
Schematic representation of the overlap-fractions (OF) quantification of FDG-uptake pre-
radiotherapy with residual metabolic-active areas post-radiotherapy. Within the pre-
radiotherapy GTV (defined with the knowledge of the FDG-PET-CT scan), the FDG-PET uptake 
areas were quantified (34-70%SUVmax). Within the residual areas, the high FDG-uptake areas 
(70-90%SUVmax) were quantified. As an example, the OF of the 50%SUVmax FDG high-uptake 
zone pre-radiotherapy with the residue was illustrated (OF about 70%). 
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Image Analysis 
The pre- and post-RT scans were analyzed and delineated using the Siemens TrueD 
system (Version VC-30, Siemens A.G., Darmstad, Germany). Descriptively, a schematic 
representation of this methodology is shown in Figure 1. The location and volume of 
the FDG uptake areas pre-RT were quantified within the primary tumour using the 
threshold 34, 40, 50, 60 and 70% of the maximal SUV (SUVmax). Residual metabolic ar-
eas were defined as FDG uptake higher than in the aortic arch (SUV>SUVaorta) 
29. Within 
the residual FDG-positive areas on the post-RT scan, the high FDG uptake areas were 
defined using the thresholds 70, 80, and 90% SUVmax. Also the fixed thresholds, SUV 
2.5 and SUV 5.0, of the residual disease were delineated on the post-RT scan (not illus-
trated). Using an automatic rigid registration algorithm based on mutual information 
of the CT scans, the images of pre-RT scan were fused to the post-RT scan on the Sie-
mens TrueD system. If the automatic registration showed a large deformation between 
the two CT scans, the images were manually registered on the surrounding anatomy of 
the tumour, e.g. the bony anatomy or great vessels.  The contour delineations on the 
post-RT scan were then transformed to the pre-RT scan using the derived registration 
matrices. The contour delineations were exported from TrueD as DICOM-RT structure 
sets. Using MATLAB 7.1 SP3 (The MathWorks Inc, Natick, MA, USA) the overlap frac-
tions (OF) and volumes of these FDG based delineations were calculated. The overlap 
fraction was defined as the volume of overlap divided by the smallest volume 30. See 
figure 1 for a schematic representation of this calculation. By using this method it is 
possible to assess which threshold on the pre-RT scan matches the residual disease on 
the post-RT scan. 
Statistical Analysis 
All data are expressed as mean ± 95% confidence intervals (95% CI). Statistical differ-
ences between the parameters were evaluated in SPSS (Version 15.0 for Windows, 
Chicago, IL), using the Mann-Whitney U test. Differences were considered to be signifi-
cant when the p-value was less than 0.05. A power calculation was performed to as-
sess the power of the patient group for the metabolic-active areas located at the FDG 
hotspot vs. at random 33.The overall survival of the patients and the 95% CI were calcu-
lated using the Kaplan-Meier method. Differences between the groups were assessed 
using the log-rank test. The Cox regression method was used to estimate the hazard 
ratio.  
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Table 1: Patient characteristics of the 22 patients with residual metabolic active areas after RT 
Patient   
Age 
G
ender 
Stage 
TTD (Gy) 
O
TT (days) 
Days pre-scan - RT  
Days RT - post 
scan 
Treatm
ent 
Response 
GTV volum
e 
(cm
3) 
SU
Vm
ax Pre-RT 
SU
Vm
ax Post-RT 
SU
V aorta Post-RT 
1 54 M T3N2M0 56 22 9 96 seq CT-RT SMD 152 6.68 5.77 3.53 
2 72 M T2N3M0 72 28 7 64 seq CT-RT PMR 72 8.80 3.50 2.03 
3 54 M T2N3M0 79 30 7 49 seq CT-RT PMR 77 10.31 5.35 3.25 
4 64 M T4N0M0 79 20 12 76 seq CT-RT PMR 29 5.50 3.60 2.90 
5 61 F T2N2M0 47 17 8 89 seq CT-RT PMR 272 7.70 4.10 2.54 
6 72 M T3N2M1 70 27 28 122 seq CT-RT PMR 87 15.65 5.78 2.45 
7 83 M T2N0M0 79 32 8 102 RT PMR 122 10.61 7.39 3.26 
8 79 M T2N2M0 72 28 12 92 seq CT-RT PMR 55 10.40 6.70 1.84 
9 83 M T2N1M0 59 22 8 106 RT SMD 87 9.63 11.94 2.96 
10 58 F T3N2M0 54 20 14 77 seq CT-RT SMD 104 18.69 17.37 3.67 
11 63 M T2N0M0 54 21 56 88 RT PMR 26 8.41 4.14 2.78 
12 44 F T2N2M0 76 30 8 112 seq CT-RT SMD 20 4.50 4.20 3.40 
13 77 M T4N0M0 54 25 12 99 seq CT-RT PMR 125 19.70 3.60 2.50 
14 63 F T2N2M0 58 21 13 76 seq CT-RT SMD 131 11.80 13.90 2.65 
15 80 M T2N1M0 54 22 41 70 RT SMD 139 8.54 7.43 2.85 
16 79 F T4N0M0 58 24 5 69 seq CT-RT PMR 19 8.50 5.80 2.95 
17 69 M T2N2M0 63 25 9 86 seq CT-RT SMD 39 11.91 11.91 3.65 
18 53 M T2N2M0 54 22 8 82 seq CT-RT PMR 128 15.90 8.90 2.88 
19 69 M T1N2M0 54 18 10 131 seq CT-RT PMR 48 16.02 7.60 3.10 
20 56 M T4N2M0 79 30 6 83 seq CT-RT PMR 102 8.40 3.90 1.75 
21 73 M T4N2M0 79 32 7 66 seq CT-RT PMR 148 4.30 3.30 2.90 
22 50 F T4N2M0 56 21 13 71 seq CT-RT PMR 121 9.20 6.10 3.65 
Mean: 66.2   64.0 24.4 13.7 86.6   95.6 10.5 6.9 2.9 
Std: 11.5   11.0 4.6 12.4 19.9   58.8 4.3 3.8 0.6 
min: 44   46.8 17.0 5 49.0   19.0 4.3 3.3 1.8 
max: 83   79.2 32.0 56 131.0   272.2 19.7 17.4 3.7 
RT: radiotherapy; M: male; F: female; TTD: total tumour dose; OTT: overall treatment time of 
radiotherapy; post scan: FDG-PET-CT scan after the end of radiotherapy; RT: radiotherapy alone; 
seq CT-RT: sequential chemotherapy and radiotherapy; Response (EORTC criteria): SMD: stable 
metabolic disease PMR: partial metabolic response; GTV: gross tumour volume 
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RESULTS 
Patient Characteristics 
To assess the location of residual metabolic active areas compared with initial FDG up-
take in the primary tumour, two 18Fluorodeoxyglucose (FDG) PET-CT scans were ana-
lyzed for all patients, one before radiotherapy (pre-RT) and one after radiotherapy 
(post-RT). Of all 55 patients, 28 showed metabolic active areas with residual FDG up-
take in the proximity or within the primary tumour on the post-RT scan. The other 27 
patients had a complete metabolic response, showing no residual metabolic activity in 
the primary tumour. Both patients with and without residual areas showed heteroge-
neous FDG uptake patterns within the macroscopic tumour before treatment, where 
the high uptake area was not necessarily in the center of the tumour. The maximum 
FDG uptake on the pre-RT scan for patients with residual areas was significantly higher 
than for patients with a complete metabolic response (SUVmax=9.6 [95%CI: 8.0-11.2] 
and 7.1 [95%CI: 5.6-8.7] respectively; p = 0.029). Also the GTV volume was significantly 
higher for patients showing residual areas (with residual areas: 117.3 cm3 [95%CI: 70.3-
164.3 cm3], without residual areas: 54.7 cm3 [95%CI: 38.7-70.6 cm3]; p = 0.003). The 
total tumour dose was not different (p = 0.547) from the patients without residual dis-
ease (65±8.6 Gy), compared to the patients with residual disease (64.3±10.9 Gy). Also 
the overall treatment time was similar for the patients without residual disease 
(26.5±5.8 days) compared to the patients with residual disease (24.8±4.7 days) (p = 
0.326). Concordant with literature 29, with a median follow-up of 29.9 months, patients 
with residual areas had a worse survival than individuals with a complete metabolic 
response (12.2 months vs. median survival not reached; hazard ratio for death: 2.94 
[95%CI: 1.44-5.99], p = 0.002; Figure 2).  
 
Twenty-two out of the 28 patients remained for further analysis. Three patients were 
excluded because the residue was not clearly distinguishable from the surrounding 
tissue due to FDG avid inflammation, pneumonitis or to the vicinity of the heart. In 
addition two patients were excluded due to large deformation of anatomical struc-
tures between the pre- and post-RT scans, because no reliable registration could be 
performed (determined by two independent observers). One patient with progressive 
disease was excluded because the residual disease was larger than the primary tu-
mour, excluding reliable calculation of overlap fractions. The characteristics of these 
patients are shown in Table 1. 
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Figure 2 
Kaplan-Meier estimates of overall survival of all 55 patients with residual metabolic active areas 
(n=28) and without residual areas (n=27) on the post-radiotherapy FDG-PET-CT scan. The hazard 
ratio for death for patients with residual areas compared to individuals without was 2.94 (95% 
confidence interval: 1.44 to 5.99; p=0.002 by the log-rank test, two-sided). 
Overlap fractions between FDG-PET-CT scans pre- and post-radiotherapy 
In Figure 3, representative images are shown of three typical patients with a large ho-
mogeneous tumour (Patient 1), a large heterogeneous tumour (Patient 2) and a small 
tumour (Patient 3). The location of the residual areas (SUV>SUVaorta) on the post-RT 
scan and the high FDG uptake areas (50% SUVmax) on the pre-RT scan are shown. The 
residual areas are transposed to the pre-RT scan, to show the overlap with 50% SUVmax 
high uptake area pre-RT. Visual evaluation shows that the location of the residual ar-
eas largely corresponds with the high FDG uptake areas pre-RT. 
Volumes of the FDG based thresholds 
The volumes of the FDG based thresholds of the tumour pre- and post-RT are shown in 
Figure 4. The high FDG uptake areas (50-70% SUVmax) within the tumour on the pre-RT 
scan were small compared to the GTV volume. The 50% SUVmax encompassed 39.0% 
[95%CI: 31.9-46.0%] of the original GTV, whereas this was 24.9% [95%CI: 20.4-29.4%] 
for the 60% SUVmax, and 13.7% [95%CI: 11.0-16.3%] for the 70% SUVmax threshold (Fig.  
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Figure 3 
Representative FDG-PET-CT images of 3 patients pre- and post-radiotherapy. The light gray con-
tours indicates the 50%SUVmax FDG high uptake areas pre-radiotherapy. The drak gray contours 
indicate the residual metabolic active areas post-radiotherapy, also transposed on the pre-
radiotherapy scan. Visual evaluation shows a large correspondence between the residual areas 
post-radiotherapy with the high FDG uptake areas pre-radiotherapy. 
 
4A). The volume of the residual metabolic active areas on the post-RT scan was 21.7% 
[95%CI: 15.1-28.3%] of the pre-RT GTV volume (Fig. 4B). The relative volumes of the 
high uptake areas within the residual areas were very small: 7.8% [95%CI: 4.4-11.2%] 
for the 70% SUVmax, 2.5% [95%CI: 1.5-3.5%] for the 80% SUVmax, and 0.8% [95%CI: 0.4-
1.3%] for the 90% SUVmax threshold. Also the absolute thresholds of the residual areas 
had a relative small volume: 31.5% [95%CI: 22.4-40.6%] and 7.0% [95%CI: 3.0-11.0%] 
for SUV2.5 and SUV5 respectively.  
Overlap Fractions 
Figure 5 depicts the overlap fractions of the FDG uptake within the primary tumour 
pre-RT with the post-RT thresholds. The residual areas were mainly located within the 
original GTV (OF = 91.8% [95%CI: 87.9-95.6%]) (Fig. 5A). The 70% and 80% SUVmax high-
uptake areas within the residual areas were also mainly located within the GTV (OF = 
94.0% [95%CI: 89.2-98.7%] and 96.5% [95%CI: 93.1-100.0%] respectively). Whereas, 
the 90% SUVmax high-uptake areas were all completely located within the GTV (OF = 
100%). Comparing the pre-RT FDG uptake with the residual areas, the 34% threshold 
pre-RT had a large overlap fraction with the residual areas (89.3% [95%CI: 84.8-93.8%]) 
and with the high-uptake areas within the residue. Moreover, the same is true for the 
pre-RT 50% SUVmax high FDG uptake area (OF = 70.4% [95%CI: 63.0-77.7%]). This pre-
RT 50% SUVmax area also largely corresponded with the 70-90% SUVmax high-uptake 
areas within the residue. The 22 analyzable patients resulted in a power of over 0.9 
(with alpha = 0.01, H0:  30% of patients with residue randomly located at FDG. 
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Figure 4 
Volumes of the SUV thresholds of the tumour pre-radiotherapy (A) and post-radiotherapy (B). All 
volumes (A and B) are relative to the pre-radiotherapy gross tumour volume (GTV). The data are 
expressed as mean ± 95% confidence intervals (error-bars). Note that the volume of residual 
metabolic active areas was on average 22% of the GTV volume. 
 
hotspot vs H1: 70% in case of non-random location of residue).The extent of the GTV 
corresponded largely with the absolute SUV2.5 (OF = 85.9% [95%CI: 79.2-92.5%]) and 
the SUV5 (OF = 96.0% [95%CI: 92.9-99.1%]) threshold on the post-RT scan (Fig. 5B). 
Also the 34% threshold pre-RT largely corresponded with the SUV2.5 and SUV5 
thresholds post-RT (OF = 82.0% [95%CI: 75.9-88.1%] and 95.4% [95%CI: 91.2-97.9%] 
respectively). The 50% pre-RT threshold had an OF of 67.8% [95%CI: 59.9-75.6%] with 
the SUV2.5 threshold and an OF of 76.4% [95%CI: 65.6-87.3%] with the SUV5 thresh-
old. 
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Figure 5 
Overlap-fractions (OF) of the pre-radiotherapy with the post-radiotherapy relative (A) and abso-
lute (B) SUVmax thresholds are shown. OF’s of the post-radiotherapy residual-areas are indicated 
with the black-bars. The other bars indicate the OF with the high FDG-uptake areas within the 
residue (A) and absolute thresholds (B). The data are expressed as mean ± 95% confidence-
intervals.  
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DISCUSSION 
There is a growing interest in radiation oncology to selectively target radio-resistant 
areas with a high probability of persisting tumour cells after treatment within the tu-
mour 18,34,35. Indeed, by selectively boosting radio-resistant areas whilst decreasing the 
dose to more susceptible zones, local tumour control rates could increase without in-
creased side effects. The availability of molecular imaging techniques that enable visu-
alization and quantification of areas with different characteristics within the tumour 
makes this a feasible strategy. FDG as a PET tracer is of particular interest in this re-
spect because first, its maximal uptake in the tumour is prognostic for survival of pa-
tients with NSCLC, both treated with surgery or radiotherapy 24-28. Second, our group 
has previously shown that the FDG uptake patterns within the tumour remain stable 
throughout a radiotherapy course 30, and third FDG is widely available.  
 
We hypothesized that areas of high FDG uptake within the tumour before treatment 
would allow identification of residual metabolic-areas after therapy. Moreover, in 
most tumours, a heterogeneous FDG uptake pattern before treatment is observed, 
where the high FDG uptake areas were often not in the centre of the tumour. This 
opens the potential prospect for clinically relevant radiation dose redistribution within 
the tumour. However, at first it has to be established whether resistant areas within 
the tumour can be defined on the basis of pre-treatment imaging. As a first step, we 
investigated the patterns of residual metabolic areas (based on FDG uptake) within the 
primary tumour after high-dose radiotherapy, mostly preceded by chemotherapy. In 
28 out of 55 patients, FDG persisted in the areas with a high uptake before radiother-
apy. The residual areas were located almost completely (OF > 91%) within the GTV. 
The residual FDG positive areas largely corresponded (OF > 70%) with the 50% SUV 
high uptake area of the pre-RT scan. The average volume of this 50% SUV threshold 
was 39% of the original GTV volume. The volume of the residual FDG-positive areas 
was on average 22% of the GTV volume. The hotspot within the residual area 
(90%SUV) was completely within the GTV (OF=100%), and had a high overlap with the 
pre-radiotherapy 50%SUV threshold (OF>84%). On basis of these findings, we conclude 
that residual metabolic active areas within the tumour can be identified using a single 
pre-RT FDG-PET-CT scan. A quantitative voxel-based analysis between the metabolic 
state of a tumour voxel after treatment and pre-treatment parameters, such as dose 
and GTV volume, was analyzed by Petit et al.36. 
 
Some limitations to our study should be addressed. First, of the 55 included patients, 
28 had residual FDG uptake, of which 6 (21 %) had to be excluded because of progres-
sive disease (1 patient), large tumour deformation (2 patients) or because FDG-uptake 
in the surrounding tissues made accurate delineation of the tumour area impossible (3 
patients). Improvements in deformation analysis and better delineation methods are 
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needed to include these patients in the analysis. Second, the 50% of SUVmax threshold 
value was found to be the most suitable amongst several other threshold levels. This 
threshold was not only chosen because it yielded good results, but also because it is a 
simple and reproducible method and the delineation software is available in clinical 
settings. A lower threshold would result in boosting the entire tumour and not only the 
most resistant areas, whereas a too high threshold would lead to only a few voxels to 
be treated, which is difficult to radiate with the equipment used currently. Third, our 
surrogate endpoint, persistent FDG uptake in the tumour, should not be regarded as 
equivalent to tumour persistence, nor does metabolic complete response equals cure. 
However, in agreement with literature 29, the present data show that survival of pa-
tients with persistent FDG uptake is significantly worse than those without, underlining 
its clinical validity. Fourth, for the image registration between the pre and post-scans a 
regid registration was performed, not incoorperating deformable tissue changes, pos-
sibly induced by the delivered therapy. This could be improved by using deformable 
registration techniques. However, these are difficult to validate and the reproducibil-
ity, especially in different institutes, is limited.  
 
We show in clinical data that high FDG areas within the tumour before radiotherapy 
can identify areas with residual metabolic-activity, which are probably more radio-
resistant. Due to the spatial resolution of the FDG-PET imaging, this could only be per-
formed on a macroscopic scale, i.e. voxel level. However, carefully designed future 
trails should provide the basis to test the assumption if FDG uptake reflects “radio-
resistance”, by boosting high FDG uptake areas. It obviously may be argued that the 
FDG uptake in the tumour does not reflect a single biological characteristic of the tu-
mour, but is influenced by many pathways that are related to therapy-resistance 27. 
Indeed, more specific tracers, such as 18F-misonidazol, may be useful for dose-painting 
within the tumour as well 37. 
 
In conclusion, our results show that the residual metabolic-active areas within the tu-
mour after radiotherapy of chemo-radiation, is located in the high FDG uptake areas 
before therapy and can be delineated. This will be the basis for new clinical studies 
with dose redistributions according to pre-radiotherapy FDG uptake. 
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ABSTRACT 
Purpose 
It was recently described that on the basis of one pre-treatment 18F-deoxyglucose 
(FDG)-PET-CT scan, radio-resistant areas within lung tumors could be defined. To vali-
date these results, we assessed the overlap-fraction (OF) of the high FDG-uptake areas 
pre-radiotherapy with the residual metabolic-active areas post-radiotherapy in an in-
dependent dataset. 
 
Methods and Materials 
Data from nineteen patients at Princess Margaret Hospital with lung cancer were ana-
lyzed. All patients underwent two FDG-PET-CT scans, one pre-radiotherapy (pre-RT) 
and one approximately three months post-RT. Sixteen patients showed residual FDG-
uptake after RT in the primary tumor. Residual FDG-uptake was defined as the FDG-
uptake within the primary tumor higher than the uptake within the aortic-arch. Seven 
of these 16 patients were excluded due to large deformations between the scans (n=3) 
and because the residual disease was not clearly distinguishable from the surrounding-
tissue (n=4). Therefore, 9 patients were included for further analysis.  Auto-
delineations based on several threshold-levels relative to SUVmax were performed on 
the pre- and post-RT FDG-PET-CT scans within the primary-tumor. The volumes and 
OF’s of these pre- and post-RT delineations were calculated. 
 
Results 
The mean volume of the residual metabolic-active areas was 20%±18% (mean±SD) 
compared to the mean volume of the gross tumor volume (GTV) pre-RT. The residual 
metabolic-active areas largely corresponded with the pre-RT GTV (OF=88%±15%). The 
pre-RT-scan threshold delineations of 34%,40% and 50% of the SUVmax had a large OF 
with the residual region, 81%±21%, 71%±21% and 57%±24%, respectively. The mean 
volumes of the 34%,40% and 50% uptake areas pre-RT were 58±47%, 43±31% and 
26±20% of the GTV pre-RT. 
 
Conclusions 
In this independent dataset, we confirmed that the location of residual FDG-uptake 
areas after radiotherapy corresponds with the high FDG-uptake areas pre-
radiotherapy. Therefore a pre-radiotherapy FDG-PET-CT scan can be used to identify 
the area that could be selectively boosted with a higher radiotherapy dose. 
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INTRODUCTION 
Lung cancer is still one of the most lethal solid tumors with a 5-year survival of about 
20% in stage III non-small cell lung cancer (NSCLC) 1,2. Although concurrent chemo-
radiation therapy improves local tumor control and long-term survival compared to 
sequential chemotherapy and radiotherapy (RT), local tumor failure is still observed in 
a significant proportion of stage III NSCLC patients 2-5. 
 
Local tumor control could be improved by radiation dose-escalation 6-8. However, 
modeling studies suggest that at least 120 Gy would be required to achieve 90% local 
tumor control 8. Delivering these high doses is presently not feasible because of dose-
limiting normal tissue toxicity. A possible solution would be to re-distribute the dose 
within the tumor, thus delivering higher doses to the most radio-resistant areas 9-11. 
Recent research has shown that tumors are not homogeneous structures, but display 
significant intra-tumor variability in biological characteristics such as perfusion, hy-
poxia, cell density, and proliferation, which may result in areas of radio-resistance 12-14.  
 
Radiation dose re-distribution within the tumor is only possible when the radio-
resistant areas within the tumor can be determined. Since it has been shown that high 
uptake of F-deoxyglucose (FDG) in the primary tumor is associated with decreased sur-
vival and local control in NSCLC patients 15-17, it is logical to hypothesize that the higher 
the FDG uptake, the more metabolically active and more radio-resistant it may be to 
radiotherapy. This was indeed shown in a recent study 18. In the present study, we 
validated these findings in an independent group of patients that not only included 
NSCLC, but also small cell lung cancer (SCLC) patients.  
 
In the present study, we assessed the overlap fraction (OF) of the pre-radiotherapy 
high FDG-uptake areas inside the primary lung tumor with the residual metabolic-
active areas 3 months post-radiotherapy found on PET-CT scans. The purpose of this 
investigation is to validate the finding that high FDG uptake pre-treatment could be a 
good predictor to localize the resistant areas within the tumor. 
MATERIAL AND METHODS 
Subjects 
Nineteen patients treated at Princess Margaret Hospital with lung cancer, 14 with 
NSCLC and 5 with SCLC with various stages were included.  Patients were treated with 
concurrent chemo-RT (n=11), RT alone (n=5) or sequential chemo-RT (n=3). The mean 
age of the patient group was 67.4 ± 11.6 years (range: 43-80 years). Patients included 
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in the study were treated from February 2007 until December 2007. For each patient 
two FDG-PET-CT scans were available: the first scan was acquired before the start of 
RT, and the last approximately 3 months after the end of RT. Health Canada approved 
the use of FDG-PET-CT imaging in radiotherapy treatment planning and local Research 
Ethics Board approval was obtained for this research. The collected data were analyzed 
for the purpose of this retrospective study. 
Radiothrapy simulation 
Patients were simulated on a PET-CT-simulator with both arms above the head in an 
immobilization device. For the FDG-PET-CT scans a PET/CT Discovery ST-16 scanner (GE 
Healthcare, Milwaukee, USA) was used. After a minimum fasting time of 6 hours after 
which the blood glucose level was tested, 5 MBq/Kg, up to a maximum of 500 MBq 
of18F-Fluoro-Deoxy-Glucose (FDG) was administered intravenously, followed by a 30 ml 
saline flush. The patients were encouraged to rest during the uptake time of at least 60 
minutes (mean pre-RT uptake time is 72 minutes, mean post-RT uptake time is 76 
minutes), after which the PET-CT-scans were acquired. All patients also received a free 
breathing four-dimensional (4D) CT scan (Discovery ST, GE, Waukesha, WI) covering 
the complete thoracic region for planning purposes. 
Radiotherapy planning 
CT images corresponding to the exhale and inhale phases of respiration were trans-
ferred to the treatment planning system (Pinnacle, version 7.6c, Philips Radiation On-
cology Systems, Milpitas, CA) using the exhale phase as the primary data set. This pri-
mary dataset was fused to the CT component of both PET-CT datasets using the rigid-
body registration algorithm available in Syntegra. A physicist and physician prior to 
contouring assessed the quality of the registration. 
Both the gross tumor volume (GTV) in the exhale phase and in the inhale phase were 
contoured on the 4D CT dataset by an experienced radiation oncologist, without using 
the initial FDG-PET data. These contours were copied onto the datasets containing reg-
istered PET-CT data and modified according to FDG uptake visualization. A 5 mm mar-
gin incorporating microscopic disease was added to the inhale and exhale GTV con-
tours to generate the corresponding clinical target volume (CTV) contours. These in-
hale and exhale CTV contours were then fused to produce the internal target volume 
(ITV). A 5 mm uniform margin around the ITV determined the planning target volume 
(PTV). A 3D conformal plan for radiotherapy treatment was prepared and the individ-
ual dose was calculated according to the current departmental standards at Princess 
Margaret Hospital.  
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Image analysis 
The pre-RT and post-RT scans were used for image analysis, and was analyzed using 
the Pinnacle treatment planning system. The GTV contour, which was delineated on 
the exhale phase of the pre-RT 4D CT scan, was used for image analysis purposes. Ad-
ditionally, high FDG uptake areas in the pre-RT scan within the primary tumor were 
contoured, using the thresholds 34%, 40%, 50%, 60%, and 70% of the maximal SUV 
within the primary tumor. These thresholds correspond to the thresholds of the Dutch 
study 18, in which the 34% threshold was found to correspond best to the GTV.  
On the post-RT scan, residual disease was defined as an uptake within the location of 
the primary tumor higher than the Standardized Uptake Value (SUV) of the aortic arch 
in the same scan 19. In addition, the commonly used fixed thresholds of SUV 2.5 and 
SUV 5.0 were delineated in the post-RT scan. Furthermore, for the post-RT scan, high 
FDG uptake areas using the thresholds 70%, 80% and 90% of the maximal SUV within 
the residual disease were contoured.  
 
Figure 1 
Schematic representations of delineations within the primary tumor on the pre-radiotherapy 
scan and within the residual disease on the post-radiotherapy scan.  On the pre-scan the gross 
tumor volume (GTV) and the 34%, 40%, 50%, 60% and 70% SUVmax FDG-PET uptake areas were 
delineated.  On the post-scan the residual disease and the 70%, 80%, and 90%SUVmax FDG-PET 
uptake areas within the residual uptake area were delineated.  As an example, the overlapping 
volume and the Overlap Fraction (OF) of the 50%SUVmax FDG high-uptake zone pre-
radiotherapy with the residual uptake area are illustrated. 
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The images of the post-RT scan were fused with those of the pre-RT scan using an 
automatic rigid registration algorithm. This automatic fusion was based on the bony 
anatomy (spine) at the level of the tumor, using a so-called clip box. If necessary, minor 
manual adjustments based on tissue surrounding the tumor were made to adjust the 
automatic fusion. After contouring on both scans, the overlap volume of all possible 
combinations of pre-RT and post-RT contours were determined using the Region Of 
Interest (ROI) expansion/contraction toolbox in Pinnacle. The volumes of these struc-
tures were also computed.  Finally, the overlap fraction (OF) was calculated, defined as 
the volume of overlap divided by the smallest volume of the two delineations 18, 20.  
A schematic representation of this method can be found in Figure 1. All data were ex-
pressed as mean ± standard deviation (SD). 
 
Table 1: Patient characteristics of the 9 patients with residual metabolic active areas after RT 
Patient 
Age 
Histology 
Stage 
TTD(Gy) / Fractions 
O
TT(days) 
Days pre-scan – RT 
Days RT - post scan 
Treatm
ent 
Response 
GTV volum
e (cm
3) 
SU
Vm
ax Pre-RT 
SU
Vm
ax Post-RT 
SU
V aorta Post-RT 
1 78 NSCLC T2N2M0 36/12 15 18 56 RT SMD 26.7 14.8 3.9 2.6 
2 62 NSCLC T2N2M0 66/33 30 35 83 conc CT-RT PMR 95.5 28.3 10.6 3.6 
3 48 NSCLC T1N2M0 45/25 36 7 42 conc CT-RT PMR 5.7 5.2 7.7 3.3 
4 71 NSCLC T3N2M0 85/33 45 19 62 RT PMR 191.2 15.6 5.6 2.8 
5 79 NSCLC T1N2M1 36/12 26 9 57 RT PMR 7.5 10.9 6.8 3.2 
6 74 NSCLC T4N0M0 66/33 20 12 93 conc CT-RT PMR 131.8 30.4 11.1 3.3 
7 59 SCLC Limited 40/15 25 9 114 conc CT-RT PMR 25.9 10.9 4.3 3.2 
8 62 NSCLC T2N0M0 36/12 18 2 72 seq RT-CT PMR 32.6 10.0 4.6 2.8 
9 56 NSCLC T2N2M1 36/12 16 12 56 seq RT-CT SMD 155.8 14.6 8.3 2.4 
Mean: 64.4    25.6 13.6 70.6   74.7 15.6 7.0 3.0 
Std: 10.6    10.0 9.6 22.5   70.3 8.4 2.7 0.4 
min: 56    15 2 42   5.7 5.2 3.9 2.4 
max: 79    45 35 114   191.2 30.4 11.1 3.6 
NSCLC = non small cell lung cancer. SCLC= small cell lung cancer. RT = radiotherapy alone. Conc 
CT-RT = Concurrent chemo-radiotherapy. Seq RT-CT = sequential radiotherapy and chemother-
apy. TTD = total tumor dose. OTT = overall treatment time (only RT). GTV = Gross Tumor Volume. 
SUV = Standardized Uptake Value. 
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Figure 2 
Representative images of a pre-RT FDG-PET-CT scan (upper) on a post-RT FDG-PET-CT scan 
(lower). The white line corresponds with the GTT. The thin gray lines correspond with the CTV and 
SUV thresholds in the pre-RT scan of 34%, 50%, 60% and 70%, respectively. The bold black line 
indicates the residual FDG-uptake higher than the aortic arch. The blod gray lines correspond 
with the SUV thresholds in the post-RT scan of 70 and 80%, respectively. 
RESULTS 
Patient Characteristics 
Ten of the nineteen patients were excluded from analysis. Firstly, patients who did not 
show residual disease in the last scan were excluded. Three patients were excluded for 
that reason: two of them were excluded because the residual uptake was lower than 
the SUV of the aortic arch and the third only showed residual uptake in the lymph 
nodes. Secondly, another four patients were excluded because the tumor was not de-
finable from the surrounding tissue on the post-RT scan. In two cases this was caused 
by radiation pneumonitis. In the other two cases it was impossible to distinguish be-
tween the tumor and the heart or great vessels due to the location of the tumor. Last 
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Figure 3 
Overlap fractions (OF) of the pre-radiotherapy with the post-radiotherapy relative (A) and abso-
lute (B) SUVmax thresholds are shown. OF’s of the post-radiotherapy residual-areas with a higher 
uptake than the aortic arch are shown in both figures. All data were expressed as mean ± stan-
dard deviation (SD). 
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ly, three patients were excluded due to large tumor deformations.  Therefore the 
analysis was performed on nine patients. Additional information about the patients 
included in this study can be found in Table 1. 
 
Overlap fractions 
Figure 2 shows the pre and post-RT FDG-PET-CT scan of a representative patient with 
several pre-RT and post-RT delineations. It can be clearly seen, that the residual meta-
bolic area appears at the high FDG uptake zone of the pre-RT scan. The residual areas 
were mainly located within the original GTV (OF = 87.5%±14.7%). This was also the 
case for the 70% and 80% SUVmax thresholds. The OF of these thresholds with the 
GTV were 94.6%±14.2% and 92.2%±17.2%, respectively. The 90% SUVmax was 100% 
located within the GTV.  The pre-RT-scan threshold delineations of 34%, 40% and 50% 
of the SUVmax had a large OF with the residual regions of 81%±21%, 71%±21% and 
57%±24%, respectively. The overlap fractions are shown in Figures 3a and 3b. 
Threhold volumes 
The relative volumes of the delineated areas on the pre-RT scan are shown in Figure 
4a. It can be clearly seen that the automatically contoured high FDG uptake areas were 
small compared to the GTV volume: 58.1%±46.6% for the 34%-threshold; 25.5%±19.7% 
for the 50%-threshold and only 6.1%±7.6% for the 70% threshold.  
The relative volumes of the delineated areas on the post-RT scan are shown in Figure 
4b. Here it can also be clearly seen that the automatically contoured high FDG uptake 
areas were small compared to the GTV volume: 20.2%±17.8% for the residual disease 
based on the uptake higher than the aortic arch and 2.5%±2.0% for the threshold of 
70%. The areas contoured by the absolute thresholds of SUV 2.5 and 5.0 were also 
quite small: 33.6%±22.2% resp. 2.6%±3.5%. 
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Figure 4 
Volumes of the SUV thresholds of the tumor pre-radiotherapy (A) and post-radiotherapy (B). All 
volumes (A and B) are relative to the pre-radiotherapy gross tumor volume (GTV). All data were 
expressed as mean ± standard deviation (SD). 
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DISCUSSION 
The identification of radio-resistant areas within the tumor would be of great impor-
tance for it is a prerequisite for redistribution of the dose in the tumor, which could 
improve the outcome in lung cancer patients treated with radiotherapy 10, 21, 22. Re-
cently, it was found that the high-uptake areas of FDG in the tumor before therapy 
identify radiation-resistant zones 18. These areas remain at the same position during 
treatment and are identifiable on the pre-treatment FDG-PET-CT scan and are thus 
suitable for selective dose re-distribution within the tumor 9, 20. Moreover, a clear 
relationship between the SUV of the FDG uptake in the tumor and the tumor control 
probability has been described 23. The results were nevertheless never validated in an 
independent data set. 
 
In the present study, residual metabolic activity after treatment was found in the areas 
that were most FDG-avid before therapy. The residual FDG uptake areas largely corre-
sponded with the 40% SUV uptake zone on the pre-RT scan, resulting in an overlap 
fraction of 71%. The 40% SUV high uptake area corresponds to 43% of the volume of 
the original tumor volume, which is comparable with the results in MAASTRO 18. The 
residual areas were located almost completely (OF = 87%) within the gross tumor vol-
ume, and always within the planning target volume, indicating no geographical miss. 
Also, the hotspot within the residual areas (90% SUVmax) was completely within the 
GTV (OF=100%). It has to be noticed that the absolute values of the thresholds of the 
high-uptake areas and the volumes differ in the present series from the Dutch publica-
tion 18. This may be due to the PET protocol that differed substantially, the inclusion of 
a variety of tumor stages and treatments, the smaller number of patients and the in-
clusion of both NSCLC and SCLC.  This underscores the necessity for thorough stan-
dardization before multi-center studies can be launched 24. 
The differences in volumes and standard deviations between the patient groups of 
MAASTRO and PMH may be caused by the patient groups: In this study both NSCLC 
and SCLC patients are included, in the Dutch group only NSCLC patients. A limitation of 
the present study is the large proportion of excluded patients due to deformation and 
high uptake in surrounding tissues, which made it impossible to delineate the tumor 
properly. However, to the best of our knowledge, no validated methods have been 
designed to solve the problem of registration of images with time intervals of weeks.  
 
Nevertheless, this validation study shows again that a single pre-RT FDG-PET-CT scan 
can identify the areas within the tumor that contain cells that will show persistent FDG 
uptake post-RT, thus pointing to defined areas in the primary tumor that might be 
beneficial for boosting. 
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SUMMARY 
It was recently described that high FDG-uptake areas pre-radiotherapy largely corre-
spond with residual metabolic-active areas post-radiotherapy. Here, an independent 
prospective validation confirmed these results using an overlap-fraction calculation of 
various FDG-uptake based thresholds. These results show that high FDG-uptake pre-
radiotherapy represent a potential target for radiation boosting. 
ACKNOWLEDGEMENTS 
The authors acknowledge financial support from the Dutch Cancer Society (KWF: fel-
lowship granted to H.J.W.L.A.), as well as technical and financial support from Siemens 
MI. 
  
Prospective Validation of Residual Activity  57
INTRODUCTION 
Lung cancer is one of the most frequent and lethal solid tumours 1. Although the prog-
nosis has improved, the 5-year survival is about 20% in locally advanced non-small cell 
lung cancer (NSCLC) 2, 3. While concurrent chemo-radiation improved local control and 
long-term survival compared to traditional sequential (chemo-) radiotherapy, local 
tumour failure is still observed in the majority of patients 4-6. Improvements in local 
tumour control can be achieved by escalating the radiation dose, where local control 
rates over 90% can be reached for tumour doses of 120 Gy 7, 8. However, the problem 
is that tumour dose escalation is limited by the radiation toxicity of normal tissues such 
as the lungs and the spinal cord.  
 
A solution to this problem may be found in the intra-tumour heterogeneity. It has be-
come increasingly clear that tumour tissue is often not homogeneous, but can have 
large spatial variations with different biological characteristics, like perfusion, hypoxia, 
cell density, proliferation and subsequent radio-resistance 9-14. Therefore, a strategy to 
increase the dose to more radio-resistant areas within the tumour, while reducing the 
dose to more susceptible zones, can result in better local control rates with the same 
healthy tissue toxicity 15.  
 
A strategy to determine the location of the radio-resistant areas within the tumour is 
the use of non-invasive imaging. Since high pre-treatment 18F-deoxyglucose (FDG) up-
take levels in the primary tumour result in lower survival in patients with NSCLC 16-18, 
we hypothesized that the regions with high FDG uptake before treatment identify 
more radio-resistant areas within the tumour. If true, an increased survival could be 
expected from radiation dose redistribution according to FDG uptake pre-
radiotherapy. In an earlier study, we demonstrated that this hypothesis holds true for 
a group of NSCLC patients in MAASTRO Clinic (Maastricht, The Netherlands) 19. Here, 
we report on an independent prospective dataset to validate that the high FDG uptake 
areas pre-radiotherapy identify the residual metabolic active areas post-radiotherapy. 
MATERIAL AND METHODS 
Patient Characteristics 
Twelve patients of Radboud University Nijmegen Medical Center (Nijmegen, The Neth-
erlands) with inoperable non-small cell lung cancer (NSCLC), UICC stage II-III, eleven 
treated with sequential chemo-radiotherapy and one with radical radiotherapy (RT) 
alone. The sequential chemo-radiotherapy schedule consisted of 1 to 3 cycles of cis-
platin and gemcitabine before the start of RT. Patients were included from June 2007 
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until August 2008. Mean age was 66.2±9.5 years (range: 52-83 years).Two FDG-PET-CT 
scans were available for each patient. The first scan was performed before start of RT 
while the second scan was performed approximately three months after the end of 
RT.For the patients receiving sequential chemo-radiotherapy was the pre-RT scan per-
formed after the chemotherapy. No treatment was given to any of the patients be-
tween the end of RT and the post-RT scan. 
Radiotherapy Simulation and Planning 
Patients were simulated in radiotherapy position on a CT-simulator, multislice spiral CT 
scanner (Philips AcQsim, Philips, Cleveland, USA) with both arms above the head. For 
the FDG-PET-CT scans a Siemens Biograph (Siemens/CTI, Knoxville, Tennessee, USA) 
was used. An intravenous injection of 250 MBq FDG (Covidien, Petten, The Nether-
lands)was followed by 10 ml normal saline. After a 60 minutes uptake period, during 
which the patient was encouraged to rest, PET-CT images were acquired. 
Radiotherapy planning was performed on a Pinnacle (version 8.0d; Philips Radiation 
Oncology System, Madison, WI, USA), the radiotherapy planning system routinely used 
which is based on a convolution algorithm using inhomogeneity corrections. The Gross 
Tumour Volume (GTV) and the Planning Target Volume (PTV) were defined for all pa-
tients, based on PET and CT data. The Clinical Target Volume (CTV) was defined as the 
GTV with a 5 mm margin incorporating microscopic disease. Subsequently, this CTV 
was expanded with 1 cm to draw the PTV to incorporate the internal respiratory mo-
tion and setup errors. A 3D conformal treatment plan was calculated on the PTV for all 
patients according to ICRU 50 guidelines. Dosimetric values were calculated on the 
basis of dose-volume histograms and dose distributions on each axial CT plan. 
Image Analysis 
The pre- and post-RT scans were analyzed and delineated using the Siemens TrueD 
system (Version VC-30, Siemens A.G., Darmstad, Germany). On the pre-RT scan, the 
location and volume of the FDG uptake within the GTV were quantified using the 
threshold 34, 40, 50, 60 and 70% of the maximal SUV (SUVmax). On the post-RT scan, 
residual metabolic areas were defined as FDG uptake higher than in the aortic arch 
(SUV>SUVaorta) 
20. Within the residual FDG-positive areas, the high FDG uptake areas 
were defined using the thresholds 70, 80, and 90% of the tumour SUVmax. Using an 
automatic rigid-registration algorithm, based on mutual information of the CT scans, 
the images of pre-RT scan were fused to the post-RT scan on the Siemens TrueD sys-
tem. If the automatic registration showed a large deviation between the two CT scans, 
the images were manually registered on the anatomy surrounding the tumour, e.g. the 
bony anatomy or large vessels. The contours of the FDG-based thresholds on the post-
RT scan were then transformed to the pre-RT scan using the derived registration ma-
trices. The contours of the pre- and post-RT scan were exported from TrueD as DICOM-
Prospective Validation of Residual Activity  59
RT structure sets. Using MATLAB (R2008b, The MathWorks Inc, Natick, MA, USA) the 
overlap fractions (OF) and volumes of these contours were calculated. The overlap 
fraction was defined as the volume of overlap divided by the smallest volume 19, 21. By 
using this methodology it is possible to assess which threshold on the pre-RT scan 
matches the residual disease on the post-RT scan. All data are expressed as mean ± 
standard deviation (SD) and range.  
RESULTS 
Patient characteristics 
To assess whether the location of the residual metabolic active areas are located 
within the initial FDG-high uptake areas of the primary tumour, two 18Fluorode-
oxyglucose (FDG) PET-CT scans were analyzed for all patients, one before radiotherapy 
(pre-RT) and one after radiotherapy (post-RT). Of the twelve analyzed patients, four 
patients showed no residual FDG uptake on the post-RT scan and had a complete 
metabolic response. The other eight patients showed residual FDG uptake within the 
primary tumour (SUVmax > SUVaorta). One of these patients had a residue that was not 
clearly distinguishable from the surrounding tissue due to FDG avid inflammation. 
Therefore, seven patients remained for further analysis. 
Overlap of FDG-uptake before RT with residual areas 
In Figure 1, pre- and post-RT CT-PET images are shown of a representative patient. The 
high FDG uptake areas (50% SUVmax) on the pre-RT scan and the location of the resid-
ual areas on the post-RT scan are shown. The residual areas are transposed to the pre-
RT scan, to show the overlap with 50% SUVmax high uptake area pre-RT. Visual evalua-
tion shows that the location of the residual areas largely corresponds with the high 
FDG uptake areas pre-RT. 
Overlap fractions of the FDG based thresholds 
Figure 2A depicts the overlap fractions and volumes of the FDG uptake based thresh-
olds within the primary tumour pre-RT and post-RT. Here it is shown that the residual 
areas were mainly located within the original GTV (OF=93.7±7.2% [range: 82.8-100]). 
Also, the 70%, 80% and 90% SUVmax high-uptake areas within the residual areas 
showed a high overlap with the GTV volume (OF = 93.5±10.6% [range: 71.6-100%], 
94.2±11.5% [range: 69.6-100.0%], and 96.1±10.2% [range: 73.0-100%] respectively).  
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Figure 1 
Representative FDG-PET-CT images of a patient pre- and post-radiotherapy. The light line indi-
cate the 50%SUVmax FDG high uptake area pre-radiotherapy. The dark lines indicate the residual 
metabolic active areas post-radiotherapy, also transposed on the pre-radiotherapy scan. Visual 
evaluation shows a large correspondence between the residual areas post-radiotherapy with the 
high FDG uptake areas pre-radiotherapy.  
 
Also, the pre-RT FDG uptake thresholds had a large overlap with the residual areas. 
The 34% threshold pre-RT had an OF with the residual areas of 86.9±8.3% [range: 77.2-
98.2%] and with the high-uptake areas within the residue. Moreover, the same is true 
for the pre-RT 40% and 50% SUVmax high FDG uptake area (OF = 77.4±8.1% [range: 
67.7-89.9%] and OF = 67.9±6.8% [range: 61.5-82.6%]). This pre-RT 50% SUVmax area 
also largely corresponded with the 70-90% SUVmax high-uptake areas within the resi-
due. 
Volumes of the FDG based thresholds 
The volumes of the FDG based thresholds within the primary tumour pre-RT and the 
post-RT thresholds are shown in Figure 2B. The FDG uptake areas (40-70% SUVmax) 
within the tumour on the pre-RT scan were small compared to the GTV. The 40% SU-
Vmax encompassed 46.4±14.4% range: [23.0-66.5%] of the original GTV, whereas this 
was 35.8±11.8% [range: 19.6-54.7%] for the 50% SUVmax, 23.9±7.8% [range: 13.2-
37.5%] for the 60% SUVmax, and 12.9±5.1% [range: 8.2-23.3%] for the 70% SUVmax 
threshold.  
 
The volume of the residual metabolic active areas on the post-RT scan was 14.6±10.0% 
[range: 4.3-31.2%] of the pre-RT GTV (Fig. 2B). The relative volumes of the high uptake 
areas within the residual areas were very small: 11.9±7.7% [range: 2.9-15.8%] for the 
70% SUVmax, 5.8±4.9% [range: 0.8-15.6%] for the 80% SUVmax, and 1.9±2.0% [range: 
0.3-6.1%] for the 90% SUVmax threshold. 
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Figure 2 
A: Overlap-fractions (OF) of the pre-radiotherapy thresholds with the post-radiotherapy relative 
thresholds. The OF of the post-radiotherapy residual-areas are indicated with the black-bars. The 
other bars indicate the OF with the high FDG-uptake (70-90%) areas within the residue. The data 
are expressed as mean ± standard deviation (error-bars).  B: Volumes of the SUV thresholds of 
the tumour pre- and post-radiotherapy. All volumes are relative to the pre-radiotherapy gross 
tumour volume (GTV). The data are expressed as mean ± standard deviation (error-bars). 
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DISCUSSION 
In radiation oncology there is an growing interest to increase the radiation dose to-
wards more resistant tumour areas whilst reducing the dose to less resistant areas 
within the tumour 15. In the present study, we confirmed in a prospective study the 
results that the areas of high FDG uptake within the tumour before treatment would 
allow identification of residual metabolic-areas after therapy 19. Together with the re-
sults of the previous study, where it was demonstrated that the high-uptake areas of 
FDG within the tumour remained stable during a course of fractionated radiotherapy 
for NSCLC 21, radiation boosting of these zones might be beneficial. 
 
Here, we have shown that the residual FDG uptake areas after treatment largely corre-
sponded to the 50% SUVmax within the tumour before treatment, resulting in an over-
lap fraction of 68%. This was similar with the previous obtained results 19, where the 
overlap between these contours was 71%. The volume of the residual FDG-positive 
areas was on average 15% of the initial GTV volume. The hotspot within the residual 
area (90%SUV) was almost completely within the pre-RT GTV (OF=96%), and had a high 
overlap with the pre-radiotherapy 50%SUV threshold (OF>74%). Based on these re-
sults, we conclude that residual metabolic active areas within the tumour can be iden-
tified before treatment using a FDG-PET-CT scan.  
 
The pre-radiotherapy 50% SUVmax threshold had a volume that encompassed 35% of 
pre-treatment GTV, similar with previous results (39%). This makes the 50% SUVmax 
threshold value a suitable threshold for future radiation boosting target to improve 
local control, not only because it yields good results, but also because it is a simple, 
reproducible, and robust method between institutions. A lower threshold would result 
in boosting the entire tumour and not only the most resistant areas, whereas a too 
high threshold would lead to only a few voxels to be treated, which is often impossible 
due to organ motion or dose delivery constraints. 
 
A limitation of our study is that for the registration between the pre and post-scans a 
rigid registration was performed, not incorporating the non-rigid tissue changes possi-
bly induced by radiotherapy. This could be improved by using deformable registration 
techniques. However, these are difficult to validate and the reproducibility, especially 
in different institutes, is limited.  
 
In conclusion, our previous results were prospectively validated in an independent 
dataset in another institute, showing that the residual metabolic-active areas within 
the tumour after (sequential chemo-) radiotherapy are located in the high FDG uptake 
areas before therapy and can be delineated. This information is the basis for an ongo-
ing randomized phase II trial to test the hypothesis that high FDG uptake areas reflect 
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“radioresistance”, by redistribution the dose according to pre-radiotherapy FDG up-
take areas. 
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ABSTRACT 
Background 
As individual tumors are heterogeneous, including for 18F-deoxyglucose (FDG) uptake 
and most likely for radioresistance, selective boosting of high FDG uptake zones within 
the tumor has been suggested. In order to do this, it is critical to know whether the 
location of these high FDG uptake patterns within the tumor remain stable during a 
course of radiotherapy.  
 
Methods 
Twenty-three patients with stage I-III non-small cell lung cancer (NSCLC) underwent 
repeated FDG-PET-CT scans before radical radiotherapy (day0), and at day7 and day14 
of radiation. On all scans, high and low FDG uptake regions were auto-delineated using 
several standardized uptake value (SUV) thresholds, varying between 34% and 80% of 
the maximal SUV. Volumes and overlap fractions (OF) of these delineations were calcu-
lated to demonstrate the stability of the high FDG uptake regions during treatment.  
 
Results 
The mean OF of the 34% uptake zones at day0 with day7 and day14, was 82.8±8.1% 
and 84.3±7.6% respectively. The mean OF of the high uptake zones (60%) was 
72.3±15.0% and 71.3±19.7% at day0 with day7 and day14 respectively. The volumes of 
the thresholds varied a lot, e.g. at day0 the volume of the 60% zone was 
16.8±20.3cm3. Whereas the location of the high FDG uptake patterns within the tumor 
during treatment remained stable, the delineated volumes varied a lot. 
 
Conclusions 
The location of the low and high FDG uptake areas within the tumor remained stable 
during radiotherapy. This knowledge may enable selective boosting of high FDG uptake 
areas within the tumor. 
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INTRODUCTION 
Lung cancer remains one of the most frequent and lethal solid tumors 1. Although the 
prognosis has improved, in locally advanced disease the 5-year survival is 20 % at best 
2-5. The higher long-term survival observed with concurrent chemo-radiation compared 
to sequential chemotherapy and radiotherapy was due to improved local tumor con-
trol, emphasizing the importance of local tumor control on survival 4,5. However, local 
tumor failure is still observed in a large amount of patients. Moreover, the major toxic-
ity of concurrent regimens excludes its use in the majority of lung cancer patients be-
cause of their co-morbidity.  
 
An important strategy to improve the effect of radiotherapy is to escalate the radiation 
dose, because a higher dose has been shown to yield a higher local control rate 6. 
However, the total tumor dose is often limited due to constraints of surrounding nor-
mal tissue. Therefore innovative strategies are needed to obtain higher local tumor 
control rates. Until quite recently, tumors were viewed as homogeneous structures, 
with similar biological characteristics. It has become increasingly clear, however, that a 
tumor is heterogeneous for varying characteristics 7-11. Indeed, molecular imaging stud-
ies showed significant differences in perfusion, hypoxia, cell density and proliferation 
within the tumor 12. As these biologic characteristics are heterogeneously distributed 
throughout the tumor, the current practice to deliver a uniform dose-distribution 
seems illogical. It has been suggested to re-distributing dose, i.e. more resistant areas 
within the tumor could receive higher doses whilst reducing the dose to more suscep-
tible zones, keeping normal tissue exposure similar 12,13.  
 
Molecular imaging might be useful to identify radioresistant areas. However, the reso-
lution of molecular imaging is in the order of millimeters. This is a large scale compared 
to the heterogeneity of tumor tissue. For instance, the distance between well oxygen-
ated tissue and hypoxic regions can be well below 100 μm, which is well below the 
resolution of Positron Emission Tomography (PET) 14. The voxel intensity thus repre-
sents an average over the voxel and small highly hypoxic regions will not be observed, 
if they are in close proximity to well oxygenized tissue. At present, it is thus not clear 
whether the resolution of molecular imaging is sufficient to outline the biological het-
erogeneity in a meaningful way for dose painting. 
 
Previously, we demonstrated that the maximal 18F-deoxyglucose (FDG) uptake does 
not remain stable during a course of radiotherapy, and a large intra-patient heteroge-
neity was found 15. One of the essential remaining questions to be answered before 
selectively boosting parts of the tumor, is whether the locations within the tumor that 
show a high tracer uptake remain stable throughout a course of fractionated radio-
therapy. As the uptake of FDG in the primary tumor is prognostic for survival of pa-
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tients with non-small cell lung cancer (NSCLC), both treated with surgery or radiother-
apy 16-20, we investigated the stability of the areas of FDG uptake in the primary tumor 
of NSCLC patients during their treatment with fractionated radiotherapy.  
MATERIAL AND METHODS 
Patient characteristics 
Twenty-three patients with medically inoperable (stage I, n=2) or locally advanced 
(stage III, n=21) histologically confirmed proven NSCLC, with a WHO performance of 
status 0-1 and good lung function (FEV1 ≥ 50 % and DLCO ≥ 50 %), were included in 
this study, starting from December 2004 until April 2006. Nineteen patients received 
induction chemotherapy, consisting of three courses of Gemcitabine in combination 
with Cisplatin or Carboplatin. In the period this study was performed, induction che-
motherapy followed by radiation treatment was the standard schedule. Therefore no 
concurrent chemotherapy was given. All patients enrolled in this study were treated as 
part of a feasibility study with High-dose Continuous Hyperfractionated Accelerated 
Radiotherapy (HI-CHART) 21. The dose was delivered in three steps from 61.2 Gy/34 
fractions/23 days to 64.8 Gy/36 fractions/24 days to 68.40 Gy/38 fractions/25 days 
(1.8 Gy BID with 8 h interval), using 3D conformal technique) 21.The Medical Ethics 
Committee according to the Dutch law approved the trial. All patients gave written 
informed consent before entering this study. 
Radiotherapy simulation  
A treatment planning PET-CT scan in radiotherapy position was performed for simula-
tion, and a 3D conformal treatment plan, using three to six coplanar 10 MV photon 
fields, was calculated according to the ICRU guidelines 22. Patients were positioned 
with both arms above the head and on an immobilization and patient laser marker 
system.  Radiotherapy technologists trained specifically for this purpose always carried 
out the simulation. The PET-CT scanner used was a Siemens Biograph (SOMATOM Sen-
sation-16 with an ECAT ACCEL PET scanner). An intravenous injection of 18F-Fluoro-
Deoxy-Glucose (FDG) (Tyco Health Care, Amsterdam, The Netherlands) of (weight * 4 + 
20) MBq was followed by 10 ml physiologic saline. After a 45 minutes uptake period, 
during which the patient was encouraged to rest, PET and CT images were acquired. A 
spiral CT with intravenous contrast was performed covering the complete thoracic re-
gion. 
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Radiotherapy planning 
Radiotherapy planning was performed on an XiO (Computerized Medical Systems, St 
Louis, Missouri) treatment planning system, using inhomogeneity corrections, based 
on a convolution algorithm. For all patients, the Gross Tumor Volume (GTV) and the 
Planning Target Volume (PTV) were defined, based on PET-CT data. Multiple GTV vol-
umes were created in case of nodal involvement. The Clinical Target Volume (CTV) was 
defined as the GTV with a 5 mm margin incorporating microscopic disease. The heart 
and esophagus were excluded from the CTV. This CTV was subsequently expanded 
with 1 cm to the PTV to incorporate the internal respiratory motion and setup errors. 
Contouring of the lungs was carried out automatically by the treatment planning sys-
tem. For the calculation of the mean lung dose (MLD), the volume of both lungs ex-
cluding the gross tumor volume (GTV) was used 23. The spinal cord was drawn 
throughout the whole CT scan and was considered to be at the inner margin of the 
bony spinal canal. Dosimetric values were calculated on the basis of dose-volume his-
tograms and dose distributions on each axial CT slice. 
Radiotherapy dose and normal tissue dose constraints  
For each patient, the radiation dose was escalated to a mean lung dose (MLD) of 19 ± 1 
Gy while respecting a maximum spinal cord dose of 54 Gy, with a maximal allowed to-
tal tumor dose (TTD) of 79.2 Gy. There were no esophageal dose constraints. Radio-
therapy was delivered twice a day (BID), and with a fraction size of 1.8 Gy. 
Study design 
The PET-CT scan for treatment planning, before radiotherapy, was defined as day 0. 
There were no scans used prior to induction chemotherapy. During the course of ra-
diotherapy, the patients underwent repeat PET-CT scans, one week (day 7) and two 
weeks (day 14) after the start of treatment. At all time points, the scans were analyzed 
and delineated using the Siemens TrueD system (Siemens A.G., Darmstad, Germany). 
Using a rigid registration based on mutual information the images of day 7 and 14 
were fused to day 0. Using a region of interest (ROI) manager a manual region was se-
lected around the tumor, avoiding high uptake areas like the heart. Within this region 
automatic contour delineations were generated using the thresholds 34, 40, 50, 60, 70, 
80 % of the maximal SUV (SUVmax). The 34% threshold is indicative for GTV in most lung 
tumors, and is correlated with pathology and validated with phantom measurements 
22,24. The contour delineations were exported from TrueD as DICOM-RT structure sets. 
MATLAB (The MathWorks Inc.) was used to calculate the overlapping fractions (OF) 
and volumes of the structure sets. The overlap fraction was defined as the overlapping 
volume of the structure sets, divided by the volume of the smallest structure set: 
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,                  (1) 
 
whereV1and V2stands for the volumes of the structure sets,  denotes the union, and 
min(V1,V2) is the smallest of V1 and V2. The OF was computed for all tumors and 
thresholds in three dimensions. The OF varies between 0 (no overlap between the 
structures) and 1 (complete overlap of one structure with the other). A schematic rep-
resentation of the OF calculation is shown in figure 1. For all patients the PET-CT data-
sets were available at day 0 and day 7. However, due to technical and logistical prob-
lems, only for 17/23 (74%) patients a complete image dataset at all three time points 
was available.  
 
 
Figure 1 
Schematic figure of the overlap fraction calculation, show the overlap of two volumes (V1 and 
V2). The overlap fraction was defined as the overlap (gray area) of the two volumes, divided by 
the smallest volume (in this case V1). 
 
Data are expressed as mean ± standard deviation (SD). Statistical differences between 
paired parameters from the three time points were evaluated in SPSS (SPSS 12.0.1 for 
Windows, Chicago, IL) using the Wilcoxon signed rank test. Differences were consid-
ered to be significant when the p-value was less than 0.05. For the triple tests, a Bon-
ferroni correction was applied and p < 0.0167 was considered significant. It should be 
noted that the power of the test was limited due to the small number of patients 
(n=23). However, the power was sufficient to find clinically relevant differences. 
 
I
1 2
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I
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Figure 2  
PET-CT images of three patients before treatment (day 0), and during treatment (day 7 and 14). 
The dark contours indicate the 60% of the maximal standardized uptake value (SUVmax) thresh-
old. Visual inspection shows that the location of the hotspot remains at the same location during 
treatment, however the volume of the hotspot changes. 
RESULTS 
Patient characteristics 
The mean age of the 23 patients (17 males, 6 females) was 66.1 ± 9.0 years [range: 52-
80 years]. The mean prescribed TTD was 61.7 ± 9.3 Gy [range: 46.8 - 79.2 Gy] in 1.8 Gy 
fractions twice daily in a mean overall treatment time (OTT) of 24 ± 4 days [range: 17 - 
31 days]. The corresponding MLD and maximal spinal cord dose were 16.1 ± 3.6 Gy 
[range: 6.8– 20.7 Gy] and 46.2 ± 13.1 Gy [range: 6.8 – 57.1 Gy], respectively. The GTV 
of the primary tumor before radiotherapy was 91.9 ± 146.9 cm³ [range: 0.4 – 660.2 
cm³]. The first repeat scan (day 7) was performed after the patient received on average 
a dose of 21.3 ± 5.0 Gy (about 12 fractions) and the second scan (day 14) after 38.4 ± 
4.9 Gy (about 21 fractions).  
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Figure 3 
Overlap fractions (in %) of day 0, 7 and 14 for the maximal standardized uptake value (SUVmax) 
thresholds ranging from 34–80%. The error-bars indicate the standard deviation. The 34-60% 
hotspots show a large overlap (>70%) for all time points. The I indicates the difference between 
the overlap of day 0-7 and day 0-14, II between day 0-14 and day 7-14, and III between day 0-7 
and 7-14 of the 34% threshold. 
Repeated PET-CT images 
In figure 2 representative PET-CT images of 3 patients before treatment (day 0), and 
during treatment (day 7 and 14) are shown. Visual inspection of the 60% SUVmax zones 
shows that the location of the hotspot remains in the same region of the tumor during 
treatment for all three patients. However, the volumes of the 60 % threshold changed 
considerately during treatment, compared to day 0.  
Overlap Fractions 
The overlap fractions of the different SUV thresholds are shown in figure 3. The 34-
60% thresholds show a large overlap (>70%) for all time points. The 70 and 80% 
thresholds show less overlap, however still the overlap is on average above 50%. The 
limited OFs applying these thresholds were due to the low volumes of the 70% (8.6 ± 
9.4 cm3, range: 0.5 - 36.8 cm3) and 80% (3.5 ± 3.9 cm3, range: 0.4 - 15.2 cm3) thresholds 
on day 0, often only a few image voxels.There was no significant difference between  
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Figure 4 
Volumes of the 50% maximal standardized uptake value (SUVmax) threshold, relative to the vol-
ume before treatment, of all patients were plotted vs. the number of days during radiotherapy 
(dotted lines). A large inter-patient variation is visible during radiotherapy. The bold black line is 
the average relative volume together with the standard deviation. The average varied non-
significant between the time-points. Due to the normalization to the volumes of day 0, no error-
bars are present at this time-point.  
the OFs of all the thresholds (34-90%) of day 0-7 with the OFs of day 0-14 (Fig 3, exam-
ple 34%, see I). The same applied to the OFs of the thresholds of day 0-14 and day 7-14 
(see II). In line with these results also no significant difference between the OFs of day 
0-7 with day 7-14 was found (see III) (results not shown). 
Threshold Volumes changes during radiotherapy 
A remarkable heterogeneity of the changes in the volumes of the different thresholds 
was observed. To illustrate this heterogeneity the volumes of the 50% SUVmax thresh-
old were plotted versus timepoints before and during radiotherapy (Fig. 4). The results 
of the 50% threshold are representative for the other thresholds. A striking inter-
patient variation is visible between the time-points, showing both a large SUV in-
creases and decreases during time. In figure 5 all volumes of the different thresholds, 
relative to the volume before treatment (day 0), were plotted for the three time-
points. A large deviation of all volume changes during treatment can be seen.Again no 
significant difference can be seen between the relative volumes of day0, day7 and day 
14 (see I, II, III) (results not shown).  
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Figure 5 
Volumes of thresholds of the maximal standardized uptake value (SUVmax), relative to the volume 
before treatment (day 0), were plotted vs. the number of days during treatment and for the SUV 
thresholds. The error-bars indicate the standard deviation. Due to the normalization to the vol-
umes of day 0, no error-bars are present at this time-point. A large deviation of all volumes dur-
ing radiotherapy can be seen. The average varied non-significantly between all the time-points. I, 
II, and III indicate the differences between the relative volumes of the 34% SUV threshold. The I 
indicates the difference between the volume of day 0 and day 7, II between day 7 and 14, and III 
between day 0 and 14 of the 34% threshold. 
DISCUSSION 
There is a growing interest in Radiation Oncology to selectively target radio-resistant 
areas within the tumor. This research is to a large extent driven by the availability of 
molecular imaging techniques that enable to visualize and quantify areas with different 
characteristics within the tumor 7-10,12. The aim is to move away from the current para-
digm of delivering a homogeneous physical dose distribution to the tumor to biological 
conformality by creating a heterogeneous dose pattern reflecting intra-tumor variation 
in biological factors of importance for response to radiation 25-27. Before launching 
clinical trials, one main issue to be resolved is the question whether the areas within 
the tumor associated with a high FDG uptake remain stable during a course of radio-
therapy.  
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We decided to investigate the time-trends of the intra-tumor uptake of 18F-
deoxyglucose (FDG) in the primary tumor of patients with NSCLC treated with radical 
radiotherapy, as the maximal uptake of this tracer is prognostic for survival of patients 
with NSCLC, both treated with surgery or radiotherapy 16-20. Moreover, results of our 
group suggest that the evolution of the maximum FDG uptake during radical radio-
therapy for NSCLC may be prognostic for survival 15.  
 
Our results show that the mean overlap fractions (OF), which were used to demon-
strate the stability in localization of FDG uptake regions during radiotherapy, of the low 
uptake zones before radiotherapy and at day 7 and 14 during therapy remained stable 
at about 83%. Also the mean OF of the high uptake areas within the tumor remained 
stable throughout a course of radiation at about 71%. However, the volumes varied 
considerably, e.g. the 60% threshold had a volume of 16.8 ± 20.3 cm3. Bosmans et al 
also reported a large heterogeneity of tumor volume changes, where the delineation 
was based on CT images 28. We therefore concluded that the location of the high FDG 
uptake regions within the tumor during treatment remained stable, although the vol-
umes of the thresholds can vary a lot between different time points.  
 
To the best of our knowledge, these are the first data showing the stability of FDG up-
take during radiotherapy for NSCLC. Indeed, although several papers have been pub-
lished on theoretical radiation delivery to inhomogeneous parts of the tumor, none 
have investigated in real patients whether the areas remain stable during fractionated 
radiotherapy 13, 29-33. Our results show that although the volumes of the tumor and 
hence the high and low FDG uptake areas within the tumor may vary considerably dur-
ing a course of radiotherapy, the location of the hot and cold spots within the tumor 
remain stable. This is not obvious, as a tumor is a complex, dynamic tissue that re-
sponds to injury. Our results nevertheless support the hypothesis that on a more mac-
roscopic, i.e. voxel level, the areas with a high FDG uptake reflect intrinsic differences 
of parts of the tumor that are not easily disturbed by radiotherapy. Therefore, dose 
painting may be feasible, as repeated PET imaging during radiotherapy is not necessary 
to identify changes in the high uptake areas. Repeated CT scans taken at different time 
points to measure changes in tumor volume may be sufficient for this purpose 28. 
 
One may argue the choice of FDG as a tracer for radio-resistance. Indeed, FDG uptake 
in the tumor does not reflect a single biological characteristic of the tumor, but is in-
fluenced by many pathways that are related to therapy-resistance 19. However, as FDG 
uptake in the primary tumor has repeatedly shown to affect the prognosis of patients 
with NSCLC 16-20, and together with its wide availability, we believe that FDG is still a 
rational choice in this respect. However, this study may not be representative for other 
PET tracers, like FMISO or FLT, and comparable studies have to be repeated. 
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The choice of the thresholds to define high and low uptake areas was based on several 
standardized uptake value (SUV) threshold based auto-delineations varying between 
34 % and 80 % of the maximal SUV. Evidence on which threshold to choose is sparse 22 
and the threshold value will depend on target to background ratio, reconstruction al-
gorithm and type of scanner 34. Nevertheless, there are studies showing a good corre-
lation between pathology and PET-based auto-contouring for NSCLC 22,24.For future 
boosting studies, by redistributing the dose within the tumor, the selected high dose 
region may be identified with FDG PET scans. However, the actual region to boost is 
still not completely clear. The region can be defined as a SUV above an absolute value 
(e.g. SUV > 5.0), however the region can also be defined as a threshold of SUVmean or 
SUVmax like used in this study (e.g. 60% of SUVmax). Future 4D-CT-PET studies and plan-
ning studies have to answer if CTV margins have to be applied to these regions, to cor-
rect for tumor motion and setup errors. 
 
In conclusion, our results show that the high FDG uptake areas within the tumor re-
main stable during a course of radiotherapy, although the volumes may change con-
siderably. This knowledge may further enable the design of clinical studies investigat-
ing the possibility of selective boosting of therapy-resistant areas within the tumor.  
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ABSTRACT 
Background and purpose 
The epidermal growth factor receptor (EGFR) is overexpressed in a significant percent-
age of human malignancies and its expression is associated with tumour aggressive-
ness and treatment resistance. The monoclonal antibody cetuximab (IMC-C225) blocks 
the ligand binding domain of EGFR with high affinity, preventing downstream signalling 
resulting in tumour growth inhibition. We developed and characterized a novel imag-
ing probe using Oregon Green 488 labelled cetuximab to evaluate its usage as an imag-
ing agent to target EGFR. 
 
Materials and Methods 
Cells with varying expression levels of EGFR or a mutant form of EGFR, called EGFRvIII, 
were used for in vitro validation. Thein vivo binding of labelled cetuximab to EGFR was 
also assessed ex vivo on tumour material. 
 
Results 
The development of Oregon Green 488 labelled cetuximab was successful, demon-
strating binding to both EGFR and EGFRvIII in vitro. Accumulation was also found in 
vivo, which was confirmed by histopathology using anti-EGFR antibodies. However, 
significant mismatch highlights differences between drug delivery in vivo, and cell ex-
pression levels of EGFR. 
 
Conclusions 
The monoclonal antibody cetuximab represents a promising probe to evaluate the bio-
logic and pharmacokinetic effects of in vivo cetuximab binding to EGFR. It not only 
visualizes the presence of the wild type EGFR, but also the presence of the mutant 
EGFRvIII. 
  
Imaging of EGFR and EGFRvIII  83
INTRODUCTION 
The epidermal growth factor receptor (EGFR) plays an important role in tumour cell 
proliferation, differentiation and survival 1,2. EGFR is highly expressed in a significant 
percentage of human malignancies and its expression is associated with tumour ag-
gressiveness and treatment resistance 3-6. Increasing evidence suggest that alterations 
within theEGFR gene may be as important as EGFR-overexpression to induce onco-
genic effects. The most common variation is an in-frame deletion of exons 2-7 of the 
coding sequence resulting in a truncated mutant (EGFRvIII) which lacks a portion of the 
extracellular ligand-binding domain. Even though no ligand binding occurs, the tyrosine 
kinase in the intracellular portion is constitutively activated, leading to a receptor tyro-
sine autophosphorylation. EGFRvIII is expressed in certain tumours and its expression 
promotes tumour growth and therapy resistance 7-9. 
 
Blockade of EGFR function provides a promising approach for cancer treatment 10-12. It 
has been shown that the human chimeric monoclonal antibody cetuximab (IMC-C225) 
blocks the ligand-binding domain of EGFR by binding to EGFR with high affinity, pre-
venting downstream signalling which results in tumour growth inhibition 13-16. Conse-
quently, cetuximab has evolved as a promising new targeting agent in oncology and is 
increasingly used in combination with chemo-/radiotherapy as standard treatment of 
solid tumours and/or metastases 14,17-19. Due to the heterogeneity of EGFR expression 
and its modulation during treatment, an imaging tool to monitor and visualize the 
binding of cetuximab non-invasively in cancer patients would be of great advantage, 
resulting in better patient selection for anti-EGFR targeted therapy. In addition, it could 
dramatically increase our knowledge of the clinical use of cetuximab and would help to 
optimize and individualize treatment. 
 
A few studies have already reported on attempts to monitor cetuximab binding by us-
ing radioisotopes, where EGFR-positive tumours have been visualized both in animal 
models and in patients using 99mTc 20,21 or 64Cu 22 labelled cetuximab. However, limita-
tions exist in using radioisotopes in the laboratory in a daily practice. Therefore, we 
developed an Oregon Green 488 labelled cetuximab imaging probe (cetuximab-OG) to 
assess the biological properties of cetuximab as an imaging and targeting agent. Here, 
we report the development and an in vitro and in vivo evaluation of a cetuximab based 
imaging probe to target EGFR and/or EGFRvIII. 
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MATERIAL AND METHODS 
Oregon Green 488 labelling of cetuximab 
Cetuximab (2 mg/ml; Merck, Germany) was dialyzed against Hepes-buffered saline 
(HBS: 25 mM Hepes pH 7.4, 175 mM NaCl) after which the protein concentration was 
determined by A280 measurement (ε1%280nm = 14.2). Cetuximab (12.1 µM; 155 kDa; 25 
ml) was incubated with succinimidyl-acetylthioacetate (SATA) at 25 µM (final concen-
tration). Cetuximab-(Lys)-ATA was de-acetylated by treatment with 50 mM hydroxyl-
amine, 2.5 mM EDTA at pH 7.4 for 1 h yielding cetuximab-(Lys)-SH. Incubation with 1 
eq (mol/mol) of Oregon Green 488 (OG488)-maleimide resulted on average in a 1:1 
labelling of cetuximab with OG488. Every reaction step was followed by analysis of 6 
pmolessamples of the intermediate and final reaction product by MALDI-TOF mass 
spectrometry (Applied-Biosystems MALDI TOF/TOF 4800) in linear high mass mode 
using sinapinic acid as a matrix. 
In vitro cell model 
Human epidermoid carcinoma (A431), breast carcinoma (T47D), glioblastoma (U373, 
U87), cervix adenocarcinoma (HeLa), colorectal carcinoma (HT29, LS174T, HCT116) and 
prostate cancer (DU145) cells were obtained from the American Type Culture Collec-
tion (ATCC) and maintained under standard conditions in the appropriate medium 
supplemented with 10% Fetal Bovine Serum (Hyclone, Logan, UT). U373 cells were 
transfected with phβAc.EGFRvIII using Lipofectamine Plus (Invitrogen) according the 
manufacturers procedures. 48h post transfection, geneticin selection was performed 
to obtain cells stably expressing EGFRvIII. The clone with the highest EGFRvIII expres-
sion, denoted U373-vIII(+), as assessed by immunoblotting, was selected for further 
experiments. A clone with no EGFRvIII expression was selected as control, denoted 
U373-vIII(-). For all experiments, cells were plated at a density of 0.5 x 106 per 6 cm 
dish the day before. 
Immunoblotting  
Cells were extracted in RIPA lysis buffer for 30 min on ice and protein concentrations 
were determined by a Bradford assay (Bio-Rad). Proteins were separated on a 10% 
SDS-polyacrylamide gel and transferred (100 V, 1h, 4°C) to nitrocellulose membranes 
(Amersham Corp.). Membranes were blocked (ON, 4°C) with 5% Blotting Grade Blocker 
non-fat dry milk (BioRad) and subsequently incubated (2h, RT), with a 1:1000 dilution 
of the anti-EGFR rabbit polyclonal antibody (sc-03, Santa Cruz Biotechnology, Santa 
Cruz, CA). Proteins were visualized by a horseradish peroxidase method using En-
hanced Chemiluminescence (Amersham Corp.). Mouse monoclonal β-Actin (Sigma) 
was used as loading control. 
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Immunofluorescence 
Immunocytochemistry was performed on cells grown on plastic 10cm dishes until 80% 
confluency and incubated with cetuximab-OG (60nM, 24h, 37°C). Cells were washed 3 
times using phosphate-buffered saline (PBS), fixed in 3mL methanol on ice (10 min). 
Propidium iodide containing 1µl/ml RNase (15min, RT) was used as nuclear marker. 
Immunohistochemistry was done on 7-μm frozen sections cut using a cryotome (Leica 
CM3050S). After thawing, the sections were fixed in cold (10 min, 4°C) acetone and 
rehydrated in PBS. In between the consecutive steps of the staining procedure, sec-
tions were rinsed with PBS. Sections were incubated overnight (4°C) with the primary 
EGFR antibody (sc-03, Santa Cruz), followed by incubation (30 min, RT) with goat anti-
rabbit Alexa fluor 594 conjugated IgG antibody (Molecular Probes). Cells and sections 
were mounted with Fluorescent Mounting Medium (DAKO) and analyzed using a Leica 
DM5000B fluorescence microscope (Leica Microsystems). The EGFR epitope binding 
sites of cetuximab (310-514) and sc-03 (1005-1016) are different 23. 
Quantitative analysis of the overlap between the cetuximab-OG and the EGFR antibody 
was assessed using the difference in fluorescence intensity. The images were normal-
ized using a multiplication of the median intensity. The overlap area of cetuximab-OG 
uptake and EGFR expression was calculated using a difference less then 20% of the 
maximum. 
Flow cytometric analysis 
After three hours of incubation with cetuximab-OG at 37 °C (concentration ranging 
from 5.2fM - 5.2µM), cells were put on ice, washed with PBS and harvested. After re-
suspension in PBS, the cetuximab-OG labelled cells were fixed with fresh 2% parafor-
maldehyde (30 min, RT). Single cell suspensions were obtained by passing cells through 
70µm nylon cell strainers (BD Biosciences). Mean fluorescence intensity was obtained 
using a FACSaria® flow cytometer (BD Biosciences) using FIT-C filter settings.  
Animal and tumour model 
Colorectal HT29 carcinoma cells were subcutaneously injected in NMRI-nu (nu/nu) fe-
male mice (28-32 gram) under anaesthesia. When tumours reached a volume of 500 
mm³, animals were injected with 100 µg cetuximab-OG via a lateral tail vein. After 5 
days, to ensure good uptake of cetuximab-OG into the tumour tissue, the animals were 
sacrificed and the tumours were excised. All animal experiments were in agreement 
with national guidelines, approved by the Animal Ethics Committee of the University 
‘KU Leuven’, Belgium. Isoflurane inhalation anaesthesia (induction 4% and mainte-
nance 1-2%) was used during all animal experiments. 
  
Chapter 6 86 
RESULTS 
Oregon Green 488 labelling of cetuximab 
Cetuximab was successfully labelled with OG488 at an average 1:1 stoichiometry (Fig. 
1A). After incubation of cetuximab with succinimidyl-acetylthioacetate (SATA), MALDI-
TOF mass spectrometry showed an approximate 100 Da increase of molecular weight 
(theoretical: 116 Da), showing that on average a 1:1 SATA-cetuximab reaction had oc-
curred (data not shown). Deacetylation by hydroxylamine resulted in a mass decrease 
of approximately 50 Da (theoretical: 42 Da) corresponding to the loss of one acetyl 
group and generation of a free sulfhydryl moiety on a lysine side-chain (data not 
shown). Incubation with 1 eq. OG488-maleimide for 2 h yielded cetuximab-OG in an 
average 1:1 stoichiometry according to MALDI-TOF mass spectral analysis (Fig. 1B). A 
total mass increase of 500 Da was observed, in good agreement with the mass increase 
of one OG488 (theoretical mass: 436 Da) coupled through one thioacetate linker (theo-
retical mass: 74 Da). 
  
By using the described random labelling procedure it is possible that lysine side-chain 
modification might affect protein function. When analyzing the crystal structure of the 
Fab fragment of cetuximab, 23 lysine residues are visible in the light (blue) and heavy 
chain (grey) that can be modified 23. However, only 1 lysine residue becomes apparent 
in the receptor-binding area of cetuximab (Fig. 1C) thereby minimizing chances on 
functional impairment of cetuximab by the labelling procedure. In addition, no signifi-
cant differences (P = 0.408) between non-labelled and labelled cetuximab (79 ± 3.7% 
and 72 ± 5%) were seen in a clonogenic survival assay using a therapeutic dose of 60 
nM on HT29 cells (Fig. 1D). 
In vitro analysis 
The cetuximab-OG binding to EGFR was first investigated in A431 cells using im-
munofluorescence (Fig. 2A). A clear membranous binding localization of cetuximab-OG 
was observed. In addition, we investigated if cetuximab-OG binds to EGFRvIII, using the 
U373-vIII(+) transfected cells. Also in these cells, membranous staining after incubation 
with cetuximab-OG was seen (Fig. 2B), indicating that cetuximab-OG binds not only 
EGFR, but also EGFRvIII. The EGFR fraction of the U373-vIII(+) transfected cells was lim-
ited, as assessed with immunofluorescence on the U373-vIII(-) cell line (data not 
shown). 
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Figure 1  
Labelling of cetuximab with Oregon Green-488. (A) Synthetic scheme of cetuximab (sphere C) 
labelling through its lysine side-chains (-NH2) by coupling succinimidyl-acetylthioacetate (SATA) 
followed by deacetylation by hydroxylamine (NH2OH), and subsequent reaction with Oregon 
Green 488 (OG488)-maleimide. (B) Linear MALDI-TOF mass spectrum of unlabelled and OG488-
labelled cetuximab showing the single and double charged state of the protein. (C) Crystal struc-
ture of the Fab fragment of cetuximab, adapted from 23, showing the 23 lysine residues in the 
light (dark) and heavy chain (light) that can be potentially modified. The binding site for EGFR is 
indicated. (D) Clonogenic survival of HT29 cells treated with non-labelled or OG-labelled cetuxi-
mab (60 nM), normalized to non treatment (blanc). 
 
Quantitative binding of cetuximab to EGFR was determined using a flow cytometry 
saturation experiment. Expression of EGFR and EGFRvIII was assessed with a panel of 
cell lines using Western blotting (Fig. 3A). As expected A431 cells demonstrated high 
expression of EGFR, while T47D cells showed limited expression. The U373-vIII(+) cells 
showed high expression of the EGFRvIII, while the U373-vIII(-) cells only demonstra- 
ted EGFR expression in comparable levels as the U373 cells. The other investigated cell  
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lines showed different levels of intermediate EGFR expression. In order to find the op-
timal experimental binding conditions a saturation experiment with the high (A431) 
and low (T47D) EGFR expressing cells was performed (Fig. 3B). Both cell lines were in-
cubated for 3 hours with cetuximab-OG, using a range of concentrations (5.2fM to 
5.2µM). Clear cetuximab-OG binding was observed in A431 cells, while the binding to 
T47D cells was comparable to background levels. The cetuximab-OG saturation point 
for A431 cells was 5.2nM. All other cell lines were analysed at this concentration to 
assure sufficient cetuximab-OG presence (Fig. 3C). T47D signals were used as negative 
control in all experiments. As shown previously, the cetuximab-OG binding to A431 
cells was high and on average 50-fold higher compared with the negative control. Also 
binding to U373-vIII(+) was high (on average 40-fold), showing primarily binding of 
cetuximab-OG to EGFRvIII. The other clinically relevant cells investigated showed in-
termediate binding of cetuximab-OG. Comparison between the binding profile of 
cetuximab-OG and the respective EGFR expression levels as determined by a densi-
tometric analysis, demonstrated a significant relationship (r² = 0.842, p = 0.001; data 
not shown). 
Ex vivo analysis 
To validate the use of the imaging agent in vivo, cetuximab-OG was injected in inter-
mediate EGFR-expressing colorectal HT29 tumour bearing mice. 120h later, the ani-
mals were sacrificed, tumours were excised and prepared for immunohistochemistry.  
Figure 2 
Immunofluorescence analysis of (A) A431 and (B) U373-vIII(+) cells incubated for 24h with 
cetuximab-OG. Propidium iodide was used for nuclear staining.  
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Figure 3 
(A) Western blot analysis of EGFR and EGFRvIII expression in cells with varying EGFR expression 
levels. 40 µg of protein was loaded on the gel. β-Actin was used as loading control. (B) FACS satu-
ration experiment of cetuximab-OG binding to EGFR using A431 and T47D, showing a saturation 
concentration at 5.2 nM. Data points are shown as mean ± SEM. (C) FACS analysis of cetuximab-
OG binding at saturation concentration to cell lines showing varying EGFR expression levels. In-
tensity levels of all cell lines were normalized to the intensity of the T47D cell line. With multiple 
measurements, the data points are shown as mean ± SEM. 
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Heterogeneous cetuximab-OG localization is shown in two representative tumour sec-
tions (Fig. 4).EGFR expression was assessed using the polyclonal EGFR antibody, which 
also showed a heterogeneous staining pattern. Merging both images demonstrated a 
partial mismatch between EGFR expression and cetuximab-OG tracer accumulation. 
The degree of match (and mismatch) was calculated by a difference map of represen-
tative sections of six tumours, where the intensity within 20% of the maximum was 
classified as overlap (a match), and larger as a mismatch. This resulted in an overlap-
ping area of 83.4 ± 5.9%, a mismatch of cetuximab-OG positive / EGFR negative of 7.9 ± 
5.3%, and a mismatch of cetuximab-OG negative / EGFR positive of 8.7 ± 2.1%. 
DISCUSSION 
We report the successful development of an Oregon Green 488 labelled cetuximab 
fluorescent imaging probe. Anticipating on future conjugation strategies of DTPA-
maleimide synthons to couple cetuximab or more general to antibodies 24 for use in 
MRI, PET, and SPECT imaging, we chose a coupling strategy, in which lysine side-chains 
were first converted to sulfhydryl moieties followed by reaction with sulfhydryl-
reactive maleimide-labels. No significant differences were found between labelled and 
non-labelled cetuximab preparations, indicating that cetuximab binding to EGFR is un-
affected by the labelling procedure. To evaluate the properties of cetuximab as an im-
aging probe, we assessed the in vitro binding of cetuximab-OG to EGFR. Cell lines ex-
pressing varying levels of EGFR, showed a corresponding accumulation of cetuximab-
OG. We also demonstrated binding of cetuximab-OG to U373 cells transfected for 
EGFRvIII. Mamot et al showed binding of cetuximab fragments to EGFRvIII expressing 
tumour cells in vitro25. However, there is no conclusive evidence that the whole 
cetuximab complex binds to EGFRvIII. 
 
Upon injection of cetuximab-OG in tumour bearing mice, we showed successful fluo-
rescent imaging of EGFR in the tumour specimen. However, the distribution of the 
cetuximab-OG binding was found to be very heterogeneous throughout the tumour. Ex 
vivo immunohistochemistry also showed heterogeneous staining patterns for EGFR. 
Using difference mapping, quantitative analysis of the overlap between EGFR expres-
sion and cetuximab-OG uptake level was performed, showing a mismatch of both high 
cetuximab-OG uptake with low EGFR expression, as visa versa. Possible explanations 
for this in vivo mismatch are multifactorial: poor drug delivery due to insufficient vas-
culature and perfusion of the tumour, dynamic tumour growth, and necrosis may limit 
the uptake of cetuximab. Also differences in internalization rates of the cetuximab-
EGFR complex may be cell type specific. However, the majority of cetuximab binding  
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Figure 4 
In vivo cetuximab-OG binding and ex vivo EGFR expression in HT29 tumours is shown in two rep-
resentative tumour sections (A and B). A merged image shows the mismatch between cetuximab-
OG and EGFR expression. Quantitative mismatch was assessed using an intensity difference map, 
showing overlap in yellow, mismatch of cetuximab-OG positive / EGFR negative in green, and 
mismatch of cetuximab-OG negative / EGFR positive in red. 
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was found at the cell membrane even at this time point. Importantly, these data indi-
cate that cetuximab uptake is dependent upon tumour factors in addition to EGFR ex-
pression levels. This may help to explain the poor correlation often reported between 
cetuximab efficacy and EGFR expression 26.  
 
An increasing number of studies report on the use of cetuximab for imaging purposes, 
most often using SPECT and PET radioisotopes in experimental tumour models 21,22. 
These studies however are limited by the short half life of the used isotopes (99mTc: 6 
hours and 64Cu: 12 hours). This short half life might be sufficient to perform imaging 
studies in mice, but for imaging studies in humans, longer durations are required to 
reach optimal tumour to blood ratios in humans as the biologic half life of cetuximab is 
longer in humans compared to mice 27. Based on the findings of Verel et al28, the posi-
tron emitter Zirconium-89 (89Zr) exhibits several advantages for the use with cetuxi-
mab. One advantage is the long physical half life of 89Zr (78 hour), sufficient for the 
long biologic half life of cetuximab in the blood pool. Another advantage is the label-
ling efficiency of cetuximab with 89Zr, because the immunoreactive fraction of the la-
belled complex stays above 95% 29, compared with 63% for 64Cu 22. Although the use of 
radioisotopes shows advantages when performing in vivo imaging, there is an urgent 
need for non-radioactive labelled probes for in vitro studies, to better understand the 
biological consequences of EGFR directed therapies. 
CONCLUSION 
We successfully developed an Oregon Green 488 labelled cetuximab imaging probe, 
which is able to bind EGFR and EGFRvIII in vitro, where quantitative binding of the 
cetuximab is correlated with EGFR expression levels. Furthermore, we demonstrated in 
vivo EGFR labelling after injection of cetuximab-OG. Thus, cetuximab-OG represents a 
promising imaging probe to further evaluate the binding properties of cetuximab and it 
can be used to visualize the presence of both EGFR and EGFRvIII. However,significant 
mismatch differences between cell EGFR expression levels and cetuximab uptake can 
be expected in vivo. 
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ABSTRACT 
Purpose 
The epidermal growth factor receptor (EGFR) is highly expressed in a significant num-
ber of human malignancies, and its expression is associated with tumor aggressiveness 
and overall treatment resistance. The monoclonal antibody cetuximab (IMC-C225) is 
increasingly used in clinical settings as a treatment modality in combination with more 
conventional therapies, such as radio- and chemotherapy. Currently, little is known 
about tumor-specific uptake and overall pharmacokinetics. Non-invasive quantification 
of cetuximab uptake could provide important diagnostic information for patient selec-
tion and therapy evaluation. To address this we have developed and validated a novel 
probe using cetuximab labeled with the long-lived positron emitter Zirconium-89 (89Zr) 
for positron emission tomography (PET) imaging. 
 
Methods 
Tumor cell lines with varying EGFR expression levels were used for in vivo tumor imag-
ing experiments. PET imaging with 89Zr-labeled cetuximab (3.75±0.14 MBq) was per-
formed on tumor-bearing NMRI-nu mice at multiple time-points post injection (ranging 
from 1 to 120 hours) and quantified by drawing regions of interest on selected tissues. 
Uptake was compared by biodistribution gamma-counting and ex vivo EGFR expression 
levels were quantified using Western blot analysis. 
 
Results 
Uptake of 89Zr-labeled cetuximab was demonstrated in the EGFR-positive tumors. 
However, the EGFR levels measured in vivo did not correlate with the relative signal 
obtained by PET. Tumor-to-blood ratios were significantly higher in the intermediate 
(compared with the high) EGFR-expressing cell lines starting from 24 hours post injec-
tion. Normal tissue uptake was unaffected by the different tumor types. Ex vivo 
gamma-counting experiments confirmed the observed in vivo PET imaging results. A 
similar disparity was found between 89Zr-labeled cetuximab tumor uptake and in vivo 
EGFR expression levels as demonstrated by Western blotting. 
 
Conclusions 
The 89Zr-labeled cetuximab imagingprobe is a promising tool for non-invasive evalua-
tion of cetuximab uptake. Our results demonstrate a disparity between in vivo EGFR 
expression levels and cetuximab uptake. In a general sense, the results indicate a dis-
parity between antibody uptake and expression levels of a biologic target in a tumor, 
suggesting that additional pharmacokinetic/pharmacodynamic mechanisms influence 
tumor delivery of this therapy. These additional mechanisms may explain why receptor 
expression levels alone are not sufficient to predict patient response.
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INTRODUCTION 
Over the past few decades monoclonal antibodies (mAbs) have increasingly been used 
as targeting agents in oncology and are currently the subject of many important clinical 
trials 1,2. One key biologic target for these mAbs is the epidermal growth factor recep-
tor (EGFR), a member of the ErbB family. EGFR has been shown to play an essential 
role in the upregulation of tumor cell proliferation, differentiation and survival 3,4. Acti-
vation of EGFR occurs when a ligand (e.g. epidermal growth factor or transforming 
growth factor alpha) binds to the extracellular ligand-binding domain, resulting in EGFR 
dimerization, internalization of the ligand-receptor complex and activation of the 
downstream signaling pathway. High EGFR expression is associated with tumor aggres-
siveness and overall treatment resistance, and is commonly found in a significant 
number of human malignancies 5,6. As a result, EGFR targeting has been explored as a 
possible anti-tumor strategy, where the extracellular ligand-binding domain or the in-
tracellular domain of the receptor is targeted with mAbs or small-molecule EGFR tyro-
sine kinase inhibitors (EGFR-TKIs) respectively 7,8. Both these therapies disrupt the 
EGFR signaling pathway, resulting in inhibition of cell cycle progression, decreased an-
giogenesis, and a reduced metastatic invasion 9.  
 
Cetuximab (IMC-225, Erbitux) is an example of a mAbs which blocks the ligand-binding 
domain of EGFR with high affinity, thereby preventing downstream signaling 9,10. Con-
sequently, cetuximab has evolved as a promising new therapy agent in oncology and is 
increasingly used in clinical trials, mainly in combination with chemo- or radiotherapy 
11,12. The overall pharmacokinetics of cetuximab are slow (elimination rate ranging 
from 66 to 97 hours), partly due to the large size (±152 kDa) of the antibody 13. Despite 
the extensive use of cetuximab in clinical settings, much is still unknown about the pa-
tient-specific pharmacokinetics and pharmacodynamics of its tumor uptake. This re-
sults in a lack of knowledge about the relationship between dosage and therapeutic 
effect. Also, a disparity between EGFR expression levels and treatment outcome has 
been reported 14-16, where even tumors negative for EGFR on biopsy responded to 
cetuximab treatment 17. Furthermore, it has been shown in patients that mAbs which 
inhibit EGFR are associated in a dose-dependent manner with several dermatological 
side effects. In general, cutaneous side effects were most common, and patients ex-
perienced a mild to moderate eruption which did not require withdrawal of treatment 
18. On the other hand, an adequate cetuximab dose must be used to obtain sustained 
tumor uptake, since the liver has the capacity to absorb infused antibody up to 40 mg. 
Higher doses result in liver saturation and consequently in sufficient tumor uptake 19. 
Therefore, the ability to monitor the in vivo cetuximab uptake in a non-invasive man-
ner could significantly increase knowledge of cetuximab’s clinical use as a targeting 
agent. We believe that this will eventually lead to the selective enrollment of patients 
and monitoring of cetuximab uptake before and during treatment. 
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Using cetuximab itself as an imaging agent has several advantages for visualizing its 
distribution in normal and tumor tissues. Several groups have therefore investigated 
cetuximab-based non-invasiveimaging probes, the majority with SPECT and PET iso-
topes 19-25. Some studies were limited by the use of relatively short half-life 
(t1/2)isotopes (
99mTc: 6 h and 64Cu: 12 h) which are incompatible with the long biologic 
half-life of cetuximab in the blood pool, and the relatively low immunoreactive fraction 
of the cetuximab radioimmunoconjugate 22. Another PET isotope often suggested for 
antibody imaging is Iodine-124, because its long half-life (t1/2 = 100.3 hours) allows im-
aging at later time points to acquire optimal information. However, an important dis-
advantage of Iodine-124 is the rapid degradation of the radioiodinated mAb upon in-
ternalization, resulting in the rapid clearance of iodine from the target cells. This leads 
to PET images with less tumor contrast and does not reflect the actual tumor uptake of 
the antibody 20. Based on the findings of Verel et al.26,27, the positron emitter Zirco-
nium-89 (89Zr) has ideal characteristics for usage with antibodies 28. 89Zrdemonstrates a 
long physical half-life (t1/2 = 78 hour) and, upon internalization of the antibody, is 
trapped intracellularly in lysosomes (phenomenon of residualization) 29,30. Moreover, 
radiolabeling of cetuximab with 89Zr does not influence its binding potential to EGFR, 
resulting in an immunoreactive fraction of about 95% 28. For these reasons, 89Zris an 
ideal radionuclide for the labeling of slow kinetic intact antibodies with high quality 
standards, and is successfully used in pre-clinical 31 and clinical settings 20,32,33.  
 
Here we report on the development and testing of the imaging probe 89Zr-labeled 
cetuximab, which was validated pre-clinically in mice bearing tumors with varying 
EGFR expression. Using PET imaging we assessed the in vivo cetuximab uptake levels 
and correlated those with the in vivo EGFR expression levels as determined by Western 
blotting. 
MATERIAL AND METHODS 
Synthesis of 89Zr-labeled Cetuximab 
89Zr was produced by a (p,n) reaction on natural yttrium-89 (89Y) as described by Verel 
et al.27. 89Zr labeling of the monoclonal antibody (mAb) cetuximab has been achieved 
as previously reported 28. Briefly, desferrioxamine B (Df) was succinylated (N-sucDf), 
temporarily filled with iron (Fe3+), and coupled to cetuximab using a tetrafluorophenol-
N-sucDf ester. The premodified mAb was purified on a PD10 column after removal of 
Fe3+ by transchelation to ethylenediaminetetraacetic acid (EDTA). Approximately one 
N-sucDf moiety was coupled per cetuximab, assessed by using 59Fe. Next, N-sucDf-
cetuximab was labeled with 89Zr in HEPES buffer at pH 7.0 and again purified on a PD10 
column to remove unbound 89Zr. The HPLC–isolated fractions demonstrated a radio-
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chemical purity in the order of 98%. Specific activity was typically in the range of 78 
MBq/mg. 
Animal and Tumor Model 
Exponentially growing human epidermoid (A-431; ATCC CRL-1555), breast (T-47D; 
ATCC HTB-133), glioblastoma (U-373 MG; ATCC HTB-17) and colorectal (HT-29; HTB-38) 
carcinoma cells were cultivated in the appropriate medium supplemented with 10% 
fetal bovine serum and incubated in a humidified 5% CO2 chamber at 37°C. Adult 
NMRI-nu (nu/nu) female mice (28–32 g) were inoculated subcutaneously in the lateral 
flanks with 3 x 106 cells resuspended in 100 µl growth medium. Tumors were meas-
ured using a Vernier Caliper in three orthogonal tumor diameters (A, B and C), each 
corrected for the thickness of the skin, and tumor volumes were calculated based on 
the formula A x B x C x π/6. Once tumor volumes reached an average of 400 mm³, 
animals were injected with 89Zr-cetuximab (3.75 ± 0.14 MBq) via the lateral tail vein. All 
procedures were performed according to the guidelines defined in “Principles of labo-
ratory animal care” (NIH publication no. 86–23, revised 1985). All animal experiments 
were in agreement with national guidelines, approved by the Animal Ethics Committee 
of the KU Leuven University, Belgium. Animals were given food and water ad libitum 
for the duration of the experiments. Isoflurane inhalation anesthesia (2% isoflurane in 
100% O2 at a flow rate of 1.5 L/min) was used during all animal experiments. 
PET Imaging and Analysis 
PET imaging was performed on a Focus 220 MicroPET (Concorde Microsystems Inc., 
Knoxville, TN) with an axial field of view of 7.6 cm and a resolution of approximately 
1.4 mm. For each animal, a custom-built alginate mold was made to obtain reproduci-
ble positioning in the opening of the camera between the imaging time points. Whole-
body scanning was performed with 95 axial slices each of 0.796 mm in a single field of 
view, yielding radioactivity concentration measurements in voxels of 0.633 by 0.633 by 
0.796 mm. After injection of 3.75 ± 0.14 MBq 89Zr-cetuximab (average dose of 100 µg) 
into the lateral tail vein for each animal a 25-min emission scan was performed (5 
frames each of 5 min) at 1, 4, 24, 48, 72 and 96 hours post injection (p.i.) with correc-
tion for random counts, dead time and decay. For the HT-29 and U-373 MG an addi-
tional scan at 120 h p.i. was also available. Each emission scan was preceded by a 10-
min transmission scan using external rods of 57Co for subsequent attenuation correc-
tion. Three-dimensional list-mode data were acquired using an energy window of 350–
750 keV and a coincidence timing window of 6 ns. The data were then sinogrammed 
and reconstructed iteratively in a 128 x 128 x 95 matrix using attenuation weighted 2D-
OSEM (Fourier rebinning, 16 subsets, 10 iterations and 5 EM iterations). The images 
were visualized with ASIPro VM software (version 6.3.3.0; Concorde Microsystems Inc., 
Knoxville, TN) and analyzed using MATLAB (Version 7.3, MathWorks Inc., Natick, NA). 
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For each data set, three-dimensional regions of interest (3D-ROIs) were manually 
drawn over the blood (heart outflow area), lungs, liver, kidneys, muscle, and tumors. 
Mean and maximum activity data (in Bq/ml) of the voxels within the ROIs were ob-
tained. All data were corrected for 89Zr decay towards injection and the injected dose 
(ID), and are therefore expressed as %ID/ml. Tumor-to-blood uptake ratios were calcu-
lated by dividing the activity data within the tumor ROI by the activity value within the 
blood ROI drawn on the outflow area of the heart. 
Immunoblotting  
Minced tumor pieces and cell pellets obtained from a 6 cm culture dish were extracted 
in RIPA lysis buffer (150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 50 
mM Tris-HCl pH 7.5, 1X protease inhibitor cocktail) for 30 min on ice, and protein con-
centrations were determined by a Bradford assay (Bio-Rad). Proteins were separated 
on a 10% SDS-polyacrylamide gel and blotted onto a nitrocellulose membrane (Amer-
sham Corp.) by electrotransfer. The membrane was blocked with 5% Blotting-Grade 
Blocker non-fat dry milk (Bio-Rad). Blots were probed with antibodies directed against 
EGFR (Santa Cruz Biotechnology) or β-Actin (Sigma). Bound antibodies were visualized 
using HRP-linked secondary antibodies (anti-rabbit [Cell Signaling Technologies] or 
anti-mouse [Sigma]) and ECL luminescence (Amersham Corp.). 
Biodistribution 
Following the last PET acquisitions, animals were sacrificed under anesthesia and dis-
sected. Blood, tumors, skin, sternum, heart, thymus, salivary glands, thyroid, trachea, 
lung, esophagus, liver, gal bladder, stomach, pancreas, spleen, ileum, colon, bladder, 
kidney, muscle, thighbone, brown fat, eyes, ears, cerebrum, cerebellum, medulla ob-
longata, fat and tail were washed and flushed with saline, weighed, and the amount of 
radioactivity in each tissue was assessed in a γ-well counter (1480 Wallac Wizard 3” 
Automatic Gamma Counter, PerkinElmer, USA). Tumors were cut into halves, one for 
quantification of 89Zr-cetuximab uptake and one rapidly frozen for protein isolation. 
Disintegrations for each sample were collected over one minute using an energy win-
dow between 48 and 1354 keV. To correct for decay, injection standards were counted 
simultaneously. Radioactivity uptake was calculated as the percentage of the injected 
dose per gram of tissue (%ID/g). 
Statistics 
All statistical analyses were performed with SPSS 12.0.1 for Windows (SPSS Inc., 2003, 
Chicago, USA). Graphs were drawn using Origin 6.0 (Microcal Software Inc., 1999, 
Northampton, USA). Correlations among the groups were assessed using a non-
parametric independent samples test (Kruskal-Wallis test). Further, to determine the 
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statistical significance of differences between two independent groups of variables, a 
non-parametric Mann-Whitney U-test for small groups was used. For all tests, p < 0.05 
was considered significant. 
RESULTS 
In Vivo Uptake of 89Zr-Cetuximab 
To evaluate the potential of 89Zr-cetuximab as an imaging agent, four cell lines with 
variable levels of EGFR expression were injected into NMRI-nu mice to form xeno-
grafts. A-431 was selected for high EGFR expression, U-373 MG and HT29 for interme-
diate, and T-47D for low EGFR expression, as previously described 16. The in vivo bind-
ing of 89Zr-cetuximab was assessed by performing PET imaging at 72 hours post injec-
tion (72 h p.i.) on tumor-bearing mice after injection of 100 µg 89Zr-cetuximab (figure 
1). A clear accumulation of 89Zr-cetuximab was found in the EGFR-positive tumors (U-
373 MG, HT-29, and A-431) compared with the low EGFR-expressing tumors (T-47D). 
Remarkably, a higher 89Zr-cetuximab uptake was demonstrated in the intermediate 
EGFR-expressing U-373 MG and HT-29 tumors compared with the high EGFR-
expressing A-431 tumor. The uptake in the low EGFR-expressing tumor T-47D was 
comparable with that in the surrounding tissues. A clear accumulation was seen in 
normal tissues like the liver, due to the hepatobiliar clearance of the antibody. Notable 
uptake was also found in the kidney.  
 
Imaging at several time points post injection was performed to assess the time-activity 
relationship of 89Zr-cetuximab uptake in the tumor. Figure 2 shows a representative 
time series of PET images of an HT-29 tumor-bearing mouse. From 24 h p.i., a clear 
localization of the tumors was seen above background uptake. The 89Zr-cetuximab up-
take accumulated with time and the highest tumor uptake was reached around 72–96 
h p.i. Furthermore, uptake of 89Zr-cetuximab was heterogeneously distributed within 
the tumor. Uptake in the outflow area of the heart decreased with time. Uptake in the 
liver also decreased, but more gradually so than that in the heart. 
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Figure 1 
Representative microPET images 72 hours after injectionof 89Zr-cetuximab. Mouse bearing U-373 
MG (left) or in HT-29 (center) tumors in both flanks. Mouse (right) bearing an A-431 and a T-47D 
(circled) tumor in the right and left flank respectively. The arrows indicate the tumors. Images at 
the mid-plane cross-section through the tumor are shown. The images are corrected for injected 
dose and decay, represented as %ID/ml. High uptake is found in the EGFR-expressing tumors (HT-
29, U-373 MG, A-431), while the uptake of the low EGFR-expressing tumor (T-47D) is comparable 
with the overall uptake in surrounding normal tissue. 89Zr-cetuximab uptake was also found in 
the catabolic organs: in the liver and kidneys (below tumors). 
 
Figure 2  
Time series of representative microPET images at indicated time points post injection of 89Zr-
cetuximab of a HT-29 tumor-bearing mouse. The red arrows indicate the tumors. Uptake levels 
plateaued from 72 hours post injection onwards. To allow comparison between the different time 
points, images are shown at the mid-plane cross-section through the tumor. The images are cor-
rected for injected dose and decay, and represented as %ID/ml. 
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Quantification of 89Zr-Cetuximab Uptake 
To quantify the uptake of 89Zr-cetuximab in the different tumor types, three-
dimensional regions of interest (3D-ROIs) were manually drawn over the heart (out-
flow area), lungs, liver, kidneys, muscle and tumors. Figure 3A shows the 89Zr-
cetuximab uptake in the different tumors at all investigated time points. The accumu-
lation in the intermediate EGFR-expressing tumors (U-373 MG and HT-29) was signifi-
cantly higher at all time points compared with the high (A-431) and low (T-47D) EGFR-
expressing tumors. Starting from 48 h p.i. the uptake levels differed significantly be-
tween all tumor types (i.e. uptake U-373 MG > HT-29 > A-431 > T-47D). Uptake in the 
U-373 MG and HT-29 rose significantly until 48 and 24 h p.i. respectively, and demon-
strated a plateau at about 9 %ID/ml and 7 %ID/ml respectively. For both tumor types, 
a 120 h p.i.time point was available, but tracer accumulation did not differ significantly 
from the 96 h p.i. time point. A similar uptake pattern was found for the A-431 tumors, 
although stable accumulation around 4 %ID/ml was seen from 24 h p.i. onwards. The 
low EGFR-expressing T-47D tumors showed no significant increase of 89Zr-cetuximab 
uptake with time (around 1 %ID/ml).  
 
Blood activity was measured using an ROI drawn on the outflow area of the heart. The 
89Zr-cetuximab uptake in the blood showed a clearance pattern as depicted in figure 
3B, starting from about 18 %ID/ml (at 1 h p.i.) to 3 %ID/ml (72–120 h p.i.). This uptake 
was not influenced by the different tumor types expressing varying EGFR expression 
levels. We also investigated whether 89Zr-cetuximab uptake in normal tissues was de-
pendent on tumor type; to this end, we quantified the uptake of 89Zr-cetuximab in sev-
eral normal tissue regions using the 96 h p.i. PET images (figure 4), since stable tumor 
uptake was found at that time point. Uptake in normal tissues was relatively low com-
pared with the tumor accumulation. Of the investigated tissues, liver and kidney up-
take was highest, since those are the antibody clearance organs (especially the liver). 
Small, but not significant, pharmacokinetic differences in normal tissue uptake be-
tween animals bearing different tumor types were found, indicating that the normal 
tissue uptake was not affected by differences in tumor uptake and vice versa. 
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Figure 3 
Quantification of 89Zr-cetuximab uptake from 1 to 120 hours post injection (p.i.). (A) Mean tumor 
uptake data for U-373 MG (n=4), HT-29 (n=4), A-431 (n=6) and T-47D (n=5) are shown and data 
are expressed as mean ± standard deviation. For the U-373 MG and HT-29 tumors, images were 
also available at 120 hours p.i. All data were corrected for decay and injected dose of 89Zr and 
are expressed as %ID/ml. (B) Mean blood uptake as measured in the outflow area of the heart. 
Data are represented as mean ± standard deviation for at least two independent mice. For com-
parison reasons, a non tumor-bearing mouse was included in the analysis. 
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Figure 4 
Normal tissue quantification of 89Zr-cetuximab uptake at 96 hours post injection from animals 
bearing U-373 MG (n=2), HT-29 (n=2), A-431/T-47D (n=3), A-431 (n=3), T-47D (n=2) and negative 
(n=1) tumor types. The data for the tumor-bearing mice are represented as mean uptake ± stan-
dard deviation. All data were corrected for decay and injected dose of 89Zr, and are expressed as 
%ID/ml. 
Tumor-to-Blood Ratios 
To assess the imaging potential of 89Zr-cetuximab, the tumor-to-blood activity ratios of 
the tracer were assessed. As shown in figure 3, an increasing tumor and a decreasing 
heart uptake was found, resulting in accumulating T/B ratios with time for the EGFR-
positive tumors (figure 5). The mean tumor-to-mean blood (mean T/B) ratios are 
shown in figure 5A. After 24 h p.i., all mean T/B ratios were significantly different be-
tween all the investigated tumor types (i.e. ratio U-373 MG > HT-29 > A-431 > T-47D). 
The intermediate EGFR-expressing tumors (U-373 MG and HT-29) showed a signifi-
cantly higher mean T/B ratio compared with the other tumors, reaching a plateau at 2 
(HT-29) to 3 (U-373 MG) from 72 h p.i. on. In addition, the 120 h p.i.time point showed 
no increase in mean T/B ratio for those tumor types. The mean T/B ratios for the A-431 
tumors increased until 48 h p.i. and demonstrated a plateau at 1.5. At no point did the 
mean T/B ratio of the T-47D tumors reach above unity.  
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Figure 5 
Tumor-to-blood ratios of 89Zr-cetuximab uptake from 1 to 120 hours post injection. The ratios 
represent the mean (A) or maximum (B) tumor uptake divided by the mean heart uptake. The 
data for U-373 MG (n=4), HT-29 (n=4), A-431 (n=6) and T-47D (n=5) are expressed as mean ± 
standard deviation. 
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Since tumors are known to be heterogeneous and the levels of heterogeneity between 
tumor types can differ, the mean and maximum uptake (i.e. the image voxel with the 
highest uptake) can vary considerably between different tumor types. Therefore, the 
maximum tumor uptake to mean blood (max T/B) ratios were also quantified (figure 
5B). However, a similar pattern of 89Zr-cetuximab uptake was found with the mean 
tumor-to-mean blood uptake ratios, although the max T/B ratios were higher for the 
EGFR-positive tumors. The max T/B ratio of the T-47D tumors also never reached 
above unity. Differences in tumor growth during the experiment between the tumors 
with varying EGFR expression could influence the mean and max T/B ratios. However, 
the growth rate of the different tumor types during the experiment was comparable, 
indicating that the T/B ratios were largely independent of the tumor growth. The vol-
ume at the end of the experiment relative to day 0 for U-373 MG was: 127 ± 33%, A-
431: 141 ± 22%, HT-29: 142 ± 17% and T-47D: 132 ± 24%. 
Gamma-counting Validation 
To validate the PET images and pharmacokinetics of 89Zr-cetuximab uptake, we per-
formed gamma-counting on ex vivo normal and tumor tissue. Our results demon-
strated that the U-373 MG tumors had the highest average uptake, followed by the 
HT-29, A-431; the lowest uptake was found in the T-47D tumors (figure 6A). Uptake in 
several selected normal tissues was available for A-431, T-47D, A-431/T-47D mixed and 
non tumor-bearing mice (figure 6B). No significant differences were found in normal 
tissue uptake between the mice bearing different tumor types. The uptake patterns, 
assessed using gamma-counting, were similar to the uptake obtained on the PET im-
ages. A full biodistribution was performed on the HT-29 tumor bearing mice (figure 
6C). Uptake of all selected normal tissues was clearly lower compared with the HT-29 
tumor uptake. The highest uptake (i.e. uptake >3% ID/g) was found in the skin, salivary 
glands, liver, spleen and bladder, while other normal tissues including stomach, pan-
creas, ileum, colon, muscles, cerebrum, cerebellum and medulla oblongata showed 
low uptake (<1% ID/g). 
Quantification of In vivo EGFR Expression 
Several micro-environmental parameters can influence in vivo EGFR expression, result-
ing in a difference between the in vivo and the in vitro tissue culture EGFR expression. 
We therefore assessed both the in vivo and in vitro EGFR expression using Western 
blotting. Figure 7A (upper panel) depicts representative Western blots of the different 
tumors, while in vitro samples are shown in the lower panel. Densitometric quantifica-
tion of the in vivo Western blots is shown in figure 7B. The in vivo and in vitro EGFR 
expression was comparable, showing the A-431 tumors as high, U-373 MG and HT-29 
as intermediate and T-47D as low EGFR-expressing cell lines. The A-431 expresses in 
vivo EGFR significantly higher compared to the other tumor types (U373-MG: p = 
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0.0002, HT-29: p = 0.0040, T-47D: p =0.0002). No significant differences were found 
between the U-373 MG and HT-29 tumor types (p = 0.0902), while the T-47D was sig-
nificantly lower compared to the other tumor types (U373-MG: p = 0.0024, HT-29: p = 
0.0015, A-431: p =0.002). 
DISCUSSION 
Little is known about patient-specific tumor uptake and the relationship between dos-
age and efficacy of the mAb cetuximab, for which a disparity between EGFR expression 
levels and cetuximab treatment efficiency has often been reported 14,15,17. To increase 
knowledge of the clinical use of cetuximab as a targeting agent, it is necessary to be 
able to monitor in vivo cetuximab uptake in a non-invasive manner. To address this, we 
developed a cetuximab-based probe for PET imaging. Here we report the in vivo vali-
dationof the 89Zr-labeled cetuximab imaging probe. The positron emitter 89Zr was cho-
sen given its ideal characteristics for usage with antibodies 27,28. Like 68Ga and 64Cu, 
89Zrdemonstrates residualization, meaning that these radionuclidesbecome trapped in 
lysosomes when the antibody internalizes and degrades 27-29. Furthermore, 89Zr shows 
a much longer physical half-life (t1/2 = 78 hour) than other residualizing radionuclides. 
Antibodies show generally slow pharmacokinetics and need several days to plateau in 
the target organ. Therefore, 89Zr is the better-suited radionuclide for combination with 
intact antibodies (like cetuximab). To assess the pharmacokinetics of cetuximab non-
invasively in order to increase current knowledge in clinical practice, using cetuximab 
itself as an imaging probe is the obvious solution.  
 
To assess the pharmacokinetics of 89Zr-cetuximab, we performed PET imaging at sev-
eral time points post injection and found a gradual increase in uptake in the high and 
intermediate EGFR-expressing tumors (figures 2 and 3A). The corresponding blood up-
take decreased with time (figure 2 and 3B), resulting in high tumor-to-blood ratios (fig-
ure 5) at the plateau phase of cetuximab uptake (72 to 96 hours post injection). On the 
other hand, normal tissue uptake at similar time points was significantly lower (figure 
4). Therefore, the tumor-to-blood ratios (maximum T/B from 3 to 5) attained are suffi-
cient for imaging purposes. Our PET results were confirmed by ex vivo biodistribution 
studies assessed with gamma-counting. Again, uptake in the intermediate and high 
EGFR-expressing tumors was significantly higher compared with the surrounding nor-
mal tissues (figure 6). Although the gamma-counting data (in %ID/g) demonstrated a 
similar trend to the quantified microPET data (in %ID/ml), the absolute values of the 
gamma-counting were higher. This can be explained by the partial volume effects of 
the microPET scanner. 
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To be able to predict which patients might benefit from cetuximab treatment, in vivo 
EGFR expression levels must be assessed. Therefore, we investigated whether the in 
vivo cetuximab uptake is associated with the EGFR expression levels. Other investiga-
tors reported the use of 64Cu-DOTA-cetuximab for PET imaging, showing prominent 
uptake in EGFR-expressing tumors but low accumulation in EGFR-negative tumors 22,24. 
A linear correlation between the %ID/g values (measured by 64Cu labeled cetuximab 
PET) and EGFR expression levels (assessed with Western blotting) was found.However, 
due to the limiting half-life of the isotope 64Cu, imaging was only possible until 48 
hours p.i.. Also, the immunoreactive fraction of 64Cu-labeled cetuximab was signifi-
cantly lower (about 63% 22) compared to 89Zr-labeled cetuximab (about 95% 28). An-
other study, with the murine counterpart of cetuximab (mC225) labeled with Indium-
111, reported a correlation between mAb uptake and EGFR expression 25. However, 
the aim of their study was not to evaluate this correlation, and the authors themselves 
state that the observed results should be compared cautiously, due to large differ-
ences in injected mAb concentration and image time points. Another explanation for 
these contradictory results can be the differences in tumor volume. Previous studies of 
De Bree et al34 and others showed that tumor volume largely determines antibody up-
take, most likely related to blood supply, interstitial pressure and transport distance 
from the interstitium. To mimic a clinical situation more closely we used larger tumors 
(≈400mm3) that displayed a relatively lower uptake of 89Zr-cetuximab compared with 
other studies with smaller tumors 22,25. However, as shown in figure 5B the maximum 
uptake voxel in the tumors ismuch higher (≈20%ID/g) and comparable with the uptake 
in the other studies. 
 
Our results demonstrated a large disparity between the uptake of the antibody and 
the in vivo EGFR expression. Quantification of the PET images indicated that the uptake 
of the intermediate EGFR-expressing cell lines (U-373 MG & HT-29) was approximately 
two times higher than the uptake in the high-expressing cells (A-431) (figure 3). How-
ever, Western blot quantification on ex vivo tumor material using anti-EGFR mAbs con-
firmed that EGFR expression of the A-431 tumors was higher than the U-373 MG and 
HT-29 tumors (figure 7). We confirmed the tumor EGFR expression by comparison with 
in vitro EGFR expression in cells and found similar results, indicating that the EGFR ex-
pression levels did not change in the tumor. We considered the possibility that differ-
ences in in vivo tumor growth could have affected the tumor uptake of the various 
xenograft lines; however, the growth was comparable between the various xenograft 
lines. 
 
Tumors originating from different cell lines have (besides EGFR expression) other 
physiologic effects, like inadequate vasculature, differences in capillary permeability 
perfusion, and differences in necrosis. All these factors can play an important role in in 
vivo drug delivery 35,36. Also, cancer cells can bypass the dependency of EGFR for cell 
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growth and survival by altering EGFR levels through promoting EGFR ubiquitination 
and degradation, resulting in overall cetuximab resistance 36. Therefore, it should be 
noted that if cetuximab is not able to reach the complete tumor, no therapeutic effect 
can be expected in these regions. However, if cetuximab is able to reach the complete 
tumor, a therapeutic effect may not necessarilyoccur given the redundancy in the 
EGFR pathway.  
 
Taken together, the relationship between EGFR expression levels, cetuximab binding 
and, ultimately, clinical outcome is complex. In vitro there is a strong relationship be-
tween cetuximab binding and EGFR expression levels 16. Also, high levels of EGFR ex-
pression are correlated with poor clinical outcomes 5. However, cetuximab’s treatment 
efficacy is not correlated with EGFR expression 14,15,17. Our results show that cetuximab 
uptake is not only dependent on EGFR expression levels, revealing additional mecha-
nisms influencing tumor delivery of cetuximab. These mechanisms may partially ex-
plain why expression alone may not be sufficient to explain therapy effects. Possible 
explanations for the mismatch may include inadequate vasculature and perfusion, re-
sulting in a heterogeneous and limited cetuximab uptake, even upon treatment at high 
mAb dose. A future quantification of the results, assessing differences in vasculature, 
perfusion, hypoxia and proliferation, could explain why the ‘reachability’ in the xeno-
grafts is disparate.  
 
The chelate labeling of 89Zr with cetuximab is very stable: indeed, it can be produced 
under good manufacturing procedure (GMP) settings, making it an ideal candidate for 
a fast translation to the clinic 27. In future clinical trials, 89Zr-labeled cetuximab may be 
used to non-invasively examine the uptake of cetuximab into the tumor, selecting pa-
tients who can potentially benefit from cetuximab treatment. Sequential imaging dur-
ing treatment can also reveal microenvironmental changes, influencing cetuximab per-
fusion and uptake. Based on these images, treatment can be monitored and dosage 
adjusted, making individualized treatment of cetuximab a possibility.  
CONCLUSION 
This study has demonstrated that cetuximab uptake in tumors can be assessed by PET 
imaging using 89Zr-labeled cetuximab. This probe can thus potentially be used to evalu-
ate the biologic and pharmacokinetic clinical effects of EGFR inhibitors, both cetuximab 
and others. A disparity was found between cetuximab uptake and in vivo EGFR expres-
sion; the imaging therefore represents cetuximab uptake instead of a quantification of 
EGFR expression levels. More generally, the results reveal additional mechanisms that 
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influence antibody uptake in tumors besides the expression levels of a biologic target 
in a tumor alone.  
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ABSTRACT 
Background and Purpose  
Non invasive PET imaging of cetuximab uptake could help to select patients with the 
highest chance to benefit from this treatment. Cetuximab labelled with Zirconium-89 is 
a promising new conjugate to determine tumour uptake of cetuximab, which has been 
tested in pre-clinical animal models with excellent results (Aerts et al, J Nucl Med 
2009). In this phase I trial (NCT00691548), we aimed to determine the toxicity of 89Zr-
cetuximab in incurable cancer patients, with tumour visualization as a secondary aim. 
 
Material and Methods 
The safety of two different dose schedules was tested. In step 1, the toxicity of two 
consecutive low radioactivity doses of 89Zr-cetuximab (60 MBq) was investigated. In 
step 2, the toxicity of a single larger dose (120 MBq) was investigated. Labelled 
cetuximab administration was preceded by a standard loading dose of unlabelled 
cetuximab. Toxicity was scored twice weekly up to 14 days after injection, according to 
the CTCAE 3.0 scoring system and with blood tests for haematological and liver/kidney 
function. Total body PET-CT scans were acquired on day 4, 5 and 6 (step 1) and 5, 6, 7 
(step 2) post injection. Images were analyzed using dedicated software. 
 
Results 
Seven patients with a histology proven solid tumour without curative treatment op-
tions were included. One patient was excluded before administration of the studied 
drug because of hypertension during the administration of unlabelled cetuximab. Six 
patients had NSCLC, whereas 1 patient had a tonsillar carcinoma. Five of six patients 
who completed the study experienced skin toxicity. No additional toxicity was associ-
ated with the administration of 89Zr-cetuximab. The maximal tumour to blood ratio 
(TBR) observed was 1.6. In general, the most optimal TBR was found at later imaging 
time points (day 6 and day 7). 
 
Conclusions  
No additional toxicity was observed for 89Zr-cetuximab administration. 89Zr-cetuximab 
is thus safe to be implemented in ummuno-PET studies guiding cetuximab therapy. 
Clinical Imaging of 89Zr-Cetxuimab  117
INTRODUCTION 
Monoclonal antibodies are increasingly used in oncology as means to specifically target 
receptors at the surface of tumour cells that are associated with tumour aggressive-
ness, such as proliferation, hypoxia and angiogenesis. Cetuximab is a monoclonal anti-
body that blocks the Epidermal Growth Factor Receptor (EGFR). The EGFR is a trans-
membrane glycoprotein which is commonly expressed in many normal human tissues. 
It is a member of the tyrosine kinase family of growth factor receptors and is over-
expressed in many human malignancies 1,2. EGFR is activated upon ligand binding to 
the extracellular domain, which results in the induction of a signal transduction path-
way that cascades many cellular operations concerning cell growth and division. EGFR 
activation and overexpression appear to be important tumour cell mechanisms in the 
development of resistance to radiation and chemotherapy in epithelial cancers, with 
decreased rates of local tumour control and survival 3-7.  
 
Cetuximab specifically binds to the EGFR with high affinity, internalising the receptor 
and thus effectively blocking ligand-induced EGFR phosphorylation. It is a promising 
molecule to combine with radiotherapy alone or with concurrent chemo-radiation, as 
it has shown to improve local tumour control without enhancing the toxicity of radio-
therapy or chemotherapy 8,9. It plays currently a role as part of the standard treatment 
for a variety of cancers, including colorectal cancer and squamous cell carcinoma of 
the head and neck. The selection of patients with the highest chance of benefit from 
cetuximab treatment is of obvious relevance, also in view of its high costs. As no direct 
relationship has been observed between EGFR expression determined with immuno-
histochemistry and response to cetuximab treatment, EGFR status of the primary tu-
mour cannot be used as a selection criterion. As the expression of EGFR can be in-
duced by radiation and chemotherapy, it is possible that an initially EGFR negative tu-
mour may become positive early during therapy, thereby still benefiting from cetuxi-
mab treatment 10-12. On the other hand, EGFR expressing tumours will not respond to 
cetuximab when cetuximab does not reach therapeutic concentrations in the tumour 
because of e.g. interstitial pressure and vascular perfusion changes in the micro-
environment of the tumour or the surrounding tissues. In this regard, non-invasive 
visualization and quantification of tumour uptake of cetuximab with positron emission 
tomography (PET) before and during therapy could contribute significantly to patient 
selection and determination of the needed dosage 13. 
 
As the biologic half-life of cetuximab in the blood is 70-100 hours, a positron emitter 
with a long half-life is needed to visualize its uptake. Zirconium-89 (89Zr), a positron 
emitter with a half life of approximately 78 hours, can successfully be labelled to 
cetuximab and has shown excellent results in preclinical animal models 14. In the pre-
clinical study, tumour cell lines with varying EGFR expression levels were used for in 
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vivo imaging experiments. PET with 89Zr-labeled cetuximab was performed on tumour-
bearing NMRI-nu mice at multiple time points after injection and uptake was quanti-
fied within regions of interest on selected tissues. Uptake of 89Zr-labeled cetuximab 
was demonstrated in the EGFR-positive tumours. Furthermore, it was shown that in-
deed, levels of EGFR expression did not correlate with 89Zr-cetuximab uptake, implying 
that pharmacokinetic and -dynamic factors strongly influence the cetuximab distribu-
tion in the tumour 14.  
 
Here, we report the results of a phase I study to determine toxicity of Zirconium-89 
labelled cetuximab in incurable cancer patients, with tumour visualisation as a secon-
dary end point.  
METHODS 
Patient selection 
Patients with a histologically or cytologically confirmed solid cancer at any site without 
curative treatment options were eligible. Inclusion criteria were as follows: WHO per-
formance status 0 to 2; adequate bone marrow, hepatic and renal function (calculated 
creatinin clearance at least 60 ml/min); life expectancy > 3 months and written in-
formed consent to the study. Patients with a recent (< 3 months) myocardial infarc-
tion, uncontrolled infectious disease, pregnancy, previous administration of cetuximab 
or concurrent treatment with anti-cancer agents or radiotherapy were excluded. EGFR 
expression and mutation status as well as k-ras mutation were assessed for the pri-
mary tumour. The study protocol (NCT00691548) was approved by the medical ethical 
committee and the radiation safety committee (MECazM 083039.7 and 2008-8, re-
spectively) 
Study design 
A two dose-step study design was used, graphically represented in Figure 1. The study 
design anticipated on the future aim, which is to determine the tumour uptake of 89Zr-
cetuximab before and during therapy. Therefore, in step 1, the toxicity of two consecu-
tive low doses of 89Zr-cetuximab was investigated. A standard loading dose of 400 
mg/m2 of cetuximab was administered, followed by administration of cetuximab la-
belled 89Zr (60 MBq) on day 0. The second injection on day 14 followed consisted of a 
dose of 250 mg/m2 of cetuximab, followed by cetuximab labelled with 60 MBq 89Zr.  
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Figure 1 Timeline of the study 
A two dose-step study design was used. In step 1, the toxicity of two lower doses of 89Zr-
cetuximab was investigated. In step 2, the toxicity of a single larger dose of cetuximab was 
tested. PET-CT imaging was performed at three consecutive days after administration, starting at 
day 4 in dose step 1. * In step 2, PET-CT scans on day 3 and 7 after injection were optional and 
depended on the imaging results in step 1: If in step 1 two or more patients had a higher tumour 
to blood ratio (TBR) on day 4 then on day 5, an additional scan on day 3 would be performed. If 
in step 1 two or more patients had a higher TBR on day 6 then on day 5, an additional scan on 
day 7 would be performed 
 
As a larger radioactive dose of 89Zr is possibly needed to obtain the best image quality, 
the toxicity of a single larger dose was investigated in step 2. A loading dose of 400 
mg/m2 of cetuximab was administered in 3 patients, followed by administration of the 
cetuximab labelled with 120 MBq 89Zr. 
 
In both steps, the 89Zr-labelled cetuximab was administered within one hour after the 
administration of the loading dose. Six patients were included, three in each dose step. 
If grade 2 or higher toxicity was observed related to the administration of the studied 
drug (89Zr-labelled cetuximab) in any patient, 3 more patients were included in this 
dose step. When at maximum 1/6 patients experienced grade 2 toxicity, the step was 
considered safe. 
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   Table 1: Grading of toxicity related with Cetuximab administration  
Toxicity Grade Clinical presentation 
1 -    Follicular localized pustules 
-    Asymptomatic 
2 -    Follicular localized pustules 
-    < 50% of body surface 
-    Itchy 
3 -    Follicular localized pustules 
-    50% of body surface 
-    Itchy 
4 -    Exfoliative or ulcerative erythroderma 
 
  
Toxicity scoring 
Toxicity was assessed during treatment, and twice weekly thereafter until 14 days after 
the last injection, according to the CTCAE 3.0 scoring system. At baseline and on days 7 
and 14 after injection, blood testing was performed for haematology (haemoglobin, 
hematocrite, mean cell volume, reticulocytes, white blood cell count and differentia-
tion, platelets), kidney function (creatinin) and liver function (aspartate aminotrans-
ferase, alanine aminotransferase, alkalic phosphatase, γ-GT, bilirubin). The most com-
mon side effect of cetuximab administration that was anticipated for was skin toxicity 
(acne form rash). The classification of the degree of skin toxicity according to the 
CTCAE is provided in Table 1 15. 
Synthesis of 89Zr labelled cetuximab 
89Zr was produced by a (p,n) reaction on natural 89Y as described by Verel et al. 16. Sub-
sequently, labelling of 89Zr to the mAb cetuximab was performed as previously re-
ported 17. Briefly, desferrioxamine B was succinylated (N-sucDf), temporarily filled with 
iron (Fe3+), and coupled to cetuximab using a tetrafluorophenol-N-sucDf ester. The 
premodified mAb was purified on a PD10 column after removal of Fe3+ by transchela-
tion to ethylenediaminetetraacetic acid. Approximately 1 N-sucDf moiety was coupled 
per cetuximab, assessed by using 59Fe. Next, N-sucDf-cetuximab was labelled with 89Zr 
in 0.5 M N-(2-hydroxyethyl)piperazine-N9-(2-ethanesulfonic acid) (HEPES) buffer at pH 
7.0 and again purified on a PD10 column to remove unbound 89Zr. 89Zr-cetuximab 
preparations contained 10 mg 89Zr-cetuximab in 5 mg/ml gentisic acid in 0.9% NaCl, 
containing 60 or 120 MBq 89Zr. 89Zr-cetuximab release criteria were: radiochemical pu-
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rity > 90%; immunoreactivity > 70%; pH = 4.7 – 5.3; sterile and free of endotoxins 
(European Pharmacopeia). 
PET-CT imaging 
Whole body PET-CT imaging was performed at day 4, 5 and 6 after injection in dose 
step 1. Imaging time points in step 2 were adapted based on the tumour to blood ra-
tios at subsequent days in step 1. A list mode acquisition of the largest tumour site was 
carried out in addition to the whole body PET-CT. Furthermore, an optional 18F-
fluorodeoxyglucose (FDG-)PET scan was performed within the study period, at least 24 
hours before or 10 days after the 89Zr-cetuximab administration. Images were acquired 
with the patient in supine position. CT and PET images were automatically registered 
based on mutual information and were subsequently fused using dedicated software 
(TrueD, version VC50, Siemens Medical, Erlangen, Germany). The tumour was deline-
ated on the CT scan by the same observer (JvL). If available, FDG-PET information was 
used in addition to the CT. The maximal standardized uptake value (SUVmax) and the 
location of the 89Zr-cetuximab uptake within the delineated tumour were determined 
using dedicated software (TrueD VC50, Siemens Medical, Erlangen, Germany). Tumour 
to blood ratios (TBRs) for 89Zr-cetuximab uptake were calculated at all time points by 
dividing the tumour SUVmax by the SUVmax in the aortic arch. For patients in whom an 
additional 18F-FDG-PET scan was performed within one week before or after the 89Zr-
cetuximab scan, the 18FDG and 89Zr-cetuximab uptake was visually compared. The loca-
tion of the FDG uptake was determined using automated SUV-thresholding with the 
threshold depending on the tumour-to-background signal ratio (SBR-method) 18, 19. 
RESULTS 
Patient characteristics 
Seven patients, with a median age of 63 years (range: 53-75), were included. The third 
patient was excluded from the study before injection of the 89Zr-labelled cetuximab, 
because of malignant hypertension during the administration of the unlabelled 
cetuximab. The tension normalized within two hours of observation without further 
sequelae. Patient and tumour characteristics are shown in Table 2. Six patients had a 
non-small cell lung carcinoma (NSCLC) and 1 had a tonsillar carcinoma. All patients had 
previously undergone anti-cancer therapy. In one patient, EGFR expression and muta-
tion of k-ras mutation status of the primary tumour could not be assessed due to insuf-
ficient quantity of the histological material. In the other patients, none of the primary 
tumours showed overexpression of EGFR or a mutation in de exons 18-21 of the EGFR 
gene. In one patient, the tumour showed a mutation in the k-ras gene. 
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Table 2: Patient characteristics  
Patient 
Age 
G
ender 
Length 
W
eight 
W
HO
-PS 
Prim
ary Tum
our 
 Site  
Histology 
M
utation k-ras 1 
M
utation EG
FR
2 
O
verexpression 
Prior therapy 
1 72 M 1.85 75 0 Lung SCC NA NA NA CTx 
2 61 M 1.76 82 1 Lung LCC + - No CTx, RT 
33 55 F 1.56 61 0 Lung LCC NA NA NA CTx 
4 75 M 1.79 74 2 Lung AC - - No CTx 
5 53 M 1.80 91 1 Lung SCC - - No CTx 
6 63 M 1.78 86 0 Lung AC - - No CTx 
7 63 M 1.86 95 1 Tonsil SCC - - No RT, CTx 
            
1k-ras: codons 12 and 13; 2EGFR: exons 18-21; 3 Excluded patient: 55 year old female, NSCLC 
WHO-PS: World Health Organization Performance Status; M = male, F = female, SCC: squamous 
cell carcinoma; LCC: large cell carcinoma; AC: adenocarcinoma; NA = not assessable; CTx: Che-
motherapy; RT: radiotherapy 
 
Each patient received 89Zr-labelled cetuximab administration as planned. In two pa-
tients (patient 2 and 4) enrolled in the first dose step, however, the second series of 
PET-CT scans could not be completed due to pain and dyspnea attributable to disease 
progression. 
Toxicity 
An overview of the toxicity per patient is presented in Table 3. As mentioned before, 
patient 3 was prematurely excluded from the study due to malignant hypertension, 
unrelated to the study drug. For this reason, an extra patient was included in dose step 
1. No toxicity other than skin rash was observed according to the CTCAE 3.0 criteria in 
the other three patients included in dose step 1. The same held true for the three pa-
tients included in step 2, with again no toxicity other than skin toxicity. Of the six pa-
tients that received the full cetuximab administration, two experienced grade 1, and 3 
experienced grade 2 acne-form rash, which was treated with local (metronidazol 
cream) and systemic antibiotics (doxycyclin) 15. No change in the baseline grade ac-
cording to the CTCAE version 3.0 was observed for haematological, kidney and liver 
function.  
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Table 3: Toxicity scoring 
Patient 
Injected activity 
(M
Bq) 
Vital signs 1 
Haem
atology 
Liver function 
Renal function 
Skin 
Sym
ptom
s 
M
edication  
1 2*60 0 0 0 0 2 0 Yes2 
2 2*60 0 0 0 0 1 0 No 
3 none NA NA NA NA NA NA NA 
4 2*60 0 0 0 0 0 0 No 
5 120 0 0 0 0 2 0 Yes2 
6 120 0 0 0 0 2 0 Yes2 
7 120 0 0 0 0 1 0 No 
         
Toxicity scored before study entry (baseline) and at days 7 and 14 after cetuximab. NA: not as-
sessed because of premature exclusion from the study. 1 Every change in vital signs or medication 
compared to the baseline values was scored, with “0” indicating no change. 2Doxycycline 100 
mg, Hydroxyzine 25 mg, Metronidazolcream 10 mg/g 
Image analysis 
Images of 89Zr-cetuximab uptake in the tumour of 2 patients are presented in Figure 2. 
For these patients, an 18F-FDG-PET scan was performed within 1 week after the 89Zr-
cetuximab scan. A heterogeneous uptake of 89Zr-cetuximab was observed throughout 
the tumourand the rest of the body. In patient 1, a remarkable mismatch was ob-
served between FDG- and 89Zr-cetuximab uptake (Figure 3). For the patients in dose 
step 1, the average maximum TBR at day 4, 5 and 6 after injection was 0.89 (range: 
0.83-0.94), 0.98 (range: 0.88-1.05) and 1.09 (range: 0.76-1.60), respectively. As the 
most optimal TBR was found at day 6 after injection, imaging in dose step 2 was per-
formed at days 5, 6 and 7. For patients in dose step 2, the average maximum TBR at 
day 5, 6 and 7 after injection was 0.88 (range: 0.57-1.05), 0.86 (range: 0.54-1.02) and 
0.91 (range: 0.42-1.20). Three patients had a maximum TBR ≥ 1 at any of the imaging 
time points: patient 4 had a maximal TBR of 1.60, patient 6 had a maximal TBR of 1.20 
and the maximal TBR of patient 7 was 1.11. 
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Figure 2.  
18FDG (left) and 89Zr-cetuximab (right) images of two representative patients: 
- Patient 6: a) FDG-PET-CT, b) 89Zr-cetuximab-PET with TBR=1.20 
- Patient 7: c) FDG-PET-CT, d) 89Zr-cetuximab-PET with TBR=1.11 
89Zr-cetuximab images at day 7 after injection are shown. 18FDG images were acquired at day 14 
after 89Zr-cetuximab administration. Note, the heterogeneous uptake of 89Zr-cetuximab in the 
tumours. 
 
Figure 3.  
Correlation between 89Zr-cetuximab and 18FDG uptake in patient 1 
a) FDG-PET-CT   b) 89Zr-cetuximab-PET-CT (day 6 after injection) 
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DISCUSSION 
Although Zirconium-89 labelled with other monoclonal antibodies has been evaluated 
in patients before without additional toxicity 20, the current phase I trial is the first in 
human study evaluating 89Zr labelled with cetuximab. No additional toxicity was asso-
ciated with the 89Zr administration. Acne form eruption was observed in 83% of pa-
tients, a rate comparable to that found with the therapeutic administration of cetuxi-
mab 8,15,21. One patient developed malignant hypertension during the administration of 
unlabelled cetuximab. Although rare, this side-effect has been described previously 22.  
 
Many preclinical data show additive anti-tumour effects for cetuximab with radiother-
apy and chemoradiotherapy in experimental models 9,23,24. The mechanisms underlying 
clinical response or resistance to treatment against EGFR with cetuximab are unknown. 
Until now, the only factors found to be associated with tumour-response to cetuximab 
are wild-type K-RAS and an increased EGFR gene copy number. EGFR status was not 
associated with significant differences in response rates or survival. Also, time-frames 
of EGFR-expression during the course of (chemo)-radiation are largely unknown. EGFR 
tyrosine kinase activity can be initiated by a single dose of radiation in experimental 
tumour models 25. Repeated doses of daily radiation, similar to standard clinical ther-
apy, stimulate increased EGFR expression in experimental models 26. Visualization and 
quantification of cetuximab uptake in the tumour with PET before and during (chemo-) 
radiotherapy would have major benefit in the appropriate selection of patients for 
cetuximab treatment 13. 
 
The maximal TBR of 89Zr-cetuximab uptake in the patients included in this phase I study 
was 1.6. Correlation of the 89Zr-cetuximab and FDG uptake showed a remarkable mis-
match between the two tracers in one patient. Although a large divergence was ob-
served between patients in the time curves of the TBR, overall, the most optimal TBR 
was observed at the latest time point of imaging, being day 6 for dose step 1 and day 7 
for dose step 2. Therefore, we would suggest the time point of 6 to 7 days after ther-
apy to perform Zr-cetuximab imaging. 
 
Several possibilities may explain the low TBRs observed in this study. First, the results 
may represent true negative findings in this selective patient group. Biopsies of the 
primary tumours of the patients enrolled in this study did not show overexpression of 
EGFR or a mutation in the EGFR gene. All patients, however, had undergone extensive 
treatment with chemotherapy or radiotherapy, of which the long term effect on EGFR 
expression is largely unknown. Five of the 6 included patients had NSCLC. Although 40-
80% of NSCLC tumours show EGFR expression 1, response rates to cetuximab mono-
therapy in pre-treated patients with EGFR expressing primary tumours of only 5% are 
reported 21. Second, the loading dose administered in this study (400 mg/m2), which is 
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the standard in therapeutic regimens might be either too low or too high to enable 
adequate tumour visualization. The rationale of the loading dose of cetuximab is that 
cetuximab first binds irreversibly to EGFR expressing liver cells, and that tumour cells 
are only targeted after the liver has been saturated 27. This rationale is supported by 
animal studies as well as by the positive relation between skin toxicity and tumour re-
sponse to cetuximab, implying that skin saturation only occurs after the liver has been 
saturated 28-30. On the other hand, it cannot be excluded that the unlabelled cetuximab 
is already sufficient to saturate the EGF receptors on the tumour cells. Future studies 
should address these critical questions. Finally, it is possible that cetuximab might not 
reach its target receptor at tumour cells due to limited blood supply and interstitial 
pressure of the tumour 31. Hereby, a disparity would result between the in vivo EGFR 
expression and the uptake of cetuximab, a finding that has been confirmed in our pre-
clinical study with 89Zr-cetuximab 14. 
 
Future studies are planned addressing the role of each of these contributing factors. 
Patients will be studied at primary diagnosis before the start of any antitumour ther-
apy, to allow correlation of EGFR expression at histology with imaging results. As radio-
therapy induces upregulation of EGFR expression, visualization of 89Zr-cetuximab up-
take before and after a single fraction of RT will be evaluated. 89Zr-cetuximab admini-
stration with different loading doses of unlabelled cetuximab will be evaluated to ad-
dress its influence on tumour visualization. Finally, kinetic imaging enables the meas-
urement of tumour perfusion, and this should thus be incorporated in future clinical 
trials. 
 
Concluding, the administration of 89Zr labelled cetuximab to image EGFR expression in 
vivo is not associated with any additional toxicity. Based on the tumour to background 
ratios, a time delay of 6-7 days after injection is advised for further research. 
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GENERAL DISCUSSION 
Due to disappointing outcomes in the treatment of cancer, poor local tumour control, 
and the heterogeneous response of patients with the same diagnosis to a specific 
treatment, it has become increasingly clear that tailored treatments are potentially 
beneficial. This problem is addressed by “personalized medicine” were the treatment 
is individualized towards the specific characteristics of a patient, instead of the cur-
rently common “one size fits all” treatment modalities. In personalized medicine there 
is a growing interest to individualize treatment by the combination of systemic thera-
pies and dose painting of radiation, as high precision radiotherapy is capable of direct-
ing a therapeutic effect in the three dimensions of space towards areas were other 
treatments are failing. It is expected that the implementation of these techniques in 
clinical settings will lead to improved local control of the tumour without an increase 
of the side effects, and consequently improved survival and quality of life. The concept 
of dose painting takes advantage of intratumour differences in the sensitivity for radio-
therapy, chemotherapy, targeted agents, and their combinations, as a tumour can be 
composed of large spacial differences in biologic characteristics related with treatment 
resistance. A precondition for dose painting is that the areas where it is likely that 
treatment will fail can be identified, i.e. areas with biologic resistance to treatment 
(investigated in part 1 of this thesis) and areas with limited drug uptake (investigated 
in part 2). Here, molecular imaging modalities able to quantify these intra tumour ar-
eas with differences in biologic characteristics and drug uptake before and even during 
treatment make this a feasible strategy. Currently, many investigators remained scep-
tic about the implementation of dose painting in clinical settings, mainly because the 
scientific basis for these studies was missing. 
 
However, the work presented in this thesis showed evidence of both the pre-
treatment identification of intra tumour areas with a high probability of treatment 
failure, as well as the non-invasive visualisation of heterogeneous drug uptake in tu-
mours. Based on the results of this thesis and previous knowledge of FDG, we postu-
late that there is a scientific basis to test dose painting in clinic settings, which can lead 
to new paradigms in radiotherapy combined with systemic treatment. 
Intra-tumour heterogeneity 
A prerequisite for intra-tumour dose painting is that a tumour is heterogeneous in re-
gions of treatment sensitivity. Indeed, several studies have shown that there are large 
intra-tumour spatial variations in biologic characteristics, like proliferation, hypoxia, 
cell density, perfusion, vasculature, gene expression, but also drug uptake. Therefore, 
it is likely that there are large spatial differences in the probability to eradicate distin-
guishable tumour sub-volumes by radiotherapy, chemotherapy, targeted agents, and 
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or their combinations. The results in this thesis confirmed these findings and showed a 
heterogeneous pattern of the glucose analogue 18F-deoxyglucose (FDG) for positron 
emission tomography (PET) imaging before (Chapter 2-4) and during treatment (Chap-
ter 5), where the high FDG uptake areas was often not in the centre of the tumour. 
Also, a heterogeneous pattern was observed for Cetuximab uptake in pre-clinical set-
tings. Ex vivo immunohistochemistryanalysis showed a very heterogeneous uptake of 
in vivo Cetuximab, but also a very heterogeneous EGFR expression throughout the tu-
mour (Chapter 6). Also, in in vivo PET images with 89Zr-Cetuximab large intra-tumour 
heterogeneity was observed in mice (Chapter 7) and in patients (Chapter 8).  
The numbers of cells are critical for resistance  
On might wonder if the volumes of treatment-resistance are sufficiently large to be 
identified with imaging and for current dose painting techniques. Several biologic 
characteristics have been associated with treatment-resistance, like hypoxia, stem 
cells, proliferation, metabolic activity, and cell density. In the case of hypoxia for in-
stance, a larger hypoxic volume results in a worse survival 1-4. This and other examples 
such as the metabolic volume based on FDG underline that factors related to resis-
tance are continuous and not dichotomous parameters 5. Therefore, it can be agrued 
that overt treatment-resistance will mostly occur when sub-volumes within the tu-
mour reach a critical volume, which may be detectable by current imaging modalities. 
Therefore, we argue that the numbers of cells are critical for resistance, i.e. for treat-
ment resistance there should be a critical volume that is measurable by imaging. In-
deed, hypoxic volumes from approximately 2-3 cm3 or more are problematic to con-
trol, not some sparse hypoxic cells spread out throughout of the tumour 1. This is in 
agreement with direct pO2 measurements with Eppendorf electrodes, which are not 
capable to measure microscopic hypoxia, but still can distinguish prognostic sub-
groups 1,6,7. As the minimal clinical relevant resistant volume is probably 1-2 cm3 and 
the technical possibility for radiotherapy to deliver doses is restricted to the same vol-
ume, even with these limitations, relevant radiation dose re-distribution may be feasi-
ble. 
FDG for the identification of radioresistance 
Probably the most investigated methodology for visualizing intra tumour radio-
resistance are hypoxia tracers, as hypoxia is known to be strongly correlated with ra-
diation sensitivity 8,9. However, the currently available hypoxia tracers show limitations 
for its applicability, e.g. low test re-test performance and low tumour to reference ac-
tivity ratios 10-12. Also, as hypoxia is only one of several characteristics linked with ra-
dioresistance, it is not well known how hypoxia tracers directly relate to radio-
resistance. Furthermore, it is unknown if intra tumour areas with high tracer uptake 
have the highest probability to relapse. Due to these reasons, we believe more evi-
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dence is desirable to use hypoxia tracers for dose painting in the clinic. Another tracer 
suggested for dose painting is FDG. The underlying biology for FDG uptake is complex 
because it measures the uptake of glucose in cells by ATP independent glucose trans-
porters. This makes FDG uptake specific to the metabolic pathway, although this 
pathway is known to be influenced by numerous other biological processes related to 
radio-resistance, like proliferation 13, cell density 14, and hypoxia 15,16. Also, the maximal 
uptake of FDG in the tumour is prognostic for survival of patients with NSCLC, both 
treated with surgery or radiotherapy 16-20. Furthermore, FDG is widely available at al-
most all oncology centres in developed countries. Therefore, we also consider FDG as a 
rational choice for dose painting studies. However, it should be stated that there are 
also limitations with FDG, such as aspecific uptake in inflammatory tissue. Also, as me-
tabolism is only one tumour characteristic of importance, it is expected that multiple 
tracers will yield better estimations of treatment sensitivity.  
Identification of residual metabolic active areas 
We hypothesized that the location of the residual metabolic-areas following treatment 
are probably the areas that are the most radio-resistant and can be identified before 
treatment starts using a single FDG-PET-CT scan. Therefore, we investigated, using an 
overlap fraction (OF) calculation, if the areas of residual metabolic activity after treat-
ment had a large overlap with the pre-treatment high FDG-uptake within the primary 
tumour. An analysis was performed in a dataset of patients treated at MAASTRO con-
sisting about high-dose radiotherapy, mostly preceded by chemotherapy (Chapter 2). 
The results showed that the pre-treatment high FDG-uptake areas largely corre-
sponded with the metabolic active areas after treatment. Also, the residual areas were 
located almost completely within the pre-treatment GTV volume, indicating no geo-
graphic miss of radiotherapy. Validations of these results were performed in an inde-
pendent dataset from the Princess Margaret Hospital in Toronto (Chapter 3) and in an 
independent prospectively gathered dataset from the Radboud University Medical 
Centre in Nijmegen (Chapter 4). The Nijmegen dataset yielded similar results with the 
same thresholds as the MAASTRO dataset. Also, the Toronto dataset yielded similar 
results, however with the pre-treatment 40% SUVmax high uptake threshold. That the 
40% SUV threshold was used instead of the 50% threshold was due to differences of 
the absolute values and volumes of the thresholds between the Toronto dataset and 
the Dutch datasets. This may be due to the PET protocol that differed substantially, as 
MAASTRO and Nijmegen used the standardization NEDPAS protocol 21,22 and Toronto 
did not. This underscores the necessity for thorough standardization before multi-
centre studies can be launched. An important limitation of the used analysis, is that for 
the registration between the pre- and post scan a rigid registration was used, not in-
corporating deformable tissue changes, possible induced by therapy. This can be im-
proved by using non-rigid registration methods, incorporating these deformations. 
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However, these techniques are difficult to validate and the reproducibility between 
institutes is limited. Therefore, in every dataset patients were excluded from analysis 
that showed large deformations of the normal tissues near the tumour. 
 
Although our surrogate endpoint, persistent FDG uptake in the tumour, should not be 
regarded as equivalent to tumour persistence, we argued that residual metabolic ac-
tive areas indicate areas of treatment resistance. In agreement with literature 5, pa-
tients with persistent FDG uptake showed a significantly worse survival than those 
without, underlining its clinical validity (Chapter 2). Based on these results, we con-
clude that residual metabolic active areas within the tumour are probably more radio-
resistant. Another study from our group investigated the relationship between FDG 
uptake in a tumour subvolume (what we call a voxel) and the probability that voxels 
contained no residual metabolic disease 23. We referred to this probability as voxel 
control probability (VCP). Apart from FDG-uptake, the effect of VCP on radiation dose, 
gross tumour volume, the SUVmax and the administration of chemotherapy before irra-
diation was investigated. It was shown that VCP decreased with increasing FDG uptake 
(p<0.001) and increasing GTV (p<0.001). No statistically significant dose effect relation-
ship was found. However, according to Martel et al. a dose of 84 Gy is needed for a 
50% tumour control 24. The patients in this dataset received doses ranging from 50.4 
Gy (given in 28 twice-daily fractions of 1.8 Gy) to 79.2 Gy (44 twice-daily fractions). 
Therefore it is likely that we are looking at the shallow part of the slope of the TCP 
curve in our patients, making it difficult to detect a relationship between dose and 
VCP. Although no dose effect relationship was found, these findings confirm that high 
FDG uptake voxels are more likely to contain residual metabolic disease after therapy 
and that more dose is needed to control them. 
Pre-clinical and clinical in vivo imaging of Cetuximab  
The visualisation of a drug like Cetuximab is of importance, as a lot is unknown about 
patient-specific tumour uptake and overall pharmacokinetics of Cetuximab 25-27. More-
over, only a small sub-population of patients benefits from Cetuximab treatment, were 
often discrepancies between Cetuximab uptake and EGFR expression levels have been 
reported 28-30. For the visualisation, we choose the long-lived positron emitter Zirco-
nium-89 (89Zr) for the labelling with Cetuximab. 89Zr has ideal characteristics for in vivo 
imaging, e.g. the long half life (78 hours) that enables imaging up to a week after injec-
tion, sufficient for the biologic half life of Cetuximab in the blood pool, but also the 
very high labelling efficiency of 89Zr-Cetuximab (immunoreactive fraction >95%). Also, 
89Zr-Cetuximab can be produced under good manufacturing procedure (GMP) settings, 
making it an ideal candidate for a fast translation to the clinic 31. In vivo PET images in 
mice showed successful imaging that revealed a clear uptake of 89Zr-Cetuximab in 
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EGFR positive tumours with high quality images (tumour-to-blood ratios from 3-5) 
(Chapter 7).  
Disparity between EGFR expression and Cetuximab uptake 
To assess the binding of Cetuximab in vitro, an image probe using Cetuximab labelled 
with the fluorescent marker Oregon-Green 488 was developed (Chapter 6). This probe 
showed that in vitro the binding of Cetuximab was strongly related with EGFR expres-
sion levels. However, ex vivo immunohistochemistryanalysis showed a very heteroge-
neous uptake of in vivo Cetuximab, but also a very heterogeneous EGFR expression 
throughout the tumour. Besides being heterogeneous, a disparity was reported were 
areas with low EGFR expression had a high Cetuximab uptake, and vice versa. In a pre-
clinical study in mice, again a large disparity was found between 89Zr-Cetuximab uptake 
and in vivo EGFR expression levels (Chapter 7). The uptake in a high EGFR expressing 
cell line was two times lower than in intermediate EGFR expressing cell lines. These 
results were confirmed with ex vivo γ-counting biodistribution studies. A phase I imag-
ing trial using 89Zr-Cetuximab in cancer patients showed no associated toxicity and se-
lective targeting of 89Zr-Cetuximab in the tumour, although with very low tumour-to-
blood ratios (Chapter 8). This was expected as Cetuximab is only efficient in a small 
number of patients, and only six patients successfully finished the study, and all of 
these patients where EGFR negative.  
 
Importantly, the disparity described in this thesis may help to explain the poor correla-
tion reported between Cetuximab efficacy and EGFR expression, as the results reveal 
additional mechanisms that can explain why EGFR expression levels alone may not be 
sufficient to explain therapy effects of Cetuximab in the clinic. A possible explanation 
for this disparity can be a poor drug delivery of the relatively large antibody (±152 kDa) 
into the tumour tissue due to inadequate vasculature, differences in capillary perme-
ability perfusion, and differences in necrosis. Also, the internalization rate of the 
Cetuximab-EGFR complex may be different per cell type. However, the biologic reason 
for this disparity needs further investigation. 
Treatment efficacy of drugs  
We hypothesize that for effective treatment of a drug like Cetuximab there are two 
prerequisites: 
 
1 the drug has to be able to reach all areas within the tumour.  
2 the cells have to be sensitive for the drug. 
 
Therefore, if Cetuximab is not able to reach the all tumour regions, no therapeutic ef-
fect can be expected in these regions. Here, Cetuximab imaging can be used for exclu-
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sion of this expensive treatment of patients with no (or limited) uptake. However, if 
Cetuximab is able to reach a tumour region, this does not guarantee there will be a 
therapeutic effect given a possible Cetuximab resistance of the cells. This resistance 
and sensitivity for Cetuximab treatment may be associated with EGFR expression lev-
els, however, can also be more complex due to overall redundancy in the EGFR path-
way. It is known that cancer cells can bypass the dependency of EGFR for cell growth 
and survival by altering EGFR levels through promoting EGFR ubiquitination and degra-
dation, resulting in Cetuximab resistance 32. Overall, the relationship between EGFR 
expression levels, Cetuximab binding and, ultimately, clinical outcome is complex. In 
vitro a strong relationship between Cetuximab binding and EGFR expression levels was 
found (Chapter 6). Also, high EGFR expression is correlated with poor clinical outcome 
27. However, no correlation is found between the efficacy of Cetuximab treatment and 
EGFR expression 28-30. Therefore, in future clinical trials 89Zr-Cetuximab may be used to: 
I) omit non-beneficial patients with no or limited uptake, and II) optimize Cetuximab 
dosage in patients with tumour targeting, possibly complemented with dose painting 
of radiation. 
Adaptation of treatment based on imaging 
In general, the results of this thesis show that non-invasive imaging of biologic charac-
teristics like metabolism can be used to identify the regions of radioresistance. There-
fore, a heterogeneous dose distribution, matching the profile of intra tumour differ-
ences of radio-curability, seems to be a rational choice. Imaging of drugs can, besides 
selecting beneficial subpopulation for specific therapies and optimizing dosage, be 
used for identifying regions with limited drug uptake that can be compensated with 
dose painting.For the introduction of dose painting in the clinic intensity modulation 
radiotherapy (IMRT) has often been suggested. IMRT is an advanced technique that 
uses computer controlled linear accelerators to deliver a precise three dimensional 
radiation dose distribution to the tumour by controlling the radiation beam in multiple 
small volumes. Therefore, the total dose to the tumour can be maintained while reduc-
ing the dose to the surrounding normal tissues, resulting in less toxicity. Currently, 
IMRT is often used in clinical settings for patients with difficult treatment plans, e.g. 
due to tumours that are closely to other organs. For the utility of dose painting using 
Image-Guided Radiotherapy, IMRT can be used to deliver a higher dose to intra tumour 
sub-volumes that are more resistant, while reducing the dose towards the more sensi-
tive tumour sub-volumes. However, this can result in treatment plans with large dif-
ferences of dose between adjacent voxels. These are considered unrealistic because of 
movement of tumour and organs during the treatment, shrinkage of the tumour due 
to the treatment, day to day differences in patient positioning, and the limited accu-
racy of imaging and voxel-wise dose delivery techniques. Therefore, larger tumour sub-
volumes are more realistic for dose painting as the dose gradient per voxel can be less 
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steep. Therefore, with current Image-Guided Radiotherapy techniques, adaptive ther-
apy has now become challenging, but realistic. 
FUTURE PERSPECTIVES  
The results of this thesis form a solid basis for future research in both clinical and pre-
clinical settings. The results of part 1 show ‘evidence’ to test personalized medicine 
using dose painting in clinical settings, by individualizing treatment based on the high 
FDG uptake areas before treatment. Based on these results, a phase II dose painting 
trial is currently ongoing at MAASTRO Clinic together with the Dutch Cancer Institute 
(NKI/AvL) in Amsterdam. In this trial patients with inoperable stage II or III NSCLC are 
randomized to receive an integrated boost to the primary tumour as a whole (arm A) 
or with an integrated boost to the 50% SUVmax area of the primary tumour (arm B). 
After one year local tumour control is assessed and overall survival is monitored of all 
patients. It is expected that these efforts will increase local tumour control and 
thereby improve survival and quality of life. If successful, this trial can set an example 
of dose painting trials. In general, the methodology presented in part 1 of this thesis 
can be used in future studies to identify the intra tumour location where a treatment 
modality fails. This can be used in evaluation of radiotherapy in combination with sys-
temic therapies, as well as targeted therapies. Also other tracers could be used, like 
hypoxia tracers. However, first further investigations have to be performed on stan-
dardisation and assessment of the location of relapse. Therefore, for the time being 
FDG represents a rational choice to be used in this context. 
 
Besides imaging the biologic characteristics of a tumour, non-invasive imaging of drugs 
can play an increasing role in the future for treatment individualization. Imaging of 
drug delivery has the potential to identify patients that show no uptake of the drug in 
the tumour and thus are expected not to benefit from it, and to optimize the dosage in 
patients with selective tumour targeting. Our results show that Cetuximab uptake is 
not only dependent on EGFR expression levels, but also on additional mechanisms. A 
possible explanation for this disparity can be a poor drug delivery into the tumour tis-
sue due to inadequate vasculature, differences in capillary permeability perfusion, and 
differences in necrosis. In a pre-clinical setting it is possible to assess EGFR expression 
and tumour perfusion in a panel of tumours, and relate this to Cetuximab uptake. Also, 
it is possible to change the vasculature of xenographs using other drugs and assess if 
the uptake of Cetuximab is altered. Furthermore, the relationship between Cetuximab 
dose, 89Zr-Cetuximab uptake, and treatment efficacy can be investigated. In clinical 
settings, it is interesting to assess if tumour uptake of 89Zr-Cetuximab is related with 
Cetuximab dose and treatment efficacy as we believe that the response rate of 
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Cetuximab treatment is largely determined by the accessibility of the antibody in the 
tumour tissue. Possibly, in a phase II trial patient specific distribution and sensitivity of 
Cetuximab can be assessed using 89Zr-Cetuximab, to select and monitor patients that 
could benefit from Cetuximab treatment. Using multiple image time points during 
treatment the uptake can be monitored before and during treatment and the outcome 
can be assessed using differences in metabolic response rate after treatment between 
patients with a high uptake vs. low uptake on the 89Zr-Cetuximab scans.  
 
Antibody imaging addresses a frequent debate that is taking place within the interna-
tional scientific community, about the affordability of new expensive drugs (e.g. 
Cetuximab, Trastuzumab, Bevacizumab, Retuximab), because patient selection is cur-
rently very difficult. Consequently, the scientific and medical community has shown a 
lot of interest in the results of studies like this. Both pre-clinical and clinical investiga-
tions presented in this thesis show a methodology to non-invasively image the biodis-
tribution of therapeutics, allowing faster and especially more effective product devel-
opment and clinical trials, possibly leading to better and cheaper medicines. We be-
lieve that the development of new therapeutic agents should be accompanied with 
visualisation of drug delivery and the tumour characteristics which it targets. At the 
end, this will allow better selection of patients whom can benefit from therapeutic 
drugs in combination with conventional treatment modalities, resulting in individual-
ized patient treatment. Since the total revenue of drugs like Cetuximab is very high, 
even a method for excluding a relatively small fraction of all patients can already save 
a considerable amount of money, which would have otherwise been spent on unnec-
essary administrations with possible toxicities. Consequently, this can result in a loss of 
market share of existing drugs and can have large financial consequences. However, 
the benefit of more effective drug development will benefit the pharmaceutical indus-
try as well.  
 
In the future, both imaging of biologic characteristics and imaging of drug uptake can 
be combined to tailor the treatment to a specific patient. Both the biologic treatment 
resistant areas and the areas with limited drug uptake should receive an increased ra-
diation dose, while decreasing the dose to sensitive regions with drug uptake. The ex-
act dose that these resistant and low drug uptake areas must receive, should be tested 
in carefully designed clinical trials. In general, these studies demonstrate how ad-
vances in molecular imaging, even using conventional tracers as FDG, directly facilitate 
individualized treatment in Radiation Oncology.   
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SUMMARY  
In personalized medicine there is a growing interest to individualize treatment by the 
combination of systemic therapies and dose painting of radiation. It is expected that 
the implementation of these techniques will lead to improved local control of the tu-
mour and consequently improved survival. In this thesis the usability of molecular im-
aging modalities for dose painting was assessed, i.e. part 1 describes the pre-treatment 
identification of areas with radioresistance to treatment, and part 2 describes the visu-
alisation of drug uptake. 
 
In Chapter 1, a general introduction is presented on the background of scientific re-
search in the field of oncology, and the increasing need for personalize medicine in the 
future. Also the role of dose painting in personalize medicine is introduced, i.e. the 
concept of dose paining of radiation as a complementary approach to systemic thera-
pies is described more in detail. More specifically, the rational behind the scientific 
research presented in this thesis is explained, why it is crucial to identify regions of 
biologic resistance (further described in part 1) and limited drug uptake (described in 
part 2). The non-invasive visualisation of drug uptake can be used to select beneficial 
drugs for patients and use the intra tumour distribution of drug uptake for dose paint-
ing, as regions with low (or limited) uptake can be compensated by higher radiother-
apy doses. 
Part 1:     Identification of radioresistance: Rational for dose painting 
In part 1 the identification of areas of biologic resistance before treatment is investi-
gated. A tracer usable for dose painting is the glucose analogue 18F-deoxyglucose 
(FDG) for positron emission tomography (PET) imaging. In Chapter 2, it was investi-
gated if the location of the residual metabolic-active areas after treatment could be 
identified before treatment starts. Overlap fractions (OF) were calculated between 
areas of residual metabolic activity with the pre-treatment FDG-uptake locations 
within the primary tumour. Visual interpretation in a dataset of patients treated at 
MAASTRO clinic showed that the pre-treatment high-FDG uptake areas largely corre-
sponded with the metabolic active areas after treatment. Further quantification of 
these results showed that the residual areas largely corresponded with the pre-
treatment 50% SUV high uptake area (OF = 70%). The average volume of this 50% SUV 
threshold was 39% of the original GTV volume. Also, the residual areas were located 
almost completely within the pre-treatment GTV (OF = 91%), indicating no geographic 
miss of radiotherapy. Validations of these results were performed in independent 
datasets from the Princess Margaret Hospital in Toronto (Chapter 3) and in a prospec-
tively dataset from the Radboud University Medical Centre in Nijmegen (Chapter 4). 
The Nijmegen dataset yielded similar results, i.e. the residual areas corresponded 
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largely with the 50% SUV threshold before treatment (OF = 68%) and were located 
almost completely within the GTV (OF = 94%). The volume of the pre-treatment 50% 
SUV threshold encompassed in this dataset 35% of pre-treatment GTV. The Toronto 
dataset yielded similar results with the pre-treatment 40% SUV threshold, i.e. the over-
lap of the residual areas was 71% with this threshold and encompassed 43% of the 
original GTV volume. That the 40% SUV threshold was used instead of the 50% thresh-
old was due to differences of the absolute values and volumes of the thresholds be-
tween the Toronto dataset and the Dutch datasets.  
 
Another important question to be answered before clinical trials can be launched is 
whether these high FDG uptake areas remain stable during a course of radiotherapy 
(Chapter 5). Therefore, the stability of the high FDG-uptake areas during radiotherapy 
was assessed in repeated FDG-PET-CT images before (day 0) and during treatment (day 
7 and 14). Visual interpretation showed that the FDG uptake patrons remained stable 
during treatment. This was further quantified using an OF calculation, showing a large 
overlap (>70%) for the 34–60% SUV FDG high uptake areas on the day 0 scan with the 
scans on day 7 and 14.   
 
Therefore we concluded that FDG is an attractive tracer for dose painting, as FDG cor-
responds with several biologic characteristics important for radioresistance, due to the 
confirmed relationship with the location of residue, the stability of the uptake patterns 
during treatment, and the wide availability with standardized imaging protocols. Based 
on the results described in this thesis, we postulate that there is sufficient scientific 
basis to embark dose painting in carefully designed clinic trials, to test the assumption 
if FDG uptake reflects “treatment-resistance”, potentially feasible using only a single 
FDG-PET scan before therapy.  
Part 2:     Non invasive imaging of Drug uptake: From the bench to the clinic 
The second part of the thesis investigates the visualisation of the drug Cetuximab non-
invasively. Cetuximab is a drug that targets the epidermal growth factor receptor 
(EGFR) that is related with tumour aggressiveness and overall treatment resistance. 
However, it is known that only a small sub-population of patients benefits from 
Cetuximab treatment, were often discrepancies between Cetuximab uptake and EGFR 
expression levels have been reported. Therefore, the non-invasive quantification of in 
vivo Cetuximab uptake tumours and healthy tissue could provide crucial prognostic 
information, i.e. selecting patients suitable for Cetuximab treatment and optimizing 
dosage, but also identifying intra tumour areas for dose painting. 
 
To assess the binding of Cetuximab in vitro, an image probe using Cetuximab labelled 
with the fluorescent marker Oregon-Green 488 was successfully developed (Chapter 
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6). Here, it was shown that binding of Cetuximab is strongly related with in vitro EGFR 
expression levels and that Cetuximab binds to the EGFR mutant EGFRvIII. Ex vivo im-
munohistochemistry analysis showed a very heterogeneous uptake of in vivo Cetuxi-
mab, but also a very heterogeneous EGFR expression throughout the tumour. Besides 
being heterogeneous, a disparity was reported were areas with low EGFR expression 
had a high Cetuximab uptake, and vice versa. 
 
Contributing to this knowledge, another probe was developed to enable non-invasively 
imaging of Cetuximab uptake in pre-clinical and clinical situations. The results are de-
scribed in Chapter 7. The long-lived positron emitter Zirconium-89 (89Zr) for PET imag-
ing was selected for the labelling with Cetuximab. As 89Zr displays ideal characteristics 
for in vivo imaging, e.g. a long half life (78 hours) and the very high labelling efficiency, 
is was selected for imaging Cetuximab uptake. In vivo PET images in mice showed suc-
cessful imaging that revealed a clear uptake of 89Zr-Cetuximab in EGFR positive tu-
mours with high quality images (tumour-to-blood ratios from 3-5). However, again a 
large disparity was found between 89Zr-Cetuximab uptake and in vivo EGFR expression 
levels. The uptake in a high EGFR expressing cell line was two times lower than in in-
termediate EGFR expressing cell lines. These results were confirmed with ex vivo γ-
counting biodistribution studies. Because of these successful pre-clinical results, a 
phase I imaging trial using 89Zr-Cetuximab was performed at MAASTRO clinic. This trial 
showed no additional toxicity associated with 89Zr-Cetuximab administration (Chapter 
8). There was also selective targeting of 89Zr-Cetuximab in the tumour, although with 
very low tumour-to-blood ratios. This was expected as Cetuximab is only efficient in a 
small number of patients, and only six patients successfully finished the trial, and all 
patients had no EGFR mutation or overexpression.  
 
Concluding, the disparity reported in these studies may help to explain the poor corre-
lation often reported between Cetuximab efficacy and EGFR expression, as the results 
reveal additional mechanisms that can explain why EGFR expression levels alone may 
not be sufficient to explain therapy effects of Cetuximab in the clinic. 
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SAMENVATTING 
Er is een sterke behoefte om de behandeling verder te individualiseren door gebruik te 
maken van systemische behandelingen in combinatie met radiotherapie. Het wordt 
verwacht dat de implementatie van deze technieken zal leiden tot betere controle van 
de tumor en daardoor een beter overleving. In dit proefschrift worden moleculaire 
imaging technieken bekeken voor het sturen van de radiotherapie dosis, zogenaamd 
dose painting. In het eerste gedeelte van de thesis wordt onderzocht of imaging tech-
nieken voor behandeling de resistente zones kunnen aangeven voor behandeling. In 
het tweede gedeelte de visualisatie van medicijnen is geëvalueerd voor dose painting.  
 
Hoofdstuk 1 beschrijft een generieke introductie over de achtergrond van het weten-
schappelijk veld in de oncologie en de daaruit voortvloeiende noodzaak voor geperso-
naliseerde behandelingen in de toekomst. Ook de rol van dose painting voor het indi-
vidualiseren van de behandeling wordt geïntroduceerd, namelijk de rol van dose pain-
ting als een aanvullende techniek t.o.v. systemische behandelingen. Meer specifiek de 
achtergrond voor het wetenschappelijke werk van deze thesis is beschreven, waarom 
het belangrijk is om de resistente zones te identificeren (part 1 van de thesis), en 
waarom het belangrijk is om de opname van medicijnen te visualiseren (part 2 van de 
thesis).  
Part 1:    Identificatie van radioresistentie voor dose painting 
De identificatie van de zones van biologische therapie resistentie door beeldvormende 
technieken is van belang voor dose painting. Een tracer geschikt voor deze taak, is de 
glucose variant 18F-deoxyglucose (FDG) voor positron emission tomography (PET). In 
Hoofdstuk 2 is onderzocht of de locatie van overblijvende (residuele) metabolisch ac-
tieve zones kunnen worden geïdentificeerd voordat de behandeling start. Hiervoor zijn 
overlap fracties (OF) berekend tussen de residuele metabolisch actieve locaties met de 
primaire tumor. Visuele interpretatie van de resultaten, in een dataset van patiënten 
behandeld in MAASTRO Clinic, lieten zien dat hoge opname zones van FDG voor be-
handeling overeen komen met de metabolisch actieve locaties na behandeling. Verde-
re kwantificatie van deze resultaten lieten zien dat de residuele zones na behandeling 
grotendeels overeenkomen met de 50% SUV hoge opname zone (OF=70%) voor be-
handeling. Het gemiddelde volume van deze 50% SUV threshold was 39% van het ori-
ginele GTV volume. Ook bevonden deze residuele zones zich bijna volledig binnen het 
GTV volume voor behandeling (OF=91%), wat laat zien dat er geen geografische misser 
is van de radiotherapie. Als validatie zijn studies gedaan in onafhankelijke dataset van 
het Princess Margaret Hospital (PMH) (Hoofdstuk 3) in Toronto en in een prospectieve 
dataset van de Radboud Universiteit in Nijmegen (Hoofdstuk 4). De dataset van Nijme-
gen liet vergelijkbare resultaten zijn, namelijk dat de residuele gebieden grotendeels 
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overeen komen met de 50% SUV hoge opname zone voor behandeling (OF=68%). Ook 
bevonden deze residuele zones zich bijna volledig binnen het GTV volume voor behan-
deling (OF=94%). Het volume van deze 50% SUV threshold omvat gemiddeld genomen 
35% van het totale GTV volume voor behandeling. Ook de Toronto dataset liet een 
vergelijkbaar resultaat zien met de 40% SUV threshold voor behandeling. De overlap 
van deze residuele zones was 71% met deze 40% SUV threshold en bevatte 43% van 
het originele GTV volume. Dat de 40% SUV threshold was gebruikt in tegenstelling tot 
de 50% threshold, kwam door verschillen in de absolute waardes van de thresholds 
gebruikt in de Totonto datasets en de Nederlandse datasets.   
 
Een ander belangrijk vraagstuk voordat klinische studies gestart kunnen worden, is of 
deze hoge FDG opname zones stabiel blijven gedurende behandeling (Hoofdstuk 5). 
Daarom is de stabiliteit onderzocht van deze FDG opname thresholds gedurende be-
handeling in een herhaalde FDG-PET-CT dataset met images voor (dag 0) en gedurende 
behandeling (dag 7 en 14). Een visuele interpretatie van de beelden liet zien dat deze 
FDG opname patronen stabiel waren gedurende behandeling. Deze resultaten zijn ver-
der gekwantificeerd een overlap fractie calculatie. De 34-60% SUV opname thresholds 
lieten een hoge OF (>70%) heeft tussen de scan op dag 0 en dag 7 en 14.   
 
Concluderend, FDG is een attractieve tracer voor het gebruik van dose painting, omdat 
FDG gecorreleerd is met verschillende biologische kenmerken belangrijk voor resisten-
tie, de bevestigde relatie met de locatie van het residu na behandeling, de stabiliteit 
gedurende behandeling, de goede beschikbaarheid en de gestandaardiseerde imaging 
protocollen. Gebaseerd op de resultaten beschreven in dit proefschrift, stellen we dat 
er voldoende wetenschappelijk bewijs is om te starten met dose painting in zorgvuldig 
opgezette klinische studies. Hier is de assumptie dat FDG opname resistentie aangeeft 
en dat deze resistentie kan worden geïdentificeerd met behulp van een enkele FDG-
PET scan voor behandeling.  
Part 2:     Imaging van de opname medicijnen: Van de bench naar de kliniek 
Het tweede gedeelte van dit proefschrift onderzoekt de visualisatie van het medicijn 
Cetuximab. Cetuximab is een medicijn welke werkt tegen de epidermal growth factor 
receptor (EGFR), welke is gerelateerd met de agressiviteit van een tumor en algehele 
behandeling resistentie. Ondanks dat het veelvuldig wordt gebruikt in de kliniek, is het 
alleen werkzaam in een kleine subpopulatie van de patiënten, waar zelfs  discrepanties 
tussen Cetuximab opname en EGFR expressie zijn vermeld. Daarom kan de kwantifica-
tie van in vivo opname van Cetuximab in individuele tumoren belangrijke prognosti-
sche informatie bevatten. Hiermee kunnen patiënten die geschikt zijn voor een Ce-
tuximab behandeling geselecteerd worden, alsook de optimale patiënt specifieke dosis 
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bepaald worden. Ook kan deze 3-dimensionale Cetuximab opname gebruikt worden 
voor dose painting.  
 
Om de in vitro binding van Cetuximab te onderzoeken is een imaging tracer ontwikkeld 
gebruikmakende van Cetuximab gelabelde met de fluorescente marker Oregon-Green 
488 (Hoofdstuk 6). De resultaten lieten zien dat de binding van Cetuximab sterk gerela-
teerd is met de in vitro EGFR expressie. Ook is er een binding waargenomen van Ce-
tuximab met de EGFR mutant EGFRvIII. Een ex vivo immuno-histochemie analyse liet 
een heterogene opname van in vivo Cetuximab zien, alsook een heterogene  expressie 
van EGFR. Buiten deze heterogeniteit, is er zelfs een discrepantie gevonden tussen ge-
bieden met lage EGFR expressie en hoge Cetuximab opname en visa versa.  
 
Aanvullend hebben we een andere image tracer ontwikkeld voor de imaging van Ce-
tuximab opname in pre-klinische en klinische situaties. De resultaten zijn beschreven in 
Hoofdstuk 7. Voor de labeling met Cetuximab is de positron emmiter Zirconium-89 
(89Zr) voor PET imaging geselecteerd. Dit omdat 89Zr ideale karakteristieken heeft voor 
de in vivo beeldvorming, namelijk een lange halfwaarde tijd van (78 uur) en de hoge 
labeling effectiviteit met Cetuximab. Een studie met in vivo PET images was succesvol 
met duidelijke opname of  89Zr-Cetuximab in EGFR positieve tumors (tumor-to-blood 
ratios tussen de 3-5). Maar opnieuw was een discrepantie gevonden tussen 89Zr-
Cetuximab opname en in vivo EGFR expressie. De opname in de hoge EGFR expressie 
cellijnen was twee keer lager dan de opname in de intermediaire EGFR expressie cellij-
nen. Deze resultaten zijn bevestigd met ex vivo gamma counting biodistributie studies. 
Gebaseerd op deze veelbelovende pre-klinische resultaten was een fase I klinische 
studie met 89Zr-Cetuximab gestart bij Maastro. Deze klinische studie liet zien dat de 
image tracer niet toxische was (Hoofdstuk 8). Er was selectieve opname van 89Zr-
Cetuximab in de tumor, maar met lage tumor-to-blood ratios. Dit was verwacht omdat 
Cetuximab een therapeutische werking heeft in een kleine groep patiënten, en alleen 
zes patiënten geëvalueerd waren. Ook hadden deze patienten allemaal geen EGFR 
overexpressie in de tumour.  
 
Concluderend, de discrepantie welke deze studies hebben laten zien, kan de slechte 
correlatie is tussen Cetuximab effectiviteit en EGFR expressie verklaren. De resultaten 
laten zien dat additionele mechanismen verantwoordelijk zijn voor Cetuximab opname 
in de kliniek. 
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Na vier jaar hard werken is mijn proefschrift een feit. Ik heb de afgelopen jaren veel 
geleerd in de dynamische omgeving bij Maastro en hier is mijn interesse in de weten-
schap pas echt tot stand gekomen. In dit dankwoord wil ik bij een aantal mensen in het 
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creativiteit in de wetenschap. Het is zeer bijzonder hoe je mensen kunt motiveren door 
je overweldigende enthousiasme. Ondanks je ontzettend drukke functie stond de deur 
altijd voor me open, zelfs als ik naar je toekwam met ‘stomme’ vragen. Je hebt me echt 
laten zien dat het denken in mogelijkheden veel beter werkt dan het denken in pro-
blemen. Daarbij kreeg ik echt het gevoel van “the sky is the limit”. Bedankt voor alle 
mogelijkheden die je me hebt geboden!  
 
Prof. Dr. Dirk De Ruysscher: Promotor. Beste Dirk, ook dankzij jou begeleiding is dit 
proefschrift tot stand gekomen. Je bent een geweldige bron van ideeën.  Het is verba-
zingwekkend hoeveel kennis je hebt van (zowel binnen als buiten) het medisch domein 
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ze enthousiasme, ik ken maar weinig mensen met zoveel passie voor de wetenschap. 
Dit resulteert dat je een inspiratie bent voor velen, alsook voor mij. Mede dankzij jou 
heb ik voor het wetenschappelijke pad gekozen.   
 
Dr. Ir. Andre Dekker: Co-promotor. Beste Andre, bedankt voor je begeleidende rol in 
de beginjaren van mijn promotie. Je gaf me veel vrijheid, maar was altijd beschikbaar 
voor me als ik je wetenschappelijke oog nodig had. Zelfs na al die jaren, verbaas je me 
tegenwoordig nog steeds over het geweldige snelle inzicht dat je hebt. Je kan de lastig-
ste vraagstukken doodsimpel laten lijken.  
 
Prof. Dr. Bradly Wouters. Dear Brad, thank you for all the help with the lab-work of my 
thesis. You inspired me in all our talks about being a physicist in a biology environment. 
Thank you for making my visit to Canada possible, I enjoyed Toronto a lot.    
 
Steven, paranimf. Bedankt voor alle mooie momenten tijdens onze reizen! Op een be-
paalde manier blijven onze levens zich kruisen, eerst op de TU en later bij de UM. Ik 
ben blij dat we gedurende onze promoties elkaar zo goed hebben leren kennen en 
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jouw inbreng waren de projecten nooit gelukt. Michel: bedankt voor je cruciale hulp bij 
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